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Abstract 
Clostridium difficile has caused significant morbidity and mortality over the last two 
decades, especially in North America and Europe. The perturbations caused to the 
gut microbiota due to broad spectrum antibiotics and consequent lack of protection 
provided by the commensal microbes is considered the main risk factor for C. 
difficile-associated diarrhea (CDAD). The emergence of hypervirulent C. difficile 
strains has exacerbated the problem over the last decade while the continuing 
problem of recurrence of CDAD following metronidazole/vancomycin 
administration has led to investigations into alternative/adjunctive therapeutic 
options for the disease. The relatively recent advancements in next generation 
sequencing (NGS) technology have aided scientists to understand and appreciate the 
extensive damage inflicted on the gut microbiota by broad spectrum antibiotics. 
As mentioned, due to recurrence of CDAD, as well as the possibility of 
metronidazole/vancomycin resistance amongst C. difficile, alternative antimicrobials 
and antimicrobial combination therapies warrant investigation. Bacteriocins are 
ribosomally synthesised peptides produced by bacteria, which can have either 
narrow or broad spectrum of activity against other bacteria. Thuricin CD is one such 
bacteriocin, which has an extremely narrow host range, restricted mainly to C. 
difficile and some Listeria monocytogenes and Bacillus strains. Thuricin CD belongs 
to a novel class of bacteriocins referred to as sactibiotics. Thuricin CD displays 
potent activity against all C. difficile isolates tested to date, while having minimal 
impact on members of the gut microbiota. Since the main etiological agent of CDAD 
and recurrence is dysbiosis caused by broad spectrum antibiotics, the narrow 
spectrum thuricin CD has the potential to replace conventional broad spectrum 
antibiotics. Antimicrobial combinatorial therapy has also attracted some attention in 
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recent years as a means of treating infections. It is plausible that resistance amongst 
target strains is less likely to develop when a combination of antimicrobials with 
different modes of action is used. Indeed, a similar concept of hurdle effects has 
existed in the food industry for years, whereby two or more antimicrobials/stressors 
are combined to inhibit the growth of pathogenic/spoilage bacteria. Here, following 
an initial determination of minimum inhibitory concentrations of five antimicrobials 
against nineteen C. difficile clinical isolates, it was observed that the sactibiotic 
thuricin CD when combined with the antibiotic ramoplanin, as well as the lantibiotic 
actagardine when combined with ramoplanin, function in a partially 
synergistic/additive manner against the majority of C. difficile targets. Other partial 
synergistic effects were also apparent in this study. The advantage of such 
antimicrobial combination therapies with bacteriocins include: i) reducing the 
concentration of antibiotics required, thus decreasing the chances of side effects, ii) 
attenuating the likelihood of resistance development amongst target strains due to 
two different modes of action of the two antimicrobials combined, iii) reducing the 
financial burden associated with the administration of more expensive antibiotics. 
Following on from such initial antimicrobial combination studies, the development 
of resistance to the bacteriocin thuricin CD was investigated in depth with the 
ultimate view to gain better insights into the mode of action of the bacteriocin. 
Different ribotypes of C. difficile strains, as well as thuricin CD-sensitive L. 
monocytogenes and Bacillus firmus strains were employed to this end. It emerged 
that low-level resistance development to thuricin CD was possible through 
incremental exposure to increasing concentrations of thuricin CD in a stepwise 
manner. Phenotypic analysis of such mutants revealed minor alterations in 
sensitivities of some of the thuricin CD-resistant mutants to the β-lactam group of 
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antibiotics compared to the wild type parental strains, suggesting that altered 
expression levels of penicillin binding proteins may be involved in resistance 
development. Furthermore, altered growth rates of L. monocytogenes resistant 
mutants on the sugars mannose and glucose suggested that the mannose 
phosphotransferase system could be a possible receptor for thuricin CD.  
Bacteriocin producers contain self-defense mechanisms to protect themselves from 
the antimicrobial activity of the bacteriocin they produce. Such innate immunity 
systems generally contain either an ABC transporter system, a dedicated immunity 
protein or a combination of both systems. Here, following detailed in silico analysis 
of the thuricin CD gene cluster and downstream experimental analysis, a novel 
immunity protein designated TrnI was identified. The experimental findings were 
consistent with in silico investigations, establishing that TrnI is a small hydrophobic 
immunity protein with two transmembrane domains. It was apparent that TrnI plays 
a key role in immunity to thuricin CD, both independently and in combination with 
an ABC transporter system.  Truncated versions of TrnI highlighted that the N-
terminus of the protein contains the most important domains for functionality. 
Finally, the entire thuricin CD gene cluster (containing eight genes involved in 
thuricin CD production, post-translational modification, export and immunity) was 
expressed heterologously in Bacillus subtilis. Such heterologous production of 
thuricin CD not only experimentally established which genes are responsible for 
thuricin CD production, it also led to the development of a heterologous host system 
in which the functions of the individual genes could be ascertained.  
Due to the studies presented in this thesis, it is highly likely that strategies will 
emerge that will eventually facilitate the generation of enhanced derivatives of 
thuricin CD and will help to gain an insight into the specific residues of importance 
4 
within Trnα and Trnβ. It is possible that any heterologous host expressing thuricin 
CD may become overwhelmed by the presence of the bacteriocin, affecting the 
viability of the host. The identification of the novel immunity gene trnI may lead to 
the development of heterologous host systems with a hyper-immune state through 
introduction of additional copies of the immunity gene, and could result in the 
overexpression of thuricin CD, thereby leading to increased yield.  Bioengineering of 
the immunity protein TrnI via site-directed/random mutagenesis could also lead to 
the identification of a derivative of TrnI with enhanced immunity which could have 
applications for the over-production of thuricin CD. The discovery of effective 
antimicrobial combinations and encouragingly, lack of any antagonistic 
combinations against C. difficile presented in this thesis may eventually prove to be 
alternative therapeutic options for CDAD in the clinic. A thorough understanding of 
the precise mechanisms of thuricin CD resistance development and investigations 
into its mode of action may reveal a specific receptor that thuricin CD binds to. 
Elucidation of the mode of action of thuricin CD will help to explain the narrow 
spectrum of activity of thuricin CD against C. difficile. This may help us gain 
insights into the structure-function and ligand-receptor binding characteristics of the 
thuricin CD peptides and eventually lead to the development of bioengineered 
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Clostridium difficile-associated infection, 
pathogenesis and therapeutic options. 
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Clostridium difficile is mainly a nosocomial pathogen and is a significant cause of 
antibiotic-associated diarrhoea. It is also implicated in the majority of cases of 
pseudomembranous colitis. Recently, advancements in next generation sequencing 
technology (NGS) have highlighted the extent of damage to the gut microbiota 
caused by broad-spectrum antibiotics, often resulting in C. difficile infection.  
Furthermore, over the last decade, the emergence and spread of ‘hypervirulent’ C. 
difficile isolates producing higher amounts of toxins as well as binary toxin, such as 
strain R027, has been a cause for concern. The increased severity of disease caused 
by such epidemic-associated strains compounded by their increased resistance to 
fluoroquinolone, exacerbate the problem. Currently the treatment of choice for C. 
difficile-associated diarrhoea (CDAD) involves the use of metronidazole and 
vancomycin. However, recurrence and relapse of CDAD, even after rounds of 
metronidazole/vancomycin administration is a problem that must be addressed. The 
efficacy of alternative antibiotics such as ramoplanin, fidaxomicin, rifaximin and 
nitazoxanide, as well as faecal bacteriotherapy has been assessed and some have 
yielded positive outcomes against C. difficile. Some bacteriocins have also shown 
promising effects against C. difficile in recent years. In light of this, the mechanisms 
of colonization, pathogenesis and recent advancements in therapeutic options against 




Clostridium difficile is a Gram-positive anaerobic sporeformer and is the etiological 
agent responsible for C. difficile-associated diarrhoea (CDAD). C. difficile was 
initially considered a harmless commensal of the gastrointestinal tract of infants, 
when originally isolated in 1935 but its role in nosocomial diarrhoea and 
pseudomembranous colitis (PMC) was appreciated only in the 1970s (1, 2).
 
The 
development of antibiotics for the treatment of infectious diseases in the 20
th
 century 
has been a significant accomplishment. However, it is ironic that antibiotics, and in 
particular broad spectrum antibiotics, are the main etiological agents of one of the 
most notorious nosocomial infections, CDAD. CDAD has significant financial 
implications, and an estimated €5000-15000 is spent per CDAD case in England and 
approximately €3 billion per year in the EU in total. The corresponding figure is 
about €2-4 billion per year in the US (3, 4).  The majority of C. difficile strains 
produce toxin A and toxin B, which are responsible for the clinical manifestation of 
the disease. The recent emergence and widespread dissemination of ‘hypervirulent’ 
outbreak-associated C. difficile strains have caused problems for clinical 
practitioners. Furthermore, the ongoing problem of CDAD recurrence post-antibiotic 
therapy, caused by perturbations of the gut microbiota, has encouraged scientists to 
seek alternative therapeutic options. Perhaps the most potent defence against CDAD 
is the maintenance/restoration of a fully intact gut microbiota, providing protection 
through a complex process referred to as ‘colonization resistance.’  
This review focuses on the processes involved in C. difficile pathogenesis, its 
virulence factors and the emergence of toxin-variant strains and outbreak-associated 
strains. Traditional approaches and the recent developments in novel C. difficile 
therapeutic options are also discussed. In particular, we focus on antibiotics and 
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adjunctive therapeutic options which have the potential to replace the current 
standard metronidazole and/or vancomycin therapy. In this regard, recent in vivo 
studies and clinical trials conducted with alternative and/or adjunct anti-C. difficile 





Colonization resistance  
The use of antibiotics acts to perturb the host-microbiota homeostasis and can lead to 
CDAD, particularly in immunosuppressed patients (5). In the late 1970s and early 
1980s, it was hypothesised that antibiotics contributed to the development of CDAD 
by means of disruption of a complex series of events referred to as ‘colonization 
resistance (6, 7).’ Indeed, the concept of ‘colonization resistance’ was first 
recognised as early as the 1940s when it was found that the administration of 
streptomycin led to a marked change in the cultivable bacteria which were recovered 
from the faeces of mice (8). An association between antibiotic-mediated disruption 
of the gut microbiota and onset of CDAD was noted when Bartlett et al. identified C. 
difficile to be the causative agent of clindamycin-associated colitis (5). Indeed, this 
overgrowth of C. difficile following antibiotics had also been shown in hamsters and 
mice (5, 7). Studies also demonstrated that the commensal gut microbiota of 
hamsters was able to inhibit C. difficile in germ-free mice and continuous flow 
cultures (7, 9).  
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C. difficile is implicated in approximately 20-30% of cases of antibiotic-associated 
diarrhoea (AAD) and in approximately 90% of cases of PMC (10). However, it is 
implicated in approximately 0.9% of hospital infections overall according to the US 
Agency for Healthcare Research and Quality. Antibiotics which predispose to 
CDAD include clindamycin, the cephalosporins and the aminopenicillins (11, 12). 
Unsurprisingly, it has also been found that consistent exposure to antibiotics 
regularly over a period of time leads to reduced ‘colonization resistance’ to C. 
difficile, most likely attributed to the extensive damage caused by broad spectrum 
antibiotics (13, 14). As noted above, recurrence of CDAD has been a serious 
problem. Recurrent CDAD can be defined as diarrhoea that is associated with a 
positive C. difficile test and occurs days to weeks after completion of treatment of an 
initial CDAD episode (15). Patients with recurrent CDAD have a markedly altered 
indigenous microbiota, which is postulated to inhibit the restoration of ‘colonization 
resistance’ and thus, increases the risk of developing CDAD again (13). In support of 
this, recent findings have suggested that faecal transplantation may be effective as a 
means of preventing recurrent CDAD (16).
 
However, it is still not a Food and Drug 
Administration (FDA)-approved therapy and an inherent risk of transmission of 
pathogens is associated with a procedure of this nature. A rise in the number of cases 
of recurrent CDAD has prompted researchers to try to elucidate the mechanisms by 
which C. difficile is suppressed by the host commensal microbiota and to harness 





Mechanisms of colonization resistance and CDAD 
The gut microbiota contributes in the transformation of bile acids in the small 
intestine. This transformation of bile acids has significant effects on the germination 
of C. difficile spores and their subsequent outgrowth. Bile salt hydrolase enzymes act 
to deconjugate bile acids from their amino acid moieties (17). These enzymes may 
also act to inactivate the antibacterial actions of bile. Bacteria also transform primary 
bile acids to secondary bile acids using the enzyme 7-dehydroxylase (17). Therefore, 
the commensal gut microbiota has an important role in altering the composition of 
bile in the intestine and may affect the antimicrobial properties of bile. In vitro 
studies have demonstrated that bile stimulates C. difficile spore germination (18). 
Indeed, taurocholate and glycine have been shown to promote the germination of 
spores by a thousand-fold, whereas the secondary bile acid deoxycholate is toxic to 
vegetative C. difficile cells (19). The use of broad spectrum antibiotics causes a 
decrease in the levels of deoxycholate, and an increase in cholate levels, and 
stimulates the germination of C. difficile spores by reducing bacteria which generate 
deoxycholate (19).  
 
Risk factors for CDAD 
The use of broad spectrum antibiotics is a key contributory factor to developing 
CDAD. Such broad spectrum antibiotics are associated with dysbiosis, or 
perturbations in the human gut microbiota (20). Indeed, over the last number of 
years, the development of next-generation sequencing (NGS) has aided in 
comprehending the extent of this damage caused by broad spectrum antibiotics. 
Several studies have reported the effects of broad spectrum antibiotics on the gut 
11 
microbiota, employing the use of clone libraries and downstream Sanger sequencing 
(21-23).  
With regards to C. difficile, other than inflicting damage to the gut microbiota, 
antibiotics such as (desacetyl)cefotaxime and clindamycin stimulate the sustained 
germination of C. difficile spores and consequent production of toxins (24, 25). 
While cefoxtaxime and desacetylcefotaxime induce germination of C. difficile during 
administration, clindamycin has been found to stimulate C. difficile germination and 
toxin production 8 days after the antibiotic is discontinued (24, 25). Therefore, it 
would appear that germination of C. difficile is promoted when clindamycin is 
present at concentrations below the minimum inhibitory concentration (MIC) (24, 
26). In addition to clindamycin and cephalosporins, other antibiotics that predispose 
to CDAD include fluoroquinolones, aminopenicillins, vancomycin and 
metronidazole (27). Even the antiviral valacyclovir has been associated with a case 
of C. difficile colitis (28).   The use of proton pump inhibitors (PPIs) in particular, as 
well as histamine H2-receptor antagonists has also been suggested to lead to an 
elevated risk of acquiring CDAD. However, it is not yet abundantly clear whether 
the apparent increased risk of CDAD due to such gastric acid production inhibitors is 
a direct or indirect effect or whether other underlying causes are involved as well 
(29). One report indicated that patients being treated with PPIs are approximately 
four times more likely to suffer from recurrent CDAD than patients not in receipt of 
PPIs (30). There are a number of other cohorts of patients that seem to be at an 
increased risk of developing CDAD. The number of reported cases of CDAD in peri-
partum women is rising, while post-transplantation patients seem to be more 
susceptible to CDAD as well (31). Patients suffering from inflammatory bowel 




been associated with dysbiosis, even without the use of antibiotics. This dysbiosis of 
the gut microbiota is likely to lead to an increased risk of CDAD. Indeed, in one case 
in an institution in Wisconsin, it was reported that the rate of CDAD in IBD patients 
rose from 7% to 16% over the space of a year from 2004-2005 (33). The association 
between CDAD and IBD is predominantly seen in ulcerative colitis patients and is 
not associated with small intestine Crohn’s disease. C. difficile toxins may worsen 
the inflammatory process in patients suffering from ulcerative colitis. A greater 
mortality rate is associated with CDAD in patients who have IBD compared to 
patients with CDAD or IBD alone (34). The fact that some patients with IBD take 
immunosuppressive medications may also contribute to their risk of acquiring 
CDAD. It is also noteworthy that CDAD has been reported in perfectly healthy 




C. difficile colonization 
C. difficile attaches to the mucus layer on the surface of enterocytes and penetrates 
the mucus layer using flagellae and proteases, such as the cysteine protease Cwp84 
(36, 37). FliC is a flagellin monomer and FliD is the flagellar cap protein, involved 
in the attachment of C. difficile to intestinal mucus whereas Cwp84 is a cysteine 
protease which is responsible for degrading various extracellular matrix proteins 
such as vitronectin, fibronectin and laminin, helping C. difficile to penetrate the  
mucus layer of enterocytes (38-40). Interestingly, a study with flagella mutant 
isolates of the strain C. difficile 630 ∆erm showed that flagella mutant strains are 
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actually more virulent than the wild type strain in hamster models (41).This 
contradictory evidence to previous studies implies that flagella may not be crucial in 
mediating pathogenicity. On the contrary, repressed motility may actually be a 
virulence factor used by C. difficile (41). Using strain C. difficile 630, Aubry et al. 
demonstrated that the flagellar regulon in C. difficile is likely to be involved in 
modulation of toxin production and consequently virulence potential of the strain 
(42). Despite this, the precise involvement of C. difficile flagellae in colonization and 
pathogenesis remain largely unclear however. Interestingly, in a recent study, 
Jarchum et al. noted that administration of a flagellin derived from Salmonella, 
which is a toll-like receptor 5 (TLR5) agonist conferred protection against C. difficile 
colitis in a murine model of infection. The stimulation of TLR5 due to the flagellin 
led to decreased epithelial cell apoptosis and consequently led to an improved 
epithelial barrier function during C. difficile infection (43).  
Degradation of host extracellular matrix proteins mediated by the above-mentioned 
Cwp84 protein enables the dissemination of C. difficile infection (37). Following the 
initial breach of the mucus layer of enterocytes, attachment of C. difficile to 
enterocytes occurs via multiple adhesins such as surface layer proteins (S-layer P36 
and P47), a 68kDa fibronectin binding protein (Fbp68) and a cell wall protein 
(Cwp66)(39, 44, 45). A recent study has also highlighted the role of Surface Layer 
Protein A (SlpA) in mediating attachment of C. difficile to enterocytes (46).
 
It was 
established that different domains of the SlpA protein are involved in this attachment 
process. Interestingly, it was also found that preparations consisting of SlpA from 
non-toxigenic strains disrupted the adherence of epidemic-associated C. difficile 
strains. Thus SlpA may be a potential target for preventing the attachment of C. 
difficile to host cells (46). In addition to the above-mentioned adhesion factors, 
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microtubule-based cell extensions mediate adhesion of binary toxin-producing 
strains of C. difficile (47, 48). Such protrusions have thus far only been demonstrated 
in strains producing binary toxin (47, 48).  
 
 
Antibiotic resistance as a virulence factor 
A significant factor contributing to C. difficile virulence is its resistance to several 
common antibiotics. Over time, C. difficile has developed resistance to antibiotics 
such as clindamycin.
 
More recently, emergence of resistance among C. difficile 
strains to fluoroquinolones has been a grave concern, in particular amongst ribotypes 
001, 106 and 027 (49, 50).  In the majority of cases, antibiotic resistance in C. 
difficile strains has been acquired via mobilization of transposons, examples of 
which include the erythromycin resistance gene ermB on Tn5398, the tetracycline 
resistance gene on Tn5397, and the chloramphenicol resistance on Tn4453 (51, 52). 
Antibiotic resistance can also be attributed to point mutations in C. difficile e.g. a 
point mutation in the gyrB gene may be responsible for fluoroquinolone resistance 
(53). Drudy and co-workers also noted that certain C. difficile isolates which are 
erythromycin-resistant due to ermB also exhibit clindamycin resistance (54). A 23S 
ribosomal RNA methylase mediates resistance of some C. difficile strains to 
erythromycin (55). PCR ribotypes 006 and 001 exhibit increased resistance to 
erythromycin, along with levofloxacin and imipenem (56). Such resistance may 
account for the relatively high prevalence of such strains. 
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The chances of acquiring CDAD after antimicrobial therapy rise if the C. difficile 
strain is already resistant to the offending antibiotic i.e. that being used to treat the 
patient for the original unrelated condition (50). Indeed, a clindamycin-resistant C. 
difficile strain was responsible for a CDAD outbreak in various hospitals in the US 
in the 1990s (55). Also, the emergence and dissemination of outbreak-associated C. 
difficile ribotype 027 strains may be due to the widespread use of fluoroquinolone in 
clinical settings, which may be behaving as a selective pressure for these epidemic-
associated R027 strains which are resistant to fluoroquinolone (27). In an in vitro 
study conducted in Spain, approximately 6% of C. difficile strains were found to be 
resistant to metronidazole and 3% of strains displayed intermediate resistance to 
vancomycin (57).  
 
Spores 
Another factor which contributes to C. difficile virulence is its ability to sporulate. 
Such spores are resistant to extremes of temperature, desiccation and exposure to 
various chemicals and can survive for months (58, 59). The contamination of 
environmental surfaces in hospitals and other health-care settings with C. difficile 
spores is a serious concern. Epidemic-associated C. difficile strains have been 
reported to be more capable of sporulating than non-epidemic strains in vitro (60-
62).  In vitro studies reported that the use of non-chlorine-based disinfectants at 
concentrations lower than the MIC actually encouraged sporulation to occur (60). 
Although other disinfectants inhibited C. difficile growth in vitro, chlorine-based 
disinfectants were the only ones effective against C. difficile spores (60).  It is 
apparent that stringent infection control measures are of paramount importance in 
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hospitals. Isolating CDAD patients in private rooms and the use of gloves and gowns 
by clinicians have proved to be effective. Hand washing with soap and water is 
recommended to remove C. difficile spores whereas the use of alcohol hand gels is 
discouraged in clinical settings where there is an outbreak of CDAD and 
consequently an inherent risk of spreading spores, according to the Society for 
Healthcare Epidemiology (SHEA), Infectious Disease Society of America (IDSA) 
and the Centre for Disease Control (CDC) guidelines. The use of disposable 
thermometers instead of electronic thermometers can also reduce the likelihood of 
disseminating C. difficile spores (63). It is also worth noting that the use of some 
antibiotics can stimulate the germination of quiescent C. difficile spores which are 
present in the gut. This germination is followed by toxin production, which is most 
prolific in the late exponential phase (24, 64). The vancomycin derivative, 
oritavancin, has been shown to successfully inhibit the germination of C. difficile 
spores (65).  
 
Paracresol production as a virulence factor 
C. difficile produces a compound called para-cresol and it has been postulated that 
para-cresol may actually inhibit the re-colonization of the gastrointestinal tract by the 
commensal microbiota, even after antibiotic treatment has been discontinued (66). 
Para-cresol possesses bacteriostatic characteristics, and its production is through the 
transamination of tyrosine to para-hydroxyphenylacetic acid. This para-
hyroxyphenylacetic acid is subsequently decarboxylated to para-cresol. Paracresol 
can also inhibit other C. difficile strains. It is noteworthy in this regard that an 
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outbreak-associated R027 strain isolated in Stoke Mandeville (20291 R027) is able 






Several factors are required for the development of CDAD. Sorg & Sonenshein 
reported that the germination of C. difficile spores is aided by the presence of bile 
salts (18). Once germination has occurred, vegetative cells begin to release toxin A 
and toxin B, possibly triggered by a change in the availability of certain amino acids 
(18). Both Toxin A and toxin B display enterotoxic and cytotoxic activity, causing 
inflammation, fluid secretion and tissue necrosis of the intestinal epithelium (67-70). 
Typically, CDAD presents as watery profuse diarrhoea 48-72 hours post-infection. 
Clinical signs of CDAD include new-onset diarrhoea, abdominal distension and 
leukocytosis (71).
 
CDAD affects the colon and the presence of colonic 
pseudomembranes by endoscopic examination is a common sign. Amongst the risk 
factors for the development of an aggressive form of C. difficile colitis include: 
underlying malignancy, immunosuppressive medications such as corticosteroids, 
patients on anti-peristaltic medication and patients being treated with clindamycin 
(72, 73). Patients with aggressive colitis have a higher chance of presenting with 
peritonitis, hypoalbuminaemia and an abnormal white blood cell count (74). 
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Expeditious diagnostic and treatment modalities are imperative for such a group of 
patients with underlying immunosuppression or illnesses.  
C. difficile toxins cause ulcers to develop on the intestinal mucosa, which in turn 
leads to the release of mucus, inflammatory cells and serum proteins, with the 
appearance of pseudomembranes. Pseudomembranes due to CDAD typically appear 
as raised yellow or white plaques approximately 2cm in size, found scattered over 
the colorectal mucosa (75). C. difficile colitis progresses to fulminant colitis in 
approximately 3-8% of cases (76). The signs of fulminant colitis include diffuse 
abdominal pain, fever, abdominal distension, lactic acidosis and significant 
leukocytosis. Further complications may include toxic megacolon and bowel 
perforation (74). Patients presenting with diarrhoea generally have stools which are 
unformed, watery and mucoid in nature. Abdominal pain, raised temperature and 
leukocytosis accompanied by diarrhoea are perhaps the most common symptoms 
(71). Despite these common signs, it must be highlighted that the clinical appearance 
of CDAD varies greatly amongst patients and can range from asymptomatic patients 
to patients presenting with mild diarrhoea to severe PMC and toxic megacolon (77, 
78).  
 
C. difficile toxins 
As noted above, the two toxins that are primarily associated with C. difficile 
pathogenesis are toxins A and B. Toxin A (TcdA) is a 308kD toxin and toxin B 
(TcdB) has a mass of 270kD (79, 80).
 
Their mode of action involves the 
glucosylation of GTPases Rho, Cdc42 and Rac, thereby causing impaired actin 
polymerization and leading to cytoskeletal disorganisation in epithelial cells (81, 82). 
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As mentioned, both TcdA and TcdB are large cytotoxins which cause significant 
epithelial tissue damage and colonic inflammation (67-69,83). The end result of this 
tissue damage and colonic inflammation is diarrhoea as a result of fluid loss into the 
lumen of the intestine. Both toxins A and B belong to a group of large clostridial 
toxins (LCT) (84, 85).
  
Other members of the group include TcsL and TcsH from 
Clostridium sordellii, TpeL from certain Clostridium perfringens isolates and the α-
toxin (TcnA) from Clostridium novyi (84, 85). Like TcdA and TcdB, other members 
of this group of toxins are monoglycosyltransferases that trigger the inactivation of 
the Rho family of GTPases, thereby rendering them inactive and thus repressing 
downstream cellular activities (84, 85). The C-terminus of LCT binds to a receptor(s) 
on the target cell surface. The precise characteristics of the toxin receptors remain 
unclear, with protein, carbohydrate or glycolipid receptors all plausible (86). 
Endocytosis of the toxins occurs through clathrin and dynamin-mediated pathways, 
making their way into the endosomes of the target cell (87).
 
Translocation of the 
toxins from the endosomes into the target cell cytosol is thought to involve 
endosome acidification. Indeed, the macrolide bafilomycin A1, which represses 
endosomal acidification via inhibition of the endosomal vacuolar ATPase pump, 
represses toxin B-mediated cytotoxicity (88). A conformational change of both 
toxins A and B takes place, which is induced by a change of pH within the 
endosome. This change of shape likely occurs between the cysteine protease domain 
and the C-terminal combined repetitive oligopeptide (CROP) region (86, 89, 90). A 
protrusion begins to form, putatively involved in membrane interaction. Toxin A 
forms pores at acidic pH, with cholesterol required for toxin A-induced pore 
formation. The hydrophobic region of toxin B, especially glutamate 970 and 976, is 
thought to be important in toxin B-mediated pore formation. Glutamate residues at 
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positions 970 and 976 serve as pH sensors for membrane interaction (86). After pore 
formation, a change of conformation within the cysteine protease domain of the 
toxin is triggered by binding of inositol hexakisphosphate. This in turn leads to 
cleavage between the cysteine protease domain and glucosyltransferase domain, 
allowing the N-terminal glucosyltransferase domain to escape into the cytosol. 
 
Toxin A and toxin B-mediated inactivation of Rho GTPases has a myriad of negative 
effects on the target cell. Actin depolymerisation is elicited and thus structural 
integrity of the cell is compromised. The inactivation of Rho GTPases by these 
toxins also affects the signalling and motility of immune cells as well as 
compromising epithelial barrier function.  The loss of the cell’s structural integrity 
eventually leads to caspase-3 and caspase-9-mediated apoptosis (91, 92). This in turn 
results in impaired tight junctions between cells and further compromised epithelial 
barrier function. Cytokines are released by the epithelial cells upon exposure to the 
toxins, resulting in activation of mast cells, neutrophils and other cells (91-93). The 
further release of pro-inflammatory cytokines and neuropeptides also compromises 
the integrity of the epithelial barriers and tight junctions, resulting in elevated 
permeability and accumulation of fluid in the intestine, the manifestation of which is 
diarrhoea (94).  
Although for decades it was thought that toxin A was the primary virulence factor, 
more recent studies have indicated the presence of toxin B-positive, toxin A-negative 
strains in patients with CDAD (53). Lyras et al. reported that isogenic mutants of C. 
difficile which lacked the toxin B gene (tcdB) exhibited reduced virulence in rodent 
models of CDAD, thus supporting the theory that toxin B is indeed an important 









Furthermore, the lack of a toxin A-specific host immune response may also 
result in more severe symptoms (97).
 
A recent study has demonstrated that cell death 
elicited by toxin B is dependent on the assembly of host epithelial cell nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase complex, while reactive oxygen 
species (ROS) also play a role. It was shown in the study that diphenyleneiodonium 
(DPI) and/or N-acetylcysteine (NAC) prevented colonic tissue damage by toxin B. 
The mechanisms for this involved a decrease in ROS-mediated tissue damage and 
may have the potential for reducing necrosis of colonic mucosa in CDAD patients 
(98). The host SLC11A1 gene has also been shown to be involved in the 
pathogenicity caused by toxin B. Upregulation of the gene caused by toxin B results 
in Rho GTPase glucosylation and consequent tissue necrosis (99).  
Certain C. difficile strains, including R027 isolates, produce a binary toxin in 
addition to toxin A and toxin B. Despite this, a definitive link between specific PCR 
ribotypes and binary toxin production remains unclear (93, 100).
 
It has been 
postulated that binary toxin acts in conjunction with TcdA and TcdB in the 
pathogenesis of both ‘hypervirulent’ and virulent isolates (93, 101).
 
This binary toxin 
is an actin-specific adenosine diphosphate (ADP) ribosyltransferase (102).
 
Other 
toxins belonging to this subgroup of two-component ADP ribosyltransferases in the 
genus Clostridium include the C. botulinum C2 toxin and the C. perfringens iota 





 strains of C. difficile are not pathogenic in hamsters (101).
 
Nonetheless, in a rabbit ileal loop test, the cell-free supernatant from such strains 
was shown to result in fluid secretion (101).  
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Pathogenicity locus (PaLoc) and C. difficile toxin production 
Until recently, investigating the role of C. difficile genes had been problematic. 
However, advancements in targeted mutagenesis systems have helped this cause (93, 
105, 106). A 19.6 kb pathogenicity locus (PaLoc) encodes the genes for these toxins 
(tcdA and tcdB) along with genes for putative positive and negative regulators of 
toxin expression (tcdR and tcdC respectively), as well as tcdE, encoding a putative 
holin protein (Fig. 1A)(107, 108). TcdR functions as an alternative RNA polymerase 
sigma factor, and thus behaves as a positive regulator of toxin gene expression (109).  
In contrast, TcdC was initially thought to serve as a negative regulator of toxin 
production, destabilising the TcdR-holoenzyme, thus hindering transcription of the 
PaLoc (107). However, in recent times, it has been demonstrated that transcription 
levels of the genes in the PaLoc and consequent total toxin production barely differs 
between a wild type C. difficile 630 ∆erm strain and its tcdC mutant, suggesting that 
TcdC may not be a key regulator of toxin expression in the strain (110).  It is 
noteworthy that earlier studies investigating the role of TcdC were in vitro 
investigations (111, 112). The in vivo mechanisms of this protein had remained 
largely unclear however. A recent in vivo study has now indicated that TcdC may not 
actually play a key role in C. difficile virulence (113). Furthermore, in another recent 
study, it was noted that there was no decrease in tcdC expression levels during 
stationary phase of growth, implying that TcdC may serve a modulatory function 
instead of a previously-hypothesised repressive function (61).   Polymorphisms in 
the tcdR-tcdB intergenic region as well as in the tcdR ribosome binding site (RBS) in 
the ‘non-hypervirulent’ VPI 10463 strain (which still produces high levels of toxins) 
likely results in increased translation of TcdR, consequently leading to read-through 
transcription of the toxin genes. Such polymorphisms may account for the increased 
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levels of toxins produced by some isolates (61).
 
In addition, the study found that 
epidemic-associated strains sporulated at an earlier stage and produced a greater 
number of spores than other non-epidemic-associated isolates. Thus, increased 
sporulation rates along with high level toxin production may explain the outbreak-
associated nature of such hypervirulent strains (61).  In an in vitro study, Vohra & 
Poxton noted that outbreak-associated R027 strains produced higher amounts of 
toxins in the logarithmic and stationary growth phases, compared to other ribotypes 
(62).  Moreover, epidemic-associated strains were found to produce more toxins and 
a greater number of spores relative to R012 (62). It was also particularly noteworthy 
that tcdC expression levels were not attenuated during stationary growth phase, as 
was previously thought, lending credence to the novel hypothesis that TcdC has a 
modulatory effect on toxin production, instead of a repressive one. In addition, an 
elevated level of expression of tcdE in R027 strains highlights its involvement in the 
release of the toxins. Therefore, it is hypothesised that a combination of factors, 
including greater toxin production, increased spore formation and increased 
expression of holin proteins may contribute to the epidemic-associated traits of 
certain strains (62). Interestingly however, using isogenic strains of C. difficile, 
Carter et al. showed that a naturally occurring mutation in tcdC is responsible for the 
hypervirulence of epidemic C. difficile isolates (111). Thus, the precise mechanisms 
of action of TcdC in vivo have yet to be definitely ascertained. 
For a long time, the elucidation of the precise functions of TcdA and TcdB using a 
genetic approach was hampered by a lack of tools to isolate C. difficile isogenic 
toxin gene mutants.  However, Lyras and co-workers as well as Kuehne and co-
workers facilitated the study of isogenic mutants (95, 114). Syrian golden hamsters 
were infected with either toxin A
-
 mutants, toxin B
-
 mutants or wild type strains in a 
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study (95). Infection with the wild type strain resulted in the death of 90% of 
hamsters included in the study.  Infection with toxin A
-
 mutants resulted in death of 
94% of hamsters, indicating that toxin A is not crucial for disease. Interestingly, 
infection with toxin B
-
 strains only caused disease in 22% of hamsters, highlighting 
that toxin B was in fact the main virulence factor rather than toxin A, contrary to 
previous assumptions. More significantly, the study helped to explain the 




 isolates in clinical settings (95).  
Importantly, the genes encoding binary toxin, designated cdtA and cdtB are not part 
of the PaLoc but are nevertheless found on the chromosome (Fig. 1B) (93, 101, 102, 
108). CdtR is a response regulator encoded by the binary toxin locus (CdtLoc) and 
controls binary toxin production (93).Isolates which do not produce binary toxin 
have a conserved 68bp sequence, in place of the CdtLoc (93).  
 
 Diagnostics 
An early and accurate diagnosis of CDAD is highly important. Currently, the most 
popular tests rely on the detection of toxins A and B by polymerase chain reaction 
(PCR), nucleic acid amplification tests (NAATs) and/or anaerobic culture of isolated 
C. difficile strains, cytotoxin assays and immunoassays. Various typing systems have 
been employed to discriminate between strains. Examples include restriction 
endonuclease analysis (REA), pulsed-field gel electrophoresis (PFGE), PCR 
ribotyping and toxinotyping. A list summarising the main diagnostic and typing 
methods used for C. difficile is included in Table 1. 
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Variant toxins and toxinotypes  
C. difficile exhibits significant chromosomal variations between different strains, 
including differences in the PaLoc and tcdA and tcdB genes (115-117).  This is the 
basis for C. difficile toxinotyping systems, in which strains are classified into variant 
toxinotypes according to restriction fragment length polymorphism-PCR (RFLP-
PCR) analysis of toxin genes (96, 117). These toxinotypes take into account specific 
mutations/changes within the toxin genes (96). Any such mutations are compared 
against the toxinotype 0 reference strain VPI 10463. To date, there are approximately 
30 C. difficile toxinotypes identified (78, 118). Mutations within the PaLoc can lead 









belong to toxinotype XIa and XIb (96, 117-119).
 
Such variant toxin strains are likely 
to have specific substrate targets as well. The toxin B protein from toxinotype VIII, 
X and XIV acts by inactivating a different set of Rho GTPases. Toxin B produced by 
toxinotypes X and VIII inactivates Rap, Ral and R-Ras GTPsases by glucosylation, 
whereas toxin B from C. difficile VPI 10463 (toxinotype 0) inactivate Rho, Rac and 
Cdc42 by glucosylation (96, 117). In a mouse model, the lethal dose of toxin B from 
a toxinotype X strain was found to be 8 times less than the lethal dose for the 
toxinotype 0 toxin (108).The toxin B from an outbreak-associated strain 20291 R027 
(toxinotype III) was compared to toxin B from C. difficile 630 (toxinotype 0)(109). 
A significant variation was noted in the C-terminal receptor binding domains of the 
toxins, with less than 80% identity in some regions of the C-terminus. Moreover, in a 
zebrafish model, the entry of purified toxin B from an outbreak-associated strain into 
target cells was shown to be much quicker than the toxin B from VPI 10463 strains, 
causing a greater degree of tissue destruction and necrosis (109). It is plausible that 
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the variations in the receptor binding domain of toxin BHV from ‘hypervirulent 
strains’ allow it to bind to multiple binding sites/receptors, compared to toxin B from 
‘non-hypervirulent’ strains. This mechanism of binding of toxins to widely 
distributed receptors may account for the epidemic-associated properties of certain 
strains. Non-toxigenic C. difficile strains have also been isolated from asymptomatic 
patients. These strains do not contain the toxin A and toxin B genes (120, 121).It has 
been proposed that non-toxigenic strains have the potential to inhibit infection and 
recurrence of infection by competing with toxigenic strains for adherence in the 
intestine and for nutrients (120, 121). A recent study with hamster models of 
infection has further highlighted the potential benefits of non-toxigenic C. difficile 
(122). The introduction of non-toxigenic C. difficile has been shown to cause 
remission of infection in two patients (123). Research is ongoing investigating the 
possibility of using non-toxigenic C. difficile as a potential prophylactic for CDAD. 




Several ribotypes of C. difficile, including the notorious R027 strains, have caused 
outbreaks in Europe and North America over the last decade. C. difficile ribotyping 
is a typing method involving the fingerprinting of C. difficile genomic DNA 
restriction fragments using specific restriction enzymes. The process involves 
amplifying specific fragments of the 16S and 23S spacer regions by PCR and 
digesting the fragments with specific restriction enzymes in order to compare the 
profiles from different strains (124). Studies have shown that PCR R027 causes more 
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severe diarrhoea, along with higher recurrence rates and mortality rates (125, 126).  
The increased severity of disease caused by ‘hypervirulent’ R027 strains is likely to 
be due to the production of higher amounts of toxin compared to other ribotypes (61, 
62). Factors other than toxin production may also account for R027 ‘hypervirulence,’ 
such as enhanced tolerance to bile salts, increased germination of spores and 
increased dissemination due to sporulation. Akerlund and co-workers reported that 
an epidemic R027 strain had enhanced sporulation capabilities relative to three other 
non-epidemic R027 isolates (127).  The 3’end of the tcdB gene, which encodes the 
binding domain of toxin B, has been shown to be variable in R027 strains, implying 
that the binding capacity of toxin B from R027 may be distinct from other less 
virulent isolates (128).  
 
C. difficile resistance to cationic antimicrobial peptides (CAMPs) 
In order to survive and proliferate in the gastrointestinal tract (GIT), C. difficile must 
contend with cationic antimicrobial peptides (CAMPs) produced by the human host 
and other bacteria. McBride & Sonenshein found that upon low level exposure to 
cationic antimicrobial peptides, C. difficile expresses genes involved in CAMP 
resistance (129). The authors discovered that an operon encoding an ATP-binding 
cassette (ABC) transporter and an orphan histidine kinase gene adjacent to the 
operon are involved in mediating resistance to CAMPs in C. difficile (129). The 
genes were designated cprABC and cprK respectively and it was subsequently 
discovered that a non-contiguous two component system (cprK and cprR) was 
involved in mediating resistance to CAMPs (130). In a separate study, it was noted 
that the dlt operon also mediates resistance to CAMPs in C. difficile (131). The dlt 
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operon is involved in adding d-alanine to teichoic acid, leading to an overall positive 
charge on the bacterial cell surface, which in turn confers protection against similarly 
charged CAMPs (131). In another study, McQuade et al. determined that epidemic-
associated C. difficile R027 strains exhibited increased resistance to the CAMP 
cathelicidin LL-37 compared to non-epidemic isolates (132).An inducible system 
involved in resistance to CAMPs has been suggested, as exposure of C. difficile to 
sub-inhibitory LL-37 concentrations led to an even further increase in resistance 
(132). Alterations in amounts of surface layer proteins, ABC transporters, cell wall 
synthesis proteins, as well as proteins involved in lysine metabolism were 
particularly noteworthy in C. difficile strains in response to cathelicidin LL-37 in the 





Current treatment of CDAD 
The current treatment modalities for CDAD involve the immediate discontinuation 
of antibiotics given to the patient for other diseases, and commencement of 
metronidazole and vancomycin administration post-haste. The rates of metronidazole 
treatment failure are significantly higher in patients who are still on other antibiotics, 
due to continued perturbations of the competing gut microbiota (133).One study 
suggested that metronidazole and vancomycin were equally effective for mild cases 
of CDAD, with treatment success rates of 90% and 98% respectively 
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(134).However, for more severe cases, vancomycin was the treatment of choice, as 
success rates for metronidazole and vancomycin were 76% and 97% respectively, 
though recurrence rates were similar i.e. 15% of metronidazole-treated patients, 
compared to 14% for vancomycin (134).In this regard, it must be noted that slightly 
different success rates are reported for metronidazole and vancomycin against C. 
difficile, depending on a variety of factors, such as type of study conducted, sample 
size and geographical location. High failure rates for metronidazole, due to the 
emergence of the outbreak-associated R027 strains and also a rise in the number of 
elderly patients in hospitals affected by CDAD who are already being treated with 
other antibiotics, have also been reported (135, 136).   The treatment for non-
epidemic and epidemic C. difficile strains appears to be similar, with metronidazole 
as the primary treatment choice for mild-moderate cases of CDAD, followed by 
vancomycin for more severe CDAD, according to the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) guidelines. Fidaxomicin has 
already been proved to have promising efficacy as a therapeutic for CDAD. Other 
antibiotics such as ramoplanin, tigecycline and the rifamycin group have shown 
potent activity against C. difficile and research is ongoing regarding their clinical 
efficacy against CDAD. Fidaxomicin and faecal microbiota transplantation (FMT) is 
also strongly advocated by ESCMID for recurrent CDAD cases (137, 138).  
For mild-moderate CDAD, 500mg of oral metronidazole three times a day for 10-14 
days is recommended, whereas 125mg of oral vancomycin four times a day for the 
same duration is indicated for more severe cases of CDAD (139).Oral vancomycin, 
supplemented with intravenous metronidazole if necessary, is recommended for 
severe CDAD by the IDSA. Although oral administration of metronidazole or 
vancomycin is optimal, metronidazole can also be administered intravenously as it is 
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capable of reaching the intestinal lumen via diffusion across the inflamed colon. A 
prospective study conducted by Wenisch et al. demonstrated that oral metronidazole 
(7.4% mortality) was more effective against C. difficile than intravenous 
metronidazole (38.1% mortality)(140). Vancomycin may also be introduced 
intracolonically or as a retention enema. 100mg of the glycopeptide teicoplanin twice 
a day in addition to metronidazole or vancomycin is recommended by the ESCMID 
for CDAD (141).However, fusidic acid and bacitracin do not seem to be as effective 
as glycopeptides or metronidazole and thus are contraindicated by ESCMID. Fusidic 
acid, oral bacitracin and teicoplanin are not recommended in the USA for CDAD 
(141).  
 
Alternative vancomycin dosing strategies 
Though vancomycin and metronidazole have been used for the treatment of CDAD 
for the last three decades, recurrence and relapse of disease still remains a serious 
problem. About 50% of cases of recurrence of disease are due to relapse, whereby 
the original C. difficile strain that was culpable for the infection causes symptoms 
again, due to spores surviving the CDAD treatment (142).  
Alternative dosing regimens for vancomycin have been investigated to circumvent 
the problem of recurrent CDAD. Pulsed vancomycin dosing, which involves short 
intermittent administration of vancomycin, as well as tapered dosing of vancomycin 
have proved successful. In a retrospective study conducted by McFarland et al. with 
a total of 163 patients, a subset received vancomycin and a smaller subset received 
tapered doses of vancomycin, whereby vancomycin was decreased incrementally 
from (500mg-3g daily) – (125-750mg daily) over 3 weeks (143). A 31% recurrence 
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rate was noted for this tapered dose strategy compared to recurrence rates of 43-54% 
with conventional vancomycin dosing for 10 days. Pulsed vancomycin 
administration of 125-500mg per day every 2-3 days for 27 days resulted in a 14% 
recurrence rate (143). Although no randomized controlled trials have assessed such 
dosing regimens, the IDSA and the SHEA recommend the use of pulsed or tapered 
vancomycin dosing for second or third recurrences of CDAD (139).In cases of 
extremely severe C. difficile colitis, intracolonic vancomycin administration may 
have the potential to be used as an adjunct, to ensure higher concentrations of the 
drug in the colon (144, 145). This may involve the use of an intracolonic bolus with 
an intravenous solution of vancomycin.  A rectal retention enema such as 500mg of 
vancomycin in 1L of saline solution may be another option.  Kim et al. reported a 
70% success rate in a recent trial whereas Apisarnthanarak et al. approximated a 
success rate of 57-75% for intracolonic vancomycin administration in a review of 
relevant case series (144, 145). 
 
Fidaxomicin 
Fidaxomicin is an oral macrocyclic antibiotic, produced by Dactylosporangium 
aurantiacum, targeted against C. difficile (146). One of the main advantages of 
fidaxomicin is that it is tailored specifically towards C. difficile, with little impact on 
the commensal gut microbiota and has been shown to inhibit spore formation and 
toxin production in C. difficile (137, 147, 148). This narrow spectrum of action is 
hugely beneficial as it permits quick restoration of the commensal gut microbiota in 
CDAD patients, and thus decreases the risk of recurrence of disease due to 
overgrowth of C. difficile (137, 148).  Another advantage is that it sustains a certain 
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level of antibacterial activity for a more prolonged period, compared to 
metronidazole and vancomycin (146). Therefore, it is capable of inhibiting C. 
difficile at concentrations lower than the MIC.   
A number of in vitro and in vivo studies have highlighted the potential of 
fidaxomicin in combating C. difficile. It is promising to note that fidaxomicin has 
potent antimicrobial activity against outbreak-associated R027 strains as well as non-
epidemic-associated strains (149-151).
 
 Phase I clinical trials conducted by Shue et 
al. reported low plasma concentrations of fidaxomicin of less than or equal to 
5ng/ml, with a concomitant near 100% recovery of fidaxomicin and its metabolite in 
faeces (152). These findings were in accordance with more recent Phase II and Phase 
III trials which reported that the concentrations of fidaxomicin in faeces were 2000-
10000-fold higher than the MIC90 value against C. difficile.
 
 
Clinical trials with CDAD patients have shown that fidaxomicin caused fewer 
recurrences and thus, is indicated for mild, moderate, severe and recurrent CDAD 
(153, 154). A Phase II trial by Louie and co-workers assessed the efficacy of several 
doses of fidaxomicin in treating CDAD (155). Response rates of 71%, 80% and 94% 
were found for patients treated with 100mg, 200mg and 400mg of fidaxomicin 
respectively. Four patients receiving either 100mg or 200mg of fidaxomicin failed 
therapy, representing an 8.9% failure rate. Two out of 41 patients in the study 
exhibited recurrence of disease a month after treatment (155). In two phase III 
clinical trials with 1105 CDAD patients, treatment with fidaxomicin resulted in 
comparable initial response rates to vancomycin.(156). Also, the group of patients 
treated with fidaxomicin had a 47% lower recurrence rate compared to vancomycin 
(156).  In patients with recurrent CDAD, 35.5% of 128 patients receiving 
vancomycin had a further recurrence whereas only 19.7% had a further recurrence 
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when treated with fidaxomicin as reported in two studies (149, 150). Although lower 
recurrence rates have been observed for fidaxomicin compared to vancomycin, the 
recurrence rates are broadly similar for R027 strains (137, 149, 150).  
 
Rifamycin antibiotics 
The rifamycin subgroup of antibiotics, which include rifaximin, rifampin, rifalazil 
and others display potent anti-C. difficile activity in vitro (157, 158).However, only a 
handful of reports regarding their clinical use are available (159).   In one instance it 
was reported that 7 patients recovered from CDAD with 3 days of rifampin 
treatment. The dose was 300-600 mg rifampin administered every 12 hours in 
combination with vancomycin (160). Another study evaluated the effects of 
metronidazole and rifampin combination therapy, but no beneficial effects were 
noted compared to metronidazole treatment alone (161). Rifaximin, another 
rifamycin antibiotic, also shows strong antimicrobial activity against C. difficile in 
vitro (157). The rates of C. difficile resistance to rifaximin are significantly lower 
compared to rifampin (159).  In an in vitro study, O’Connor and co-workers found 
that 14 C. difficile isolates were resistant to rifaximin, out of 80 strains tested in the 
study whereas rates of  metronidazole resistance amongst C. difficile strains have 
been reported to vary from 15-35% in a separate study (162, 163). Rifaximin 
resistance has been associated with mutations in the rpoB gene. 
A clinical trial conducted by Johnson et al. showed that 7 of 8 patients administered 
rifaximin following vancomycin displayed no recurrence of CDAD (164). Rifaximin 
was effective in eradicating symptoms of diarrhoea in three liver transplant patients, 
within 36-48 hours of administration (158). A success rate of 64% for rifaximin was 
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reported by Patrick-Basu and co-workers in 25 patients who failed metronidazole 
treatment (165).  
 
Nitazoxanide 
Nitazoxanide is a nitrothiazole benzamide which displays potent antimicrobial 
activity against intestinal parasites and GIT pathogens including C. difficile 
(166).Musher et al. conducted a randomized, prospective double blind study with 
hospitalised patients with C. difficile colitis. Patients included in the study were 
those who had primary CDAD (a minimum of 3 unformed stools per day), with 
symptoms such as abdominal pain, fever or leukocytosis and an enzyme 
immunoassay indicating C. difficile infection(167).89.5% of CDAD patients 
responded to nitazoxanide therapy, which was better than the 82.4% response rate 
for metronidazole, after a week of therapy in the trial. Furthermore, the sustained 
response to nitazoxanide a month after therapy was comparable to metronidazole 
rates (167).The same authors further investigated the efficacy of nitazoxanide in 
treating CDAD patients who had failed metronidazole treatment. Initially, a 74% 
response rate for nitazoxanide was noted with this patient group. However, 
subsequent recurrence of disease resulted in a final cure rate of 54% for nitazoxanide 
in treating CDAD patients not responding to metronidazole (168).Another recent 
prospective double blind randomized study in 2009, also conducted by Musher et al. 
compared the efficacy of 10 days of nitazoxanide therapy versus 10 days of 
vancomycin therapy with 50 CDAD patients. Patients included in the study were 
those who had confirmed positive tests for C. difficile toxins, had more than three 
unformed stools within a 24 hour period and presented with at least one of the 
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following: abdominal pain, fever or leukocytosis (169).   Response rates of 77% for 
nitazoxanide and 74% for vancomycin were noted initially. Initial response rates in 
the study were defined as the absence of any CDAD symptoms between days 11-13 
(169). Amongst the patient group who completed nitazoxanide and vancomycin 
therapy, 94% and 87% final response rates were noted respectively. One patient 
treated with nitazoxanide and 2 patients treated with vancomycin displayed relapse 
of disease. Although a small sample size was used in the study, acknowledged by the 
investigators, the findings of the study led to the conclusion that nitazoxanide was 




Tigecycline, a derivative of minocycline, is a drug which undergoes very little 
metabolism, resulting in a large percentage of the active compound being excreted in 
the faeces (170). In a study by Baines et al. using a human gut model, tigecycline 
prevented the growth of C. difficile and consequent toxin production (171).Similar 
observations were made by Jump et al. studying tigecycline using a mouse model of 
infection (172). A few case reports have described the success of tigecycline in 
combination with other antibiotics, in treating CDAD in patients failing conventional 
metronidazole and vancomycin therapy (173, 174) while another study has 
highlighted the success of tigecycline on its own in resolving CDAD (170). One 
report however stated that tigecycline administration for as long as 14 days still 
failed to treat a case of CDAD (175).Despite a few case reports highlighting the 
success of tigecycline and rifaximin, the guidelines drafted by the SHEA/IDSA in 
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2010 do not include tigecycline, rifaximin or linezolid as part of CDAD therapeutic 
options (139). 
       
Ramoplanin 
Ramoplanin is a lipoglycodepsipeptide antibiotic which was developed as an oral 
agent for use in patients colonized with vancomycin-resistant enterococci but also 
exhibits potent anti-C. difficile activity mediated through the inhibition of cell wall 
synthesis (25, 176).Using a hamster model of C. difficile-induced colitis, Jabes and 
co-workers reported that ramoplanin was a better treatment choice than vancomycin, 
while in a separate study, Freeman and co-workers found the efficacy of ramoplanin 
to be comparable to vancomycin in hamster models of infection (177, 25).
,
 The study 
by Freeman et al. showed that administration of ramoplanin resulted in a resolution 
of symptoms in a hamster model of CDAD and a reduction in toxin titre in an in 
vitro gut model (25). The study also showed the superior efficacy of ramoplanin over 
vancomycin against C. difficile spores, as spores were recovered less often from the 
ramoplanin-treated hamsters, compared to vancomycin-treated hamsters (25).
 
Doses 
of 200-400mg of ramoplanin administered twice a day for 10 days were effective 
and comparable to vancomycin for the treatment of CDAD, according to a phase II 
trial (178). Although ramoplanin is not yet used to treat CDAD, it may eventually 





Bacteriocins against C. difficile 
Bacteriocins are ribosomally synthesised antimicrobial peptides with either narrow 
spectrum or broad spectrum activity against other bacteria (179).
 
To date, the activity 
of a few bacteriocins has been assessed against C. difficile. Bacteriocins, due to their 
ribosomally-synthesised nature, can also be the subject of bioengineering strategies 
to find derivatives with ameliorated bioactivity against specific bacterial targets, 
such as C. difficile. Furthermore, some probiotic strains have the ability to produce 
bacteriocins in situ. Since bacteriocins are currently not used in the clinic against C. 
difficile, the development of resistance amongst target C. difficile strains has not 
been a problem thus far. When considering the use of bacteriocins as an 
alternative/adjunctive therapeutic option for CDAD, the mode of delivery of the 
bacteriocin to the colon must be carefully evaluated. Encapsulation of the bacteriocin 
may be a means to overcome proteases. It must be noted that the anti-C. difficile 
activities of the bacteriocins described herein are predominantly based on in vitro 




Thuricin CD is a recently discovered bacteriocin with potent narrow spectrum 
activity against C. difficile (180). The main advantage of thuricin CD is that its 
antimicrobial activity is largely restricted to C. difficile and has little or no impact on 
other commensal gut microbes. This was demonstrated using a model of the human 
distal colon and a high-throughput sequencing approach which revealed that thuricin 
CD had minimal impact on the numbers of Firmicutes, Bacteroidetes and 
38 
Proteobacteria, compared to vancomycin and metronidazole which elicited a 
decrease in Firmicutes and Bacteroidetes numbers, concomitant with an increase in 
Proteobacteria numbers (181).  
 
Nisin and lacticin 3147 
Nisin is a member of the lantibiotic family of bacteriocins with broad spectrum 
antimicrobial activity against a range of Gram-positive bacteria, including antibiotic-
resistant bacteria and food pathogens (182).Studies by Field et al. showed that a 
bioengineered derivative of nisin A, designated M21V, displayed more potent 
antimicrobial activity against a variety of Gram-positive pathogens, including C. 
difficile R027, compared to wild type nisin A (182). Lacticin 3147 is a two-peptide 
lantibiotic produced by Lactococcus lactis DPC 3147 (183).It has a broad spectrum 
of antimicrobial activity against Gram-positive pathogens.  Lacticin 3147 seems to 
trigger a rapid lysis of log phase C. difficile cells, measured by quantifying the 
release of acetate kinase. Addition of high lacticin 3147 concentrations of 6 µg/ml 
results in the decrease of C. difficile ATCC 43593 cell numbers from 10
6 
cfu/ml to 
zero in 2 hours. Subsequent studies with lacticin 3147 using a model of the human 
distal colon showed that it caused a decrease in Firmicutes numbers with a 
concomitant increase in Proteobacteria numbers (181).
 
 
Actagardine and NVB302  
Actagardine A is a 19-amino acid lantibiotic with potent antimicrobial activity 
against Gram-positive bacteria, including C. difficile. A bioengineered V15F 
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derivative of actagardine A exhibited lower MIC values against the same C. difficile 
targets compared to the wild type actagardine (184). NVB302 is a semi-synthetic 
type B lantibiotic, derived from actagardine and is effective against C. difficile. 
Crowther et al. conducted a recent study investigating the efficacy of NVB302 
compared to vancomycin in treating CDAD employing an in vitro gut model (185). 
The gut microbiota count as well as the C. difficile viable counts and spores were 
enumerated following NVB302 and vancomycin administration and a decrease in 
viable C. difficile counts with vancomycin and NVB302 administration was noted.  
NVB302 performed better than vancomycin as cytotoxin levels were undetectable 7 
days subsequent to NVB302 administration compared to undetectable cytotoxin 
levels 5 days after vancomycin instillation. C. difficile spores did not germinate 
following either vancomycin or NVB302 instillation (185).
 
 
LFF571 (GE2270 derivative) 
GE2270 is a thiopeptide bacteriocin which inhibits translation in bacteria 
(186).LFF571 is a semi-synthetic derivative of the thiopeptide GE2270, developed 
by Novartis, which displays antimicrobial activity against a range of Gram-positive 
bacteria, including C. difficile (187). The in vivo activity of LFF571 against C. 
difficile was compared with vancomycin in a study with Golden Syrian hamster 
models (188).
 
LFF571 was administered orally 24 hours post-infection. Doses of 0.2, 
1, 2, 5 or 10mg/kg of LFF571 were used. Administration of 5mg/kg LFF571 resulted 
in a 71% initial response rate, whereby 5 out of the 7 hamsters survived after 21 
days, while 37.5% of animals survived 21 days when treated with 20mg/kg 
vancomycin. In terms of recurrence rates, LFF571 once again fared better than 
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vancomycin. Only 2.2% of hamsters had recurrence at the conclusion of treatment 
with 5mg/kg LFF571, whereas 37.8% of hamsters which survived at the termination 
of treatment with 20mg/kg vancomycin, experienced recurrence (188).  
Recently, a randomized double blind trial was conducted, investigating the efficacy 
and safety of LFF571 in healthy volunteers (189).Encouragingly, no serious side 
effects of LFF571 were noted amongst 56 volunteers. LFF571 largely remained in 
the gut with very low concentrations noted in serum (the highest concentration being 
3.2ng/ml in serum in one volunteer). Moreover, LFF571 was tolerated equally well 
irrespective of single or multiple doses in healthy volunteers participating in the 
study (189).
 
A summary of MIC values of antibiotics being investigated to replace 
metronidazole/vancomycin as well as various bacteriocins against C. difficile, as 
reported in published studies, is included in Table 3.  
 
Faecal transplantation 
Since the main risk factor for acquiring CDAD appears to be the perturbation of the 
gut microbiota due to broad spectrum antibiotics, and subsequent overgrowth of C. 
difficile, the restoration of the intestinal microbiota via faecal transplantation/faecal 
bacteriotherapy seems like an appropriate therapeutic option.  Faecal bacteriotherapy 
is the process of introducing faeces from a healthy donor, in a liquid suspension, into 
the GIT of a patient (200).
 
Typically, patients considered for faecal bacteriotherapy 
are those who have confirmed C. difficile colitis and have had at least two relapses 
following antibiotic therapy. Stool donors are screened for HIV-1, HIV-2, hepatitis 
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A, B, C and faecal samples tested for bacterial/parasitic pathogens such as 
Salmonella, C. difficile, S. aureus (200, 201).The majority of cases of faecal 
transplantation occur through the rectum, but nasogastric, nasoduodenal, nasojejunal 
instillations are common as well.  250mg of vancomycin every 8 hours for 4 days 
and two 20mg doses of omeprazole per day for 4 days are administered to the 
transplant recipient to decrease C. difficile numbers and allow the introduced bacteria 
to colonize by decreasing acid production in the stomach and consequently elevating 
the pH, in the event of nasogastric instillations (202-204).  The treatment success 
rate of faecal bacteriotherapy for recurrent CDAD has been reported to be 
approximately 90% in a study involving 18 subjects, while a response rate of 100% 
was reported when 12 recurrent CDAD patients were treated with faecal 
bacteriotherapy in a separate study (200, 205). Over the last 5 years, investigators 
who have used faecal transplantation to treat recurrent cases of CDAD have reported 
success rates ranging from 86-100% (201, 205-207).The first clinical trial comparing 
faecal bacteriotherapy against vancomycin was recently conducted by van Nood et 
al. and an 81% success rate for faecal bacteriotherapy after the first infusion (13/16 
cases resolved) was significantly better than the 31% success rate found for 
vancomycin alone (208).A mix of 33 different bacteria from healthy stool samples 
was effective in treating CDAD in two patients, in a recent study (209). The 
etiological agent of the recurring diarrhoea should be confirmed to be C. difficile 
before considering faecal bacteriotherapy as a treatment option.  
Faecal bacteriotherapy can lead to alterations in the composition of the gut 
microbiota. A rise in Bacteroides, Faecalibacterium and Roseburia with a 
concomitant decrease in Enterobacteriaeceae in C. difficile patients who are treated 
with faecal bacteriotherapy is common (206). Hamilton et al. also noted a rise in 
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Bacteroidetes and Firmicutes numbers in 3 patients treated with FMT (207).An 
increase in Bacteroidaceae, Porphyromonadaceae and Rikenellaceae families of the 
Bacteroidetes phylum, accompanied by an increase in Ruminococcaceae and 
Lachnospiraceae families of the Firmicutes phylum following FMT were noted in a 
study and it has been hypothesised that the presence of such families is associated 
with gastrointestinal health (207).  
In vivo studies involving mouse trials can also be invaluable in terms of providing 
information and optimizing successful FMT procedures. Six different bacteria were 
used to cure C. difficile R027-infected mice, in a recent in vivo trial (210). During 
CDAD resolution, four out of the six bacterial strains managed to colonize the mice 
while several other commensals also proliferated, increasing the microbial diversity 
in doing so. Despite the promising in vivo and clinical trial outcomes, there has been 
a general reluctance in resorting to faecal bacteriotherapy amongst both patients and 
doctors due to the unattractive nature of the procedure, as well as the extensive 
screening of donor samples for pathogens that is required prior to transplantation 
(211).Banking of frozen stool samples which have already been screened for the 
presence of pathogens, may be a means of expediting the  processes involved in 
performing FMT for CDAD cases. 
 
CONCLUSIONS 
The overuse of broad spectrum antibiotics has led to numerous C. difficile outbreaks, 
especially in North America, Canada and Europe over the last two decades. The 
advent of next-generation sequencing technology in recent years has helped to 
emphasise the extent of damage caused to the gut microbiota due to broad spectrum 
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antibiotics. The perturbation of the gut microbiota as a result of antibiotics removes 
the most potent defence against opportunistic pathogens such as C. difficile i.e. the 
presence of a fully intact gut microbiota. This often leads to a continuous cycle of 
CDAD and recurrence, as further treatment with broad spectrum antibiotics inhibits 
the restoration of the commensal gut microbiota, leading to acquisition of CDAD 
again. Thus, it is clear that there is an urgent need to develop alternative/adjunctive 
therapeutic options to metronidazole and vancomycin in order to circumvent this 
ongoing problem of recurrence of disease. Fidaxomicin has already been proved to 
have promising efficacy as a therapeutic for CDAD. Other antibiotics such as 
ramoplanin, nitazoxanide, tigecycline and the rifamycin group have shown potent in 
vitro activity and some promising in vivo results against C. difficile and research is 
ongoing regarding their clinical efficacy against CDAD. Development of these 
alternative antibiotics is crucial as the overuse of the current antibiotics 
metronidazole and vancomycin may lead to development of resistance amongst C. 
difficile targets. Furthermore, there is an inherent risk with the overuse of 
vancomycin with respect to the spread of vancomycin-resistant enterococci in 
hospital environments.  
The restoration of the commensal gut microbiota using faecal bacteriotherapy has 
also shown encouraging results in recent years. Faecal bacteriotherapy has 
tremendous potential in this regard, as it directly tackles the root cause of the 
problem i.e. dysbiosis caused by broad spectrum antibiotics, resolved by restoring 
the commensal microbiota via faecal transplantation. Perhaps the most elusive 
therapeutic option over the years to arrest the cyclic pattern of relapse and recurrence 
of CDAD, however, has been a narrow spectrum antimicrobial with potent anti-C. 
difficile activity and lack of activity against the commensal gut microbiota. It may be 
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the case that a narrow spectrum antimicrobial targeted against C. difficile and/or 
restoration of the gut microbiota via FMT may eventually prove to be the most 
effective treatment regimens for CDAD. Overall, due to the vast number of studies 
investigating anti-C. difficile therapeutic options in recent years, scientists are closer 
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Tables and Figures:  
Table 1: Common diagnostic and typing tests to detect C. difficile and toxins. 
Summary of diagnostic methods used to detect C. difficile, its toxins or a 
combination thereof. Common typing methods are also included.  
Diagnostic methods Detection 
Toxin -culture Toxigenic C. difficile 
EIA
a
-toxin A or A/B Toxin A or A/B 
EIA-GDH (Glutamate dehydrogenase) C. difficile 
EIA-GDH + EIA toxin A/B C. difficile & toxins 
RT-PCR
b
 toxin A/B gene Toxigenic C. difficile 




Toxin genes (usually tcdB) 
Typing methods Principle 
Ribotyping PCR amplification of spacer regions of 
16S and 23S rRNA 
Toxinotyping RFLP-PCR
d
 analysis of toxin genes 
taking into account any mutations within 
the toxin genes 
REA
e 
Use of restriction enzymes that cut 
bacterial genomic DNA at frequent sites, 




Use of a restriction enzyme that cuts 
genomic DNA at infrequent sites leading 
to large DNA fragments 
MLST
g 




Based on number of repeat alleles 
present in the genome following PCR 
amplification of conserved loci 
AFLP
i 
Use of restriction enzymes to cut 
genomic DNA and subsequent ligation 
of adaptors to restricted fragments 
a
EIA, enzyme immunoassay; 
b
RT-PCR, real-time polymerase chain reaction; 
c
NAATs, nucleic acid amplification tests; 
d
RFLP-PCR, restriction fragment length 
polymorphism-polymerase chain reaction; 
e
REA, restriction endonuclease analysis; 
f
PFGE, pulsed-field gel electrophoresis; 
g
MLST, multi-locus sequence typing; 
h
MLVA, multilocus variable number tandem repeat analysis; 
i
AFLP, amplified 
fragment length polymorphism.  
84 
Table 2: List of C. difficile toxinotypes. Toxinotypes of C. difficile and toxin 
production profiles. Adapted from http://www.mf.uni-mb.si/mikro/tox/, Rupnik et al. 




 denote Toxin A and Toxin B production 
respectively. CDT
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Table 3:  Summary of minimum inhibitory concentration values (MIC) of anti-
C. difficile antibiotics and bacteriocins. In vitro MICs of alternative antibiotics to 
metronidazole and vancomycin as well as as in vitro MICs of bacteriocins and 
bioengineered derivatives thereof against C. difficile strains as reported in the 
literature.  

































0.03-0.25 (MIC90) 157,195,196 
Ramoplanin Lipoglycodepsipe
ptide 
Inhibition of cell 
wall synthesis 
0.03-0.5 (MIC90) 197 




Thuricin CD Sactibiotic  Unknown 0.7-2.8 198 
Nisin A Lantibiotic Inhibition of cell 








Inhibition of cell 
wall synthesis and 
pore formation 
4.19 182 
Lacticin 3147 Lantibiotic Inhibition of cell 
wall synthesis and 
pore formation 
3.6(MIC50) 183 
Actagardine A Lantibiotic Inhibition of cell 
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 Figure 1A: Clostridium difficile pathogenicity locus (PaLoc). 
Schematic organization of the C. difficile PaLoc, which is 19.6kb in length.  tcdA 
and tcdB (shaded in grey) are the two genes encoding the two large C. difficile 
toxins, TcdA and TcdB respectively. tcdR (dashed outline) encodes a positive 
regulator of transcription, whereas tcdC (dashed outline) encodes a putative negative 
regulator/modulatory protein. tcdE (shaded in white) encodes a holin protein. 
Adapted from Dupuy et al. (107) and Carter et al. (108). 
 
Figure 1B: Binary toxin (Cdt) locus.  
Schematic organization of the binary toxin locus (6.9kb in length), typically found in 
outbreak-associated R027 strains. cdtA and cdtB (shaded in grey) are the two toxin 
genes. cdtR (dashed outline) is the regulatory gene, involved in controlling the 
amount of binary toxin produced.  Adapted from Carter et al. (108).  
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Clostridium difficile is a nosocomial pathogen and is the etiological agent of C. 
difficile-associated diarrhea (CDAD) and pseudomembranous colitis. The current 
antibiotics of choice to treat C. difficile infection are vancomycin and metronidazole. 
Other antimicrobial agents with anti-C. difficile activity, such as thuricin CD, 
actagardine and ramoplanin, are at various stages of development. The sensitivity of 
a collection of clinical C. difficile isolates to these antimicrobials, both individually 
(minimum inhibitory concentrations) and in pairs (fractional inhibitory concentration 
index), was assessed using the checkerboard microdilution method. The specific 
activity of thuricin CD against C. difficile strains was determined for the first time 
and molar minimum inhibitory concentration values revealed it to consistently be the 
most or second most active antimicrobial tested, after ramoplanin. 34 cases of partial 
synergistic/additive effects were evident out of a total of 117 combinations assessed 
(29%). The most promising partial synergistic/additive effects were observed when 
ramoplanin and actagardine were combined.  8 of the 13 strains (61.5%) tested 











The commensal gut microbiota plays a crucial role in the protection of the host 
against pathogens by means of ‘colonization resistance’ (1). Perturbations of this gut 
microbiota due to overuse of broad spectrum antibiotics can have deleterious effects 
(2, 3, 4, 5). Such disruptions of the commensal gut flora provide opportunities for the 
overgrowth of the opportunistic pathogen Clostridium difficile. C. difficile is the 
etiological agent responsible for approximately 20% of cases of antibiotic-induced 
diarrhea (AAD) and has been implicated in approximately 90% of cases of 
pseudomembranous colitis (PMC)(6). The initial treatment regimen for a positive C. 
difficile toxin test and AAD involves the expeditious discontinuation of the 
offending antibiotic. If the CDAD is mild, 500mg of metronidazole is recommended 
every 8 hours for 10 days and, in more severe cases, 125mg of vancomycin is 
administered every 6 hours for 10 days (7).  However, treatment failure (14.2% for 
vancomycin; 22.4% for metronidazole) and recurrence of CDAD (24% for 
vancomycin; 22.4% for metronidazole) are serious concerns in the clinical setting 
(8). The danger of the emergence of vancomycin-resistant clostridia and 
dissemination of vancomycin-resistant enterococci in clinical settings also make it an 
unattractive treatment choice for mild to moderately severe cases of CDAD (9).  
Thus, it is becoming increasingly more important to find other antimicrobials and/or 
effective antimicrobial combinations against C. difficile. Indeed, investigations 
involving fidaxomicin, rifampicin, fusidic acid and teicoplanin have been reported 
(10, 11, 12). With respect to combinations of antimicrobials, Bacon et al. (13) 
reported synergistic activity against 85% of C. difficile strains tested when rifampin 
was combined with bacitracin in vitro but Hames et al. (14) found a fractional 
inhibitory concentration index (FIC) of 1.5-3, i.e. an indicator of indifference, when 
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metronidazole and vancomycin were combined. Lagrotteria et al. (9) combined 
metronidazole and rifampin in a randomised clinical trial on patients presenting with 
early stage CDAD but synergistic effects (15) were not observed.  Although 
tigecycline and rifaximin have shown promising antimicrobial effects against C. 
difficile in vitro, recurring disease has been an issue when administered to patients 
(16, 17).  
In recent years the potency of a number of peptides against C. difficile has also been 
highlighted. Thuricin CD is a sactibiotic (a novel class of post-translationally 
modified bacteriocins) (18) which exhibits narrow spectrum antimicrobial activity 
against C. difficile isolates (19). As thuricin CD has little impact on other 
gastrointestinal microorganisms it has been suggested that the recurrence of CDAD, 
which has been linked with further rounds of antibiotic-mediated microbial 
perturbations, will be less likely. Actagardine is a member of another group of 
modified bacteriocins, the lantibiotics. It is active against a range of Gram-positive 
pathogens such as C.difficile, Staphylococcus aureus, Streptococcus pneumonia and 
enterococci (20, 21). Finally, ramoplanin is a glycolipodepsipeptide, which displays 
potent antimicrobial activity against C. difficile as well as a number of other targets 
(22, 23, 24).  Ramoplanin, like vancomycin, functions by targeting lipid II in 
bacterial cell envelopes but, importantly, binds in a manner which is distinct from 
that of vancomycin (25). Notably, it has been established that ramoplanin remains 
active against C. difficile strains which are relatively resistant to vancomycin or 
metronidazole (22) and performs well in a hamster model of C. difficile-induced 
colitis (26). Also, a recent clinical study has shown that pseudomembranous colitis 
(PMC) patients failed to absorb ramoplanin from their GIT, suggesting that its 
antibacterial activity remained largely localized in the gut (23). 
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Here we compare the in vitro activity of thuricin CD, actagardine, ramoplanin, 
metronidazole and vancomycin against clinical isolates of C. difficile and use 
checkerboard assays to assess the consequences of using combinations of pairs of 

















Materials and Methods 
Sources of antimicrobials 
Thuricin CD was purified as in Rea et al. (18) with some minor modifications. Brain 
Heart Infusion (BHI) broth was clarified using Amberlite XAD-16 beads (Sigma 
Aldrich). A single colony of Bacillus thuringiensis DPC 6431 was inoculated into 
10ml BHI broth and incubated for 16 hours at 37°C with agitation. The overnight 
culture was sub-cultured twice and 0.1% was sub-cultured into 1L of clarified BHI 
and incubated at 37°C for 16 hours. The overnight culture was centrifuged at 
8000rpm for 15 minutes and the cell free supernatant was passed through 60g of 
Amberlite beads pre-washed with 1L of distilled water. The beads were washed with 
500ml of 40% ethanol and the active fraction eluted in 400ml of 70% isopropanol 
(IPA) supplemented with 0.1% trifluoroacetic acid (TFA). The cell pellet was treated 
with 250ml of 70% IPA, 0.1% TFA at 4°C for 4 hours and centrifuged at 8000rpm 
for 15 minutes. Supernatant S1 (cell extract resuspended in isopropanol) and 
supernatant S2 (passed through Amberlite beads) were combined and the 
isopropanol was removed by rotary evaporation (Buchi). The remaining solution was 
passed through a C-18 column, pre-equilibrated with 60ml of methanol and 60ml of 
water. The C-18 column was washed with 120ml of 40% ethanol and the active 
fraction eluted in 100ml of 70% IPA, 0.1% TFA. This preparation was further 
concentrated by rotary evaporation, prior to separation of the α α and β peptides by 
HPLC. 4ml aliquots of concentrated preparation were added to a Vydac C8 reverse 
phase HPLC column (250 x 10mm, 5µ), which was previously equilibrated with 
25% acetonitrile and 0.1% TFA.  A gradient of 25% acetonitrile (0.1% TFA) to 75% 
acetonitrile (0.1`% TFA) was developed from 5-40 minutes, using a flow rate of 2.5 
ml/min. Vancomycin, metronidazole and ramoplanin were purchased from Sigma-
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Aldrich (Vale Road, Arklow, Wicklow, Ireland) and actagardine was kindly 
provided by Novacta Biosystems Ltd (BioPark Hertfordshire, Broadwater Road, 
Welwyn Garden City, Hertfordshire, UK). 
 
C. difficile strains 
13 C. difficile clinical isolates were kindly provided by the Wellcome Trust Sanger 
Institute, Hinxton, Cambridge, UK.  6 other C.difficile strains were obtained from 
Moorepark Research Centre Culture Collection.  All C. difficile strains were grown 
on Fastidious Anaerobic Agar (FAA)(LabM Ltd; Lancashire, UK), supplemented 
with 7% defibrinated horse blood (TCS Biosciences Ltd; Botolph Claydon, 
Buckingham, UK) at 37°C in an anaerobic workstation (Davidson & Hardy). The 
strains were allowed to sporulate on the FAA plates for 48-72 hours. Overnight 
cultures were grown in Reinforced Clostridial Medium (RCM) broth (Oxoid Ltd; 
Basingstoke, Hampshire, England) for 16 hours in anaerobic conditions. 
 
Minimum inhibitory concentration (MIC) assays 
MIC assays were conducted as in Field et al. (27), with some minor modifications. 
Thuricin α and β peptides were weighed and resuspended in RCM broth to give a 
stock concentration of 2µM. Metronidazole, vancomycin, ramoplanin were 
resuspended in RCM broth as well. Actagardine was resuspended in 50% RCM 
broth, 50% dimethyl sulphoxide (DMSO). The starting stock concentrations of the 
antimicrobials were as follows: metronidazole (40µM), vancomycin (20µM), 
ramoplanin (5µM), actagardine (50µM). Two-fold serial dilutions in RCM were 
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performed in 96-well microtitre plates in triplicate. Overnight cultures of C. difficile 
were grown in RCM broth for 16 hours at 37°C in an anaerobic workstation. The 
overnight cultures were sub-cultured at 4% into 10ml RCM broth until mid-log 
phase (OD600 of 0.5) was attained, at which point the culture was diluted 1/5000 and 
100µl inoculated into each well in a 96-well plate (inoculum of 5 X 10
5
 cfu/ml) to 
which serially diluted antimicrobial had been added as described above (total volume 
of 0.2ml). The 96-well plate was incubated for 18 hours in an anaerobic workstation 
and the MIC determined. The MIC was defined as the lowest concentration of the 
antimicrobial which completely inhibited the growth of the target C. difficile strain 
after 18 hours. 
 
Broth microdilution checkerboard assay 
The consequences of combining pairs of antimicrobials was assessed using the broth 
microdilution checkerboard assay. These assays were performed as in Orhan et al. 
(28), with some minor modifications. Briefly, two-fold serial dilutions of the 2 
antimicrobial combinations were carried out in the same 96-well plate (whereby 
antimicrobial A was serially diluted from top to bottom and antimicrobial B was 
serially diluted from right to left along the 96-well plate) and inoculated with a C. 
difficile strain in a similar manner to an MIC assay.  The 96-well plate was incubated 
anaerobically for 18 hours and any synergistic, additive, indifferent or antagonistic 
effects were determined. In total, 9 antimicrobial combinations were assessed against 
13 C. difficile clinical isolates (117 checkerboard assays). The following 
combinations were tested against each of the 13 C. difficile strains: Thuricin CD & 
metronidazole, thuricin CD & vancomycin, thuricin CD & ramoplanin, 
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metronidazole & vancomycin, metronidazole & ramoplanin, vancomycin & 
ramoplanin, metronidazole & actagardine, vancomycin & actagardine, ramoplanin & 
actagardine. The fractional inhibitory concentration index (FIC) was calculated as 
follows: FICA + FICB   = (MIC of antimicrobial A in combination/ MIC of 
antimicrobial A alone) + (MIC of antimicrobial B in combination/MIC of 
antimicrobial B alone). FIC indices were interpreted as in Bacon et al. (13) and 
Naghmouchi et al. (29): full synergy (FIC ≤ 0.5), partial synergy (0.5 ≤ FIC ≤ 0.75), 

















Results & Discussion 
While the antimicrobial activity of thuricin CD against C. difficile has been 
highlighted previously, the MIC has not previously been determined. When 
calculated in terms of molar concentrations, the MICs of thuricin CD and ramoplanin 
were consistently lower than that of metronidazole, vancomycin and actagardine for 
all 19 strains tested (Table 1). The ramoplanin MIC value was lowest for 13 targets 
and that for thuricin CD was lowest against 6 strains. These 6 included the 2 
hypervirulent C. difficile ribotype 027 strains CD196 R027 and R20291 027. Of the 
other antimicrobials, the MIC of vancomycin was lower than that of metronidazole 
with respect to 15/19 (79%) of strains assessed and higher than that of metronidazole 
in only one case. It should be noted that, when expressed in μg/ml, the relative 
effectiveness of the antimicrobials differed. This was most notable in the case of 
thuricin CD as a consequence of it consisting of two peptides and thus having a 
higher combined molecular weight. Actagardine was consistently the least active 
antimicrobial. However, it is noteworthy that a V15F derivative of actagardine A has 
recently been found to possess greater anti-C. difficile activity (20) and its activity, 
relative to these other antimicrobials, will merit investigation in the future. In fact, 
the MIC of V15F has been shown to be 2-4-fold lower than its wild type against 4 C. 
difficile strains tested by Boakes et al. (20). The MIC values we obtained for 
actagardine against the 19 C. difficile strains tested ranged from 1.477 µg/ml to 
11.813 µg/ml. Bacon et al. (13) found that the MIC for vancomycin was less than or 
equal to 1.6 µg/ml  and the MIC for metronidazole ranged from 0.8-3.2 µg/ml for 
their 47 C. difficile strains. Others have reported MIC values of between 0.125-2 
µg/ml for vancomycin (30) and 0.032-1.0 µg/ml for metronidazole against C. 
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difficile isolates (31). Our MIC values for vancomycin ranged from 0.464-1.856 
µg/ml and corresponding metronidazole values from 0.084-0.428 µg/ml. Peláez et al. 
(22) reported MIC50 and MIC90 values for ramoplanin against C. difficile strains 
ranging from 0.03-0.5 µg/ml. We determined that MIC values for ramoplanin against 
the 19 C. difficile strains we tested were between 0.088-0.704 µg/ml. 
 
In a previous in vitro antimicrobial combination study with C. difficile, Bacon et al. 
(13) observed that bacitracin and rifampin combinations were most effective as 
synergistic effects were obtained against 29 out of the 34 C. difficile strains tested 
(85%). However, the authors found that metronidazole-rifampin combinations and 
vancomycin-rifampin combinations were less effective, yielding mainly indifferent 
effects. Here, out of the 117 checkerboard assay antimicrobial combinations tested, 
we found 34 cases (29.05%) of partial synergy/additive effects (0.5≤FIC ≤1.0). No 
antagonistic effects were observed (FIC index > 2.0). The other 83 out of the 117 
combinations (70.94%) yielded indifferent effects (1.0≤ FIC≤ 2.0). 8 of the 
antimicrobial combinations were additive against at least one strain, but thuricin CD-
metronidazole combinations had indifferent effects against all 13 strains tested.  The 
most promising partial synergistic/additive effects were apparent when actagardine 
and ramoplanin were combined in that 8 of the 13 (61.5%) strains tested provided 
FIC indices of between 0.5-1.0. Furthermore, metronidazole and actagardine 
produced partial synergism/additive effects against 7 of 13 strains (53.4%) tested. 
Vancomycin and actagardine combinations gave a mixture of partial 
synergism/additivity (38.46%) and indifferent results. Additive effects were 
observed for 5/13 strains (38.46%) tested with a combination of ramoplanin and 
vancomycin. Indeed, ramoplanin-vancomycin, along with ramoplanin-actagardine, 
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metronidazole-vancomycin and actagardine-vancomycin combinations, yielded 
additive effects against the most notorious hypervirulent R027 strains. The lowest 
FIC index obtained was 0.5, an indicator of full synergy, which was observed when 
ramoplanin was combined with actagardine against C. difficile Liv022 R106. FIC 
indices of 0.508 were also obtained with ramoplanin-actagardine combinations 
against C. difficile CD196 R027, C. difficile CD305 R023 strains and vancomycin-
actagardine combinations against C. difficile CD196 R027.  Thuricin CD seemed to 
be most effective when combined with ramoplanin (4 cases of partial 
synergism/additivity out of 13 strains) and 2 cases of partial synergism/additivity 
were evident when thuricin CD was combined with vancomycin. Metronidazole-
ramoplanin combinations only yielded 1 case of additive effects.  FIC indices of 1.0 
were noted for 2 of the 13 strains with metronidazole and vancomycin combinations. 
In contrast, Hames et al. (14) consistently observed indifferent effects with such a 
combination against all C. difficile strains tested in their study. The absence of 
antagonism is reassuring as it indicates that there are no deleterious effects when the 
antimicrobials tested are combined.  
 
The frequency of relapses and recurrences of CDAD following treatment with 
vancomycin and metronidazole has prompted the search for and development of new 
antimicrobials to treat the disease. In particular, there are serious concerns about the 
newly emerged hypervirulent R027 strains which are characterized by their 
fluoroquinolone resistance and binary toxin production. It is apparent that 
ramoplanin and thuricin CD, both alone and in combination, exhibit considerable 
anti-C. difficile activity. A number of other partial synergistic/additive effects are 
also apparent. These antimicrobials, combinations, or other combinations involving 
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rifamycin or fidaxomicin, may ultimately lead to novel chemotherapeutic treatments 
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Table1: MIC values of thuricin CD, metronidazole, vancomycin, ramoplanin and 
actagardine against 19 C. difficile strains (including 13 clinical isolates). 
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Table2: FIC values of various combinations of antimicrobials against 13 C. difficile 
clinical isolates.  








T-VAN ΣFIC Activity T-R 
ΣFIC 
Activity 
CF5 R017  1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 
M68 R017  1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 
630 R012  1.01-2.0    I 1.01-2.0    I 0.75    PS 
CD305 R023  1.01-2.0    I 1.01-2.0    I 0.625    PS 
M120 R078  1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 
Liv024 R001  1.01-2.0    I 0.625    PS 1.0    Ad 
Liv022 R106  1.01-2.0    I 1.0    Ad 1.01-2.0    I 
CD196 R027 1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 
TL178 R002 1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 
TL174 R015 1.01-2.0    I 1.01-2.0    I 0.625    PS 
20291R027 1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 
TL176 R014 1.01-2.0    I 1.01-2.0    I 1.01-2.0    I 





Activity M-R  
ΣFIC 
Activity VAN-R   
ΣFIC 
Activity 
CF5 R017  1.01-2.0    I 1.01-2.0    I 1.01-2.0 I 
M68 R017  1.01-2.0    I 1.01-2.0    I 1.01-2.0 I 
630 R012  1.01-2.0    I 1.01-2.0    I 1.0 Ad 
CD305 R023  1.01-2.0    I 1.01-2.0    I 1.01-2.0 I 
M120 R078  1.01-2.0    I 1.01-2.0    I 1.0 Ad 
Liv024 R001  1.01-2.0    I 1.01-2.0    I 1.0 Ad 
Liv022 R106  1.01-2.0    I 0.75    PS 0.75 PS 
CD196 R027 1.0    Ad 1.01-2.0    I 1.01-2.0 I 
TL178 R002 1.01-2.0    I 1.01-2.0    I 1.01-2.0 I 
TL174 R015 1.01-2.0    I 1.01-2.0    I 1.01-2.0 I 
20291R027 1.01-2.0    I 1.01-2.0    I 1.0 Ad 
TL176 R014 1.0    Ad 1.01-2.0    I 1.01-2.0 I 
BI-9 R001 1.01-2.0    I 1.01-2.0    I 1.01-2.0 I 
C.difficile  
strain 
M-A   
ΣFIC 
Activity VAN-A   
ΣFIC 
Activity R-A   
ΣFIC 
Activity 
CF5 R017  1.0 Ad 1.0 Ad 0.625 PS 
M68 R017  1.0 Ad 1.01-2.0 I 1.01-2.0 I 
630 R012  1.0 Ad 1.01-2.0 I 1.01-2.0 I 
CD305 R023  1.01-2.0 I 1.01-2.0 I 0.508 PS 
M120 R078  1.0 Ad 1.0 Ad 0.75 PS 
Liv024 R001  1.0 Ad 1.01-2.0 I 1.01-2.0 I 
Liv022 R106  1.0 Ad 1.01-2.0 I 0.5 S 
CD196 R027 1.01-2.0 I 0.508 PS 0.508 PS 
TL178 R002 1.01-2.0 I 0.75 PS 0.75 PS 
TL174 R015 1.01-2.0 I 1.0 Ad 1.0 Ad 
20291R027 1.01-2.0 I 1.01-2.0 I 1.01-2.0 I 
TL176 R014 0.75 PS 1.01-2.0 I 0.75 Ad 
BI-9 R001 1.01-2.0 I 1.01-2.0 I 1.01-2.0 I 
       
       
a
T, thuricin CD; M, metronidazole; VAN, vancomycin; R, ramoplanin; A, 
actagardine 
b
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Bacteriocins are ribosomally synthesised peptides that can have a narrow or broad 
spectrum of antimicrobial activity. Bacteriocin producers typically possess dedicated 
immunity systems which often consist of an ATP-binding cassette (ABC) transporter 
system and/or a dedicated immunity protein. Here, we investigate the genes 
responsible for immunity to thuricin CD, a narrow spectrum two-peptide sactibiotic 
produced by Bacillus thuringiensis DPC6431.  Heterologous expression of putative 
thuricin CD immunity determinants allowed us to identify and investigate the 
relative importance of the individual genes and gene products that contribute to 
thuricin CD immunity. We establish that TrnF and TrnG are the individual 
components of an ABC transporter system that provides immunity to thuricin CD. 
We also identify a hitherto overlooked open reading frame located upstream of trnF 
predicted to encode a 79 amino acid transmembrane protein.  We designate this 
newly-discovered gene trnI and establish that TrnI alone can provide protection 










Thuricin CD is a two-peptide bacteriocin produced by Bacillus thuringiensis 
DPC6431 with potent narrow spectrum activity against Clostridium difficile clinical 
isolates, including hypervirulent strains (1). Both thuricin CD peptides, Trnα and 
Trnβ, are post-translationally modified resulting in the formation of three sulphur to 
α-carbon bridges in each peptide (2). As a consequence of this characteristic feature, 
thuricin CD has been classified as a member of a novel class of bacteriocins 
designated sactibiotics (sulphur to alpha-carbon) (3). Other sactibiotics include 
subtilosin A and propionicin F (4, 5). Previous studies with thuricin CD have shown 
that it is as effective as vancomycin and metronidazole in reducing C. difficile 
numbers in a human distal colon model but, in contrast to the broad-spectrum 
antibiotics, it did not dramatically impact on other members of the gut microbiota 
(6). This narrow spectrum activity is advantageous as one of the main causes of C. 
difficile-associated diarrhea (CDAD), and its recurrence, is the ‘collateral damage’ to 
gut microbes caused by conventional broad spectrum antibiotics. Although the 
putative thuricin CD gene cluster has been identified on the basis of bioinformatics 
analysis, the contribution of the individual genes has not been established (1). 
Bacteriocin gene clusters typically contain dedicated immunity genes, required to 
protect the producer from self-destruction. In the case of bacteriocins from the 
lantibiotic and other bacteriocin families, these immunity systems typically consist 
of immunity proteins (designated LanI in lantibiotics) and/or ABC transporter 
systems (designated LanFE(G) in lantibiotics) (7). These LanI immunity proteins 
and LanFE(G) ABC transporter systems can act independently or in concert with 
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each other (7, 8). A non-essential LanH protein is sometimes encoded within 
lantibiotic gene clusters and functions as an ancillary protein in order to contribute to 
assembly of a fully functional ABC transporter system (9). ABC transporter systems 
represent the most common family of proteins found in nature. They typically 
consist of two highly conserved cytoplasmic ATP binding domains and two 
hydrophobic integral membrane domains (7). 
Perhaps the most extensively studied bacteriocin immunity system is the NisIFEG 
system associated with the lantibiotic nisin. NisI is a 226 amino acid LanI protein 
associated with nisin immunity (10). There is little or no homology between the LanI 
proteins associated with different lantibiotics, which may explain their highly 
specific nature (10). The NisI protein contains a hydrophobic N-terminal region 
possessing a consensus lipoprotein sequence. About 50% of NisI is bound to the 
outside of the cell membrane, whereas the other 50% is secreted from the cell (11). 
The NisI protein which is not membrane anchored functions by aggregating nisin 
extracellularly, thus providing immunity to the host cell (12, 13). A study with C-
terminally truncated NisI proteins revealed that 21 amino acids located in the C-
terminus are essential in providing specific immunity to nisin (14). This was 
confirmed by the creation of fusion proteins, replacing the C-terminus of SpaI, the 
LanI protein of the subtilin system, with the 21 C-terminus amino acids from NisI. 
These fusion proteins were capable of providing immunity to nisin when expressed 
heterologously in Lactococcus lactis (14). While LanI and LanFE(G) are known to 
function in a co-operative manner in several lantibiotic immunity systems (13, 15),  
it has been shown that while the C-terminus of NisI is directly involved in binding 
nisin, it has no role in co-operating with NisFEG (14). 
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The NisFEG ABC transporter is also involved in nisin immunity (16). NisF contains 
two ATP-binding sites at the N-terminus. NisE and NisG are primarily hydrophobic 
proteins and are thought to form the integral membrane domain of the functional 
ABC transporter system; i.e. the assembled transporter consists of two hydrophobic 
membrane-bound domains (Nis E and G) and two cytosolic ATP-binding subunits (2 
Nis F) (16). Quantification of the cell-bound nisin in Bacillus subtilis cells 
transformed with the nisFEG genes indicated that the nisin ABC transporter acts by 
extruding nisin molecules from the cell membrane and that this function is 
independent of the NisI protein (10, 17). A variety of nisF, nisE, nisG and nisI 
mutants has revealed that NisI has a larger role in immunity (16), with NisI 
providing as much as 80% of total immunity (15, 18).  It should be noted that there 
are several varieties of bacteriocin immunity systems but they all generally involve a 
specialised immunity protein or an ABC-transporter system; e.g. immunity to class 
IIa, IIb and IId bacteriocins is provided by a specialised immunity protein alone, 
whereas an ABC-transporter system alone is responsible for immunity to class IIc 
bacteriocins (19).   
Based on previous in silico analysis of the thuricin CD cluster, it was hypothesised 
that TrnF and TrnG are components of an ABC transporter system and thus may be 
involved either in export of the mature thuricin α and β peptides and/or immunity 
(1). The putative TrnF and TrnG proteins showed 48% and 28% sequence identity to 
ATP binding cassette transporter proteins (ABC transporters) respectively (1). Due 
to the presence of a Walker A consensus motif and a Walker B motif, TrnF was 
hypothesised to act as the ATP-binding component of an ABC transporter system (1, 
20). TrnG was proposed to be an integral membrane component of an ABC 
transporter system.  In light of this, and what is known about ABC transporters, it is 
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predicted that TrnF and TrnG both dimerise and form a complex with one another at 
the cell membrane (20, 21). The last gene identified as part of the thuricin CD cluster 
is trnE. In silico studies revealed that trnE is homologous to the S41-type 
superfamily of C-terminal processing peptidase genes (1). Given the lack of a signal 
sequence, trnE was predicted to have an intracellular function, perhaps involved in 
cleavage of the leader sequence from the Trnβ and Trnα pre-peptides and/or a 
putative immunity function (1). 
In this study, we employ heterologous expression as a means of identifying the genes 
from the thuricin CD cluster that are responsible for providing immunity to the 
sactibiotic (Fig 1A). We establish that an open reading frame (ORF) located 
upstream of trnF, which we have designated trnI, encodes a small dedicated 
immunity protein and that TrnFG likely constitutes a fully functional ABC 
transporter system. Both TrnI and TrnFG respectively provide considerable 












Materials and Methods 
In silico investigations 
In silico investigations of the DNA sequences and amino acid sequences of trnI and 
TrnI respectively, were conducted in order to find homologues using NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov). A list of homologues of TrnI is included in Table 1. 
In depth analysis of the TrnI and TrnG proteins was conducted using the software 
HMMTOP (22), TMHMM (23), SPLIT version 4.0 (24), TMpred (25), SOSUI (26), 
Phobius (Stockholm Biotechnology Centre) and TopPred(MOBYLE)(27, 28) to 
predict the membrane topology of the proteins. A number of servers were also used 
to predict the secondary structure of TrnI including DAS-TMfilter (29), TOPCONS 
(30), PRED-TMR2 (31), GOR (32), SOPMA (33) and Porter (34).  
 
Growth conditions 
E. coli Top10 cells (Invitrogen) were grown in Luria Bertani (LB) broth with 
vigorous agitation at 37°C. B. thuringiensis DPC6431 (1) and Listeria 
monocytogenes 33013 (35) were grown in Brain Heart Infusion (BHI) broth (Oxoid 
Ltd, Basingstoke, Hampshire, England) with agitation at 37°C. Antibiotics were used 
at the following concentrations: chloramphenicol 10 µg/ml for both E. coli and L. 
monocytogenes 33013 transformants.  Bacillus subtilis 168, B. subtilis JH642, B. 
thuringiensis HD2 and B. thuringiensis subsp. monterrey were obtained from the 
Bacillus Genetic Stock Centre (BGSC) and  grown in BHI broth and agar at 37°C. 
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Lactococcus lactis NZ9700 and L. lactis subsp. lactis DPC3147 were grown at 30°C 
in M17 broth and agar (Oxoid Ltd, Basingstoke, Hampshire, England) supplemented 
with 0.5% (wt/vol) glucose (GM17). A list of strains and constructs used in this 
study are included in Table 2. 
 
General molecular biology techniques 
Plasmids were isolated from E. coli Top10 cells utilizing the Roche High Pure 
Plasmid Isolation kit (Roche Diagnostics, Mannheim, Germany), following 
manufacturer’s instructions. Plasmids were isolated from L. monocytogenes 33013 in 
the same manner, following treatment with protoplast buffer (5mM EDTA, 10 
mg/ml lysozyme, 0.75M sucrose, 50U/ml mutanolysin, 20mM Tris-HCl pH7.5). 
Genomic DNA was extracted from B. thuringiensis DPC6431 using the Invitrogen 
PureLink Genomic Extraction kit (Invitrogen, Carlsbad, California, USA). 
Chemically competent E. coli Top10 cells (Invitrogen) were used as intermediate 
hosts for plasmids pNZ44 (36) and constructs. L. monocytogenes 33013 was made 
electrocompetent as in Monk et al. (37) and electroporations were executed using an 
Electro cell manipulator (BTX-Harvard apparatus). Polymerase chain reactions were 
performed using Extensor Hi-Fidelity polymerase (ABgene, Blenheim Road, Epsom, 
UK) using standard procedures. Plasmids and PCR products were digested with the 
relevant FastDigest restriction enzymes (Thermo Scientific). PCR products were 
purified using the GeneJET Gel Extraction Kit (Thermo Scientific). DNA ligations 
were performed using T4 ligase (Roche Diagnostics, Mannnheim, Germany), 
according to manufacturer’s instructions. Transformants were screened by colony-
PCR using 10% Igepal CA-630 (Sigma Aldrich) at 95°C for 12 minutes to access 
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DNA. Colony PCRs were routinely performed using Taq Polymerase (Bioline). 
DNA sequencing to ensure the integrity of the constructs was performed by Source 
BioSciences (Dublin, Ireland). Oligonucleotides used in this study are indicated in 
Table 3. 
 
Creation of truncated trnI, trnF and trnG 
PCRs for cloning were performed using Extensor Hi-Fidelity polymerase (ABgene, 
Blenheim Road, Epsom, UK). Oligonucleotides used in this study are listed in Table 
3. B. thuringiensis DPC6431 genomic DNA was used as a template to facilitate 
creation of N-terminus and C-terminus truncated trnI, trnF and trnG genes. PCR 
products were digested using Fast-Digest restriction enzymes (Thermo Scientific), 
cloned downstream of the P44 constitutive promoter in pNZ44 and transformed into 
chemically competent E. coli Top10 cells. Transformants were plated on LB agar, 
supplemented with 10µg/ml chloramphenicol, screened by colony PCR and 
sequenced to ensure the integrity of the constructs. Electrocompetent L. 
monocytogenes 33013 cells were made as in Monk et al. (37). The constructs were 
introduced into electrocompetent L. monocytogenes 33013 cells to evaluate the 
degree of immunity provided by each of the constructs.  
 
Purification of thuricin CD 
Thuricin CD β and α peptides were purified as in Rea et al. (1), with some minor 
modifications. Following the elution of the preparation containing the antimicrobial 
fraction, the preparation was further concentrated by using a rotary evaporator 
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(Buchi) and trn β and α peptides were separated by HPLC. Briefly, 4ml aliquots of 
concentrated preparation were applied to a Proteo Jupiter reverse phase HPLC 
column (250 x 10mm, 4μ, 90Å), previously equilibrated with 25% acetonitrile 
containing 0.1% trifluoroacetic acid (TFA).  Peptides were eluted from the column 
using a gradient of 25-75% acetonitrile 0.1% TFA over 35 minutes. The flow rate 
was 2.5 ml/min and eluent was monitored at 214 nm. Purified actagardine was 
kindly provided by Novacta Biosciences Ltd.  
 
Minimum inhibitory concentration (MIC) determination 
Broth based MIC assays were conducted as in Field et al. (38) with minor 
alterations. Briefly, L. monocytogenes 33013 wild type strains and recombinant 
constructs were incubated overnight in triplicate in BHI broth at 37°C with agitation. 
These overnights were sub-cultured into fresh BHI broth at 2% and again incubated 
at 37°C with agitation until an OD600 of approximately 0.5 was attained. At this 
point, the cultures were diluted 1/5000 and 100µl inoculated into each well in a 96-
well microtitre plate (inoculum of approximately 5 X 10
5
 cfu/ml) to which two-fold 
serially diluted antimicrobial had been added (total volume of 0.2ml). The 96-well 
plate was incubated for 18 hours at 37°C and the MIC determined. The MIC was 
defined as the lowest concentration of the antimicrobial which completely inhibited 





Kill curve analysis 
Time kill studies were conducted as in Field et al. (38) with some minor changes. 
Overnight cultures containing approximately 10
9
 cfu/ml of the relevant indicator 
strains/constructs were diluted to approximately 10
7
 cfu/ml in a final volume of 1ml 
of BHI broth. A sub-inhibitory concentration of thuricin CD (2.2µM) against the 
relevant indicator was added in this final volume of 1ml and incubated at 37°C. 
Aliquots were taken at time points 60 minutes, 180 minutes and 300 minutes and 
viable cell counts were conducted to enumerate the cell numbers as cfu/ml. Viable 
counts were performed by diluting aliquots 1/10 in BHI broth and enumeration on 
BHI agar plates after 24 hours to calculate the numbers killed due to the specific 
concentration of thuricin CD being tested.  All assays were performed in triplicate.  
 
Accession numbers of thuricin CD immunity proteins 
The accession numbers for the thuricin CD immunity genes are as follows: TrnI, 
KJ507827; TrnF, AED99781.1; TrnG, AED99780.1; TrnE, AED99786.1. The 
newly-discovered immunity protein TrnI (Accession number KJ507827) has been 
submitted to GenBank (February 2014) and is now part of the thuricin CD gene 







In silico analysis of putative thuricin CD immunity determinants 
The thuricin CD gene cluster predicted previously contains seven genes, 
trnFGβαCDE (Fig 1A) (1).  It was predicted that trnF and trnG encode components 
of an ABC-transporter involved in thuricin CD immunity. trnE was predicted to 
encode a C-terminal processing peptidase belonging to the S41-type superfamily (1). 
Here, initial in silico analysis of the gene cluster has highlighted the presence of two 
additional ORFs (orf11 and orf12), located upstream of trnF. It was speculated that 
orf11 may encode a transmembrane protein with a putative immunity function based 
on these in silico analyses. Another ORF (orf12) found between orf11 and trnF was 
not predicted to be a gene due to the presence of a Rho-independent transcriptional 
terminator sequence at the 5’ end of orf12. Despite this Rho-independent 
transcriptional terminator sequence, a ribosome binding site (RBS) was found 
upstream of trnF. A more detailed in silico analysis of orf11 (hereafter referred to as 
trnI) and the associated protein TrnI was carried out, using a variety of 
bioinformatics tools including HMMTOP (22), TMHMM (23), SPLIT version 4.0 
(24), TMpred (25), SOSUI (26), Phobius (Stockholm Biotechnology Centre) and 
TopPred(MOBYLE)(27, 28) as well as the secondary structure prediction servers 
DAS-TMfilter (29), TOPCONS (30), PRED-TMR2 (31), GOR (32), SOPMA (33) 
and Porter (34). 
All of the above-mentioned topology prediction tools strongly predict that TrnI 
contains hydrophobic regions, corresponding to two transmembrane domains 
(TMDs). All predictions indicate that both the N and C-termini of TrnI are located 
intracellularly, with two transmembrane helices (TMD1 and TMD2) spanning the 
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cell membrane (Fig 1B). Other than subtle differences, the predicted location of 
these TMDs is consistent regardless of which in silico tool is used. Using the 
TMpred tool as an example, amino acid residues 26-45 of TMD1 have an outside to 
inside orientation while amino acid residues 51-72 have an inside to outside 
orientation, whereas the TMHMM server predicts that residues 28-45 and 50-72 
form part of the two transmembrane helices respectively, with residues 46-49 located 
extracellularly. Tools used to predict the secondary structure of TrnI support the 
membrane topology prediction tools in that they suggest that TrnI has 
transmembrane properties. An in silico screen for TrnI homologues in other genome 
sequenced strains and translated draft genome sequences was also conducted using 
NCBI BLAST  (http://blast.ncbi.nlm.nih.gov) using both DNA sequences and amino 
acid sequences. Using DNA sequences alone, no homologues of trnI whatsoever 
were obtained using BLASTn. However, when using BLASTp and psi-BLAST, six 
homologues of TrnI were obtained with E-values lower than the default threshold, all 
in Bacillus strains (Table 1). Despite this, no putative conserved domains were found 
using either BLASTn, BLASTp or psi-BLAST. Furthermore, all homologues of TrnI 
were hypothetical unknown proteins in Bacillus strains, which have yet to be 
annotated. No homology to known bacteriocin immunity proteins was apparent. 
 The same topology prediction servers mentioned above were used to predict the 
topology and orientation of the hydrophobic domains of TrnG, the predicted integral 
membrane protein of an ABC-transporter system (Fig 1C). All servers predicted the 
presence of six transmembrane helices. Again, while subtle differences with respect 
to the predicted location of these TMDs were apparent, there was a broad consensus. 
TMD1 was predicted to range from amino acid residue 10 to residue 34, TMD2 
between residues 38-60, TMD3 between residues 80-107, TMD4 between residues 
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111-138, TMD5 between residues 142-167 and TMD6 between residues 177-201. 
All analyses predict that both the N and C-termini of TrnG are found inside the cell. 
In terms of orientations of the transmembrane, all analyses predicted that TMD 1, 3 
and 5 have an inside to outside orientation, whereas TMD 2, 4 and 6 have an outside 
to inside orientation.  
 
Heterologous expression to identify thuricin CD immunity determinants 
To determine the contributions of the products of trnI, trnF, trnG and trnE to 
thuricin CD immunity, the genes were cloned downstream of the constitutive P44 
promoter in pNZ44 (to facilitate continuous expression of the cloned genes) and 
heterologously expressed in the thuricin CD-sensitive strain L. monocytogenes 
33013 (Table 2). The contribution of the respective genes to thuricin CD immunity 
was assessed by MIC assays (Table 4) and time-kill studies (Fig 2). While no 
statistically significant differences (P > 0.05) were observed between any of the L. 
monocytogenes immunity constructs and wild type after 1 and 3 hours of incubation 
in the presence of sub-lethal thuricin CD concentrations (2.2µM), it is apparent after 
5 hours that trnI provides significant protection against thuricin CD, as can be seen 
in Figure 2. Expressing trnI in L. monocytogenes 33013 resulted in an approximately 
1.5 log increase in cell numbers after 5 hours of incubation (P < 0.05), in contrast 
with the wild type L. monocytogenes 33013 strain, whose numbers decreased after 5 
hours (Fig 2). However, trnE and trnG do not confer the same level of protection as 
trnI, with statistically insignificant (P > 0.05) increases in cell numbers even after 5 
hours of incubation in the presence of sub-lethal concentrations of thuricin CD (Fig 
2). These observations are in agreement with MIC values, whereby the MIC against 
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thuricin CD was increased to greater than 18µM in the case of strains expressing 
trnI, compared to only a slight increase in trnG (3µM) and trnE (5µM)-expressing 
strains, relative to the wild type (2.5µM) (Table 4). trnF did not provide any 
protection (Table 4).  
The genes trnFG, trnIF, trnIFG and orf12trnF were also cloned into pNZ44. It was 
apparent that trnFG, trnIFG, trnIF provided significant protection against thuricin 
CD, with MIC values increasing to >18µM (Table 4). However, orf12trnF did not 
confer any protection. These observations are consistent with viable count analyses, 
with statistically significant increases (P < 0.05) in CFU/ml counts noted for trnIF, 
trnFG and trnIFG-expressing strains in the presence of 2.2µM thuricin CD relative 
to the wild type in the presence of thuricin CD after 5 hours of growth (Fig 2). 
pNZ44trnIFG did not provide a greater degree of immunity than pNZ44trnI or 
pNZ44trnFG independently, even after 5 hours. The growth of L. monocytogenes 
33013 wild type in the absence of thuricin CD was comparable to the growth rates of 
L. monocytogenes constructs expressing immunity genes (trnI, trnFG, trnIFG in the 
presence of thuricin CD) (Fig 2). 
Investigations were also carried out to determine if the putative immunity 
determinants conferred any cross-resistance to other bacteriocins including: thuricin 
(produced by B. thuringiensis HD-2), the sactibiotic subtilosin A, as well as the 
lantibiotics actagardine, nisin and lacticin 3147, which possess anti-Listeria activity. 
No cross immunity was apparent, regardless of whether MIC or agar based assays 




Creation of truncated constructs 
In order to gain a better insight into the importance of specific domains within the 
immunity determinants, we created a number of constructs in which regions of the 
genes corresponding to the N- or C-terminus of the associated proteins were 
removed (Table 2). pNZ44trnI∆NT1-13 lacked the first 13 amino acid residues of 
TrnI and pNZ44trnI∆NT1-30 lacked the amino acid residues 1-30. 
pNZ44trnI∆CT64-79 and pNZ44trnI∆CT50-79 lacked residues 64-79 and 50-79 of 
TrnI respectively. pNZ44trnI∆CT64-79 was designed such that the TrnI produced 
would have a truncated transmembrane region (TMD2) whereas the modified TrnI 
produced by pNZ44trnI∆CT50-79 would completely be devoid of TMD2. Finally, 
the TrnI produced by pNZ44trnI∆NT1-13∆CT64-79 lacked amino acid residues 1-
13 and 64-79 of TrnI. The strains producing TrnI proteins devoid of its original N-
terminal regions i.e. pNZ44trnI∆NT1-13, pNZ44trnI∆NT1-30 and pNZ44trnI∆NT1-
13∆CT64-79 were no longer resistant to thuricin CD (Table 4). In contrast, strains 
producing TrnI proteins with C-terminal truncations still provided appreciable levels 
of protection, with MICs of 18µM noted.  
 
Further constructs were generated from which regions of trnF or trnG were deleted 
(Table 2) and subjected to MIC analysis.  pNZ44trnFG∆NT1-144 provided only 
slight protection (MIC 3µM) and pNZ44trnFG∆NT1-144∆CT93-210 provided no 
protection (Table 4). The MICs against both pNZ44trnG∆NT1-54 and 
pNZ44trnG∆CT93-210 were also 2.5µM, identical to the wild type (Table 4).  
Unsurprisingly, the thuricin CD MIC of pNZ44trnFΔNT 1-144 was also identical to 
wild type levels of 2.5µM. The construct pNZ44trnIF∆CT195-285 contained the 
essential ATP-binding Walker A motif at position 33 and Walker B motif at amino 
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acid position 152 of TrnF.  The MICs against pNZ44trnIF∆CT195-285 and 


























We identified the genes responsible for encoding immunity to the two-component 
sactibiotic thuricin CD.  This was facilitated through use of L. monocytogenes 
33013, also known as L. monocytogenes Scott A, a laboratory strain originally 
associated with an outbreak of listeriosis (39). This strain is sensitive to thuricin CD 
at concentrations of 2.5µM or higher.  Although less sensitive to thuricin CD than 
the many C. difficile strains tested to date, the relative ease with which genes can be 
sub-cloned and expressed in L. monocytogenes made strain 33013 a useful host with 
respect to these investigations.  
Based on previous bioinformatics analysis it was suggested that there were seven 
genes involved in thuricin CD production, maturation, export and/or immunity (1). 
trnF, trnG, trnβ, trnα, trnC, trnD and trnE are each preceded by  RBS sequences and 
their predicted products are homologous, or share features with, other bacteriocin-
associated peptides/proteins. Initial in silico analysis in this study indicated the 
potential involvement of two ORFs (orf11 and orf12) located upstream of trnF but 
their roles in thuricin CD production/regulation/immunity were unclear. It was 
speculated that orf11 could encode a small transmembrane protein. Further extensive 
in silico analysis has provided a more detailed insight into orf11 and we have 
consequently established that it is actually a small immunity gene (trnI), encoding a 
transmembrane protein (TrnI) which is 79 amino acids in length and 9.09kDa in size. 
An assessment of TrnI topology using seven topology prediction servers indicates 
that TrnI contains two transmembrane helices (TMD1 and TMD2). TMHMM and 
SPLIT4.0 are most reliable (40) and, although there are slight disparities with respect 
to which amino acid residues are involved in different domains of the protein, both 
agreed that TrnI possesses two transmembrane regions. Similar TMDs have also 
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been found within the small immunity proteins of lacticin 3147 as well as the 
sactibiotic propionicin F, while PepI, the immunity protein associated with Pep5, 
also contains membrane-associated hydrophobic stretches (41, 42, 43, 44). Such a 
small immunity protein, most likely associated with the cell membrane due to the 
presence of the putative TMD sequences, may sequester the thuricin CD peptides or 
somehow block the insertion of the peptides into the membrane. Immunity proteins 
generally tend to be very specific and are not easily recognisable in homology 
searches. Extensive bioinformatics analysis of TrnG (the N-terminal integral 
membrane component of the ABC transporter system) using seven topology tools 
was also conducted and it was established that TrnG contains 6 transmembrane 
helices. As was the case with TrnI, a few minor dissimilarities between the servers 
were apparent. Nonetheless, the agreement between all seven servers helped to 
establish that TrnG is likely to be the hydrophobic integral membrane domain of a 
functional ABC transporter system, TrnFG. 
Introduction of pNZ44trnIFG into L. monocytogenes 33013 conferred the strain with 
the ability to grow in the presence of thuricin CD, establishing that trnFG and/or trnI 
are involved in thuricin CD immunity. The creation and use of pNZ44trnI and 
pNZ44trnFG facilitated experiments which established that trnFG and trnI both 
provided protection against thuricin CD. The fact that orf11 independently provided 
protection against thuricin CD confirmed that it is a small immunity gene, henceforth 
designated trnI. Concurrence between biological data and detailed in silico analysis 
in this study lent further credence to the hypothesis that TrnI could function on its 
own, as it appears to be a small membrane protein, with two TMDs. Unsurprisingly, 
pNZ44trnF and pNZ44orf12trnF both failed to provide any immunity to L. 
monocytogenes 33013, since TrnF (the ATP-binding domain of a fully functional 
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ABC transporter system) is not expected to function without a membrane 
component. In addition, it proves that orf12 is not involved in thuricin CD immunity. 
TrnE, a putative peptidase with a probable intracellular function, also confers a 
minor degree of immunity to the L. monocytogenes strain. The exact role of TrnE, an 
unusual serine-like protease belonging to the S41-superfamily of C-terminal 
processing peptidases, remains unclear. Generally, such C-terminal processing 
peptidases are not involved in cleavage of double glycine motifs. TrnE may assume a 
role in immunity by cleaving the thuricin CD peptides at an alternative site and 
consequently, restricting the concentration of the bacteriocin in the immediate 
environment of the producer cell.  The precise mechanism remains unclear and 
merits further investigations.   
Cross immunity between bacteriocin producers is a relatively rare occurrence. 
However, cross immunity between lacticin 481 and nukacin ISK-1 and between 
epicidin and Pep5 have been reported (8, 45). In this study, we also carried out 
investigations to determine if trnIFG provided cross immunity to thuricin produced 
by B. thuringiensis HD-2 (BGSC), the sactibiotic subtilosin A, as well as the anti-
Listeria lantibiotics actagardine, nisin and lacticin 3147. All three lantibiotics display 
potent antimicrobial activity against Gram-positive pathogens, including L. 
monocytogenes and C. difficile, similar to thuricin CD (46, 47, 48).  However, nisin, 
lacticin 3147 and actagardine have a broad spectrum of action, in contrast to the 
highly narrow spectrum of activity of thuricin CD, which is mainly restricted to C. 
difficile, L. monocytogenes and Bacillus firmus (1). It was reassuring that thuricin 
CD immunity determinants did not confer cross immunity to thuricin, subtilosin A, 
nisin, lacticin 3147 or actagardine as it indicates that thuricin CD and the 
aforementioned bacteriocins can potentially be used in combination with each other, 
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with no danger of cross resistance in the rare and unlikely event of target strains 
acquiring potential immunity gene homologues from the environment. This lack of 
cross immunity was anticipated, as bacteriocin immunity systems, and in particular 
dedicated immunity proteins, are highly specific.  
The creation and introduction of constructs designed to produce immunity proteins 
with N and C-terminus truncations provided a better insight into the relative 
contributions of each of the immunity determinants. The abrogation of the protection 
provided by TrnI as a consequence of creating derivatives with an N-terminal 
truncation, lacking either the first 13 amino acids or lacking both the cytoplasmic 
loop as well as TMD1 highlighted the importance of this region of the protein. As 
intermediate levels of immunity were provided by C-terminally truncated versions of 
TrnI, it is apparent that the C-terminus of TrnI and the associated TMD2 are of lesser 
importance. Due to the predicted membrane location of the immunity protein TrnI, it 
may be that the receptor for thuricin CD also resides in the membrane. Since 
immunity proteins generally work by ‘target shielding’ or bacteriocin interception, it 
may be the case that TrnI (and in particular the N-terminus associated cytoplasmic 
loop and TMD1) sequester the thuricin CD peptides. Alternatively, the cytoplasmic 
loop and TMD1 of TrnI may block a putative membrane receptor for the thuricin CD 
peptides, consequently preventing the peptides from binding the target site. 
Since pNZ44trnFGΔNT1-144 resulted in MIC levels similar to wild type and 
identical to pNZ44trnG, it became clear that the N-terminus of TrnF, containing the 
essential Walker A motif at amino acid position 33 was important in TrnF 
functionality. Furthermore, as pNZ44trnIFΔCT195-285 contained a truncated trnF 
gene and still provided immunity, it helped to establish that TrnI is an independent 
immunity protein, and is not part of a tri-partite ABC-transporter system (consisting 
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of TrnIFG), as is the case with some lantibiotic gene clusters. One would expect a 
complete loss of immunity due to a truncated version of the TrnF protein (the ATP-
binding component) had TrnI been a component of this ABC-transporter system. In 
contrast, as pNZ44trnFGΔNT1-144 resulted in a significant loss of immunity, it was 
definitively established that TrnFG form components of a fully functional bi-partite 
ABC transporter system. Thus, it is highly likely that the ABC transporter system 
TrnFG functions by expelling the thuricin CD peptides from the membrane.  Lack of 
the crucial ATP-binding motif of TrnF leads to a loss of functionality of the ABC 
transporter as the system operates in an energy-dependent manner.  
A few other studies have been conducted with respect to immunity to sactibiotics, 
including propionicin F, subtilosin A and thurincin H (4, 44, 49). The immunity gene 
for the sactibiotic propionicin F is called pcfI. While TrnI contains only two 
transmembrane helices, PcfI is a small 127 amino acid membrane-bound protein 
with three transmembrane helices. As is the case with most bacteriocin systems 
which are highly regulated, the expression of the pcfI gene was found to be 
concomitant with expression of the propionicin F structural gene (44). AlbB is a 
small 59 amino acid hydrophobic immunity protein involved in providing protection 
against the sactibiotic subtilosin A (4). While AlbB independently provides 
immunity, AlbC and AlbD are also required for optimal immunity to subtilosin A. 
AlbC is an ABC transporter protein, involved in both immunity and export of 
subtilosin A. Thurincin H is another sactibiotic produced by B. thuringiensis (49). 
The immunity determinants for thurinicin H have not definitively been identified. 
However, thnT encodes a putative ABC transporter protein, with a possible role in 
immunity while thnI is thought to encode a dedicated immunity protein 95 amino 
acids in length. Interestingly a lack of homologues of thnI amongst genome based 
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sequences was also noted by Lee et al. (49). This reflects the highly specific nature 
of dedicated immunity proteins. thnD and thnE are thought to encode the ATP-
binding components and permease components of an ABC-transporter system 
respectively, possibly involved in thurincin H immunity. 
In conclusion, this is the first study conducted to investigate immunity to the two-
peptide sactibiotic, thuricin CD. We conclude that TrnF and TrnG are the individual 
components of a dedicated bipartite ABC-transporter system, with TrnE playing a 
minor role in thuricin CD immunity. It has been experimentally established that TrnI 
is a dedicated immunity protein.  ABC-transporter proteins in bacteriocin systems 
can be involved in providing both an immunity function as well as an export 
function. Interestingly, Rea et al. (1) reported that Trnβ and Trnα peptides both 
possess leader sequences containing a double-glycine motif and cleavage/transport 
of such leader peptides typically involves a cognate ABC transporter. Indeed, a 
group of translocator proteins, which contain a supplementary cysteine protease-like 
N-terminal proteolytic domain, was reported by Havarstein et al. (50). However, 
TrnF and TrnG do not show any homology to protease enzymes and due to the 
absence of N-terminus proteolytic sequences, they are highly unlikely to be involved 
in the cleavage of the thuricin CD leader peptides. Thus, while it is clear that TrnFG 
are involved in thuricin CD immunity, their role, if any, in the export of Trnα and β 
peptides requires further study. Regardless of the precise mechanisms involved, we 
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Bacillus thuringiensis serovar monterrey 
BGSC 4AJ1 
84 4e-36 WP_000676622.1 
Bacillus cereus FRI-35 64 4e-25 YP_006599094.1 
Bacillus cereus BAG4X12-1 61 3e-23 WP_000853250.1 
Bacillus thuringiensis IBL 200 58 2e-22 WP_003308783.1 
Bacillus thuringiensis IBL 4222 56 4e-20 WP_000853266.1 











Table 2: List of strains and L. monocytogenes 33013 constructs used in this study. 
Construct Description Source 
E. coli Top10 cells Intermediate cloning host Invitrogen 
L. monocytogenes 33013 Thuricin CD-sensitive strain Clayton et al. (35) 
pNZ44 
B. thuringiensis DPC6431 
B. subtilis 168 
B. subtilis JH642 
B. thuringiensis HD2 
B. thuringiensis 
subsp.monterrey 
L. lactis NZ9700 
L. lactis DPC3147 
E. coli-Listeria expression 
vector 
Thuricin CD producer 
Subtilosin A producer 
Subtilosin A producer 
Thuricin producer 
Subtilosin producer 
Nisin A producer 
Lacticin 3147 producer 
McGrath et al. (36) 






Field et al. (47) 
Draper et al. (43) 
pHM16 pNZ44trnI This study 
pHM17 pNZ44trnF This study 
pHM18 pNZ44trnG This study 




pHM26 pNZ44trnIF This study 
pHM27 pNZ44trnFG This study 








pHM32 pNZ44trnI∆CT64-79 This study 
pHM33 pNZ44trnI∆CT50-79 This study 




pHM36 pNZ44trnGΔCT93-210 This study 
pHM37 pNZ44trnGΔNT1-54 This study 
pHM38 pNZ44trnFΔNT1-144 This study 
pHM39 pNZ44trnIFGΔCT93-210 This study 
pHM40 pNZ44trnIFΔCT195-285 This study 
a
BGSC, Bacillus Genetic Stock Centre; 
b









Table 3: List of oligonucleotides used in this study. Restriction sites are underlined 
and highlighted in bold. 
a
ΔNT, N-terminus truncation; 
b
ΔCT, C-terminus truncation. 
Oligonucleotide Sequence 5’ to 3’ 
pNZ44 MCS For CTAATGTCACTAACCTGCCCCGTTAG 
pNZ44 MCS rev GGCTATCAATCAAAGCAACACGTG 
Pre11 for NcoI CACTGCCATGGAATTTATGCGCTGACTG 
Trn rev PstI GAACCTGCAGTAATATTCAGAAAG 
Trn G rev PstI GAACTGCAGAGATCCTCTTCTTCAAAATG 



































Table 4: MICs of thuricin CD against L. monocytogenes 33013 wild type and 
constructs expressing thuricin CD immunity genes. MICs are indicated in µM with 
µg/ml values included in parentheses.   
Construct Thuricin CD MIC 
L. monocytogenes 33013 2.5µM (14.06) 
pNZ44 2.5µM (14.06) 
pNZ44trnI >18µM(>101.2) 
pNZ44trnF 2.5µM (14.06) 
pNZ44trnG 3µM (16.87) 














pNZ44trnI∆CT64-79 18µM (101.2) 
pNZ44trnI∆CT50-79 18µM (101.2) 
pNZ44trnFGΔNT1-144 3µM (16.87) 
pNZ44trnFGΔNT1-144 ΔCT93-210 2.5µM (14.06) 
pNZ44trnGΔCT93-210 2.5µM (14.06) 
pNZ44trnGΔNT1-54 2.5µM (14.06) 




ΔNT, N-terminus truncation; 
b
ΔCT, C-terminus truncation. The numbers included 
after ΔNT and ΔCT indicate the amino acid residues which are excluded from their 












             






        
trnI trnF trnG trnβ trnα trnC trnD trnE 
(orf11) orf12 
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Fig 1:  
A) Organisation of the thuricin CD gene cluster. Immunity genes are shaded in 
gray. trnI (formerly orf11) is a small immunity gene encoding a transmembrane 
immunity protein. trnFG encode a fully functional ABC-transporter system. trnβ and 
trnα are the two structural genes (shaded in black). trnC and trnD are the two post-
translational modification genes, encoding S-adenosylmethionine proteins (shaded in 
white). trnE encodes a C-terminal processing peptidase with a minor role in thuricin 
CD immunity (shaded in gray). orf12 (dashed outline), located between trnI and trnF 
is unlikely to be a gene. B) TrnI topology prediction. Hydrophobicity plot and 
membrane topology prediction of TrnI based on TMHMM (23).  Index: red line; 
transmembrane helix, blue line; beta preference, gray line; modified hydrophobic 
moment index, violet boxes; predicted transmembrane helix positions. C) TrnG 
topology prediction. Hydrophobicity plot and membrane topology prediction of 
TrnG based on TMHMM (23).  Index: red line; transmembrane helix, blue line; beta 
preference, gray line; modified hydrophobic moment index, violet boxes; predicted 













Fig 2: Kill curve analysis. Survival and growth of L. monocytogenes 33013 wild 
type and strains expressing trnFG, trnIF, trnE, trnG, trnI (formerly orf11), trnF and 
trnIFG when challenged with a sub-lethal level (2.2µM) of thuricin CD. The growth 
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Thuricin CD is a narrow spectrum two-peptide bacteriocin that displays potent 
antimicrobial activity against Clostridium difficile. Thuricin CD consists of 2 
peptides, Trnα and Trnβ, which act in a synergistic manner to kill a variety of C. 
difficile isolates. Each of the peptides is post-translationally modified at amino acid 
residues 21, 25 and 28. These post-translational modifications result in the formation 
of three cysteinyl sulphur to α-carbon bridges across the two peptides.  Such sulphur 
to α-carbon bridges are relatively rare in bacteriocins, but have previously been 
identified in propionicin F and subtilosin A. These bacteriocins, together with 
thuricin CD, belong to a novel class of bacteriocins referred to as sactibiotics. Here, 
we report the heterologous production of the sactibiotic thuricin CD in Bacillus 
subtilis 1012. This represents an important step in definitively establishing the 
composition of the thuricin CD gene cluster. In addition, the importance of trnCDE 
(putative post-translational modification/processing genes) as well as trnFG 
(putative exporters of thuricin CD peptides) is highlighted through the creation of 
constructs lacking these genes and which are no longer capable of thuricin CD 
production. To the best of our knowledge, this is the first study describing the 








Thuricin CD is a narrow spectrum two-peptide bacteriocin exhibiting potent 
antimicrobial activity against Clostridium difficile, Bacillus firmus and some Listeria 
monocytogenes isolates (1). The producing strain, Bacillus thuringiensis DPC6431, 
was isolated through a screen for anti-C. difficile activity from over 30,000 
sporeformers isolated from faecal samples. The narrow spectrum of activity of 
thuricin CD is particularly useful in light of the fact that exposure to broad spectrum 
antibiotics, and their associated negative impact on the gut microbiota, is a risk 
factor with respect to the development and recurrence of C. difficile-associated 
diarrhea (CDAD)(1, 2). This narrow spectrum activity of thuricin CD is evident 
through culture based studies that have demonstrated the absence of activity against 
many targets, including probiotics from the Lactobacillus and Bifidobacterium 
genera (1). Furthermore, while thuricin CD performed as well as the traditional anti-
C. difficile antibiotics vancomycin and metronidazole in a human distal colon model, 
it differed from the antibiotics in that it did not induce major fluctuations in the 
composition of the microbiota (3). Due to this potent, target-specific activity, it 
would seem that thuricin CD merits consideration as an alternative to metronidazole 
and vancomycin. Indeed, when the in vitro antimicrobial activity of thuricin CD 
against nineteen C. difficile clinical isolates was investigated recently, it emerged 
that when assessed on the basis of molar concentrations, thuricin CD was 
consistently more active than metronidazole and vancomycin (4). Furthermore, 
investigations of the efficacy of thuricin CD in combination with other anti-C. 
difficile antimicrobials revealed partial synergistic/additive effects against 31% of C. 
difficile strains, when combined with ramoplanin (4). Recently, the bioavailability of 
thuricin CD in the gut has also been studied using murine and porcine models and it 
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was established that rectal administration of thuricin CD was effective at controlling 
C. difficile numbers (5). 
The 3-D structure of thuricin CD has been elucidated and it was shown that both of 







 residues (1, 6). These post-translational modifications are 
thought to be mediated by radical S-adenosylmethionine (SAM) proteins. Due to 
these sulphur to α-carbon linkages, which are predicted to be crucial for bioactivity, 
thuricin CD has been assigned to a novel class of bacteriocins designated sactibiotics 
(7). Other sactibiotics include subtilosin A and propionicin F (8, 9). Subtilosin A is a 
cyclic peptide produced by Bacillus subtilis that exhibits potent antimicrobial 
activity against L. monocytogenes. The formation of the  biologically active form of 
subtilosin A involves the loss of a seven amino acid leader sequence, N and C-
terminal cyclization and subsequent modification of Cys, Thr and Phe residues (9, 
10). In the case of subtilosin A, the SAM protein AlbA behaves as an oxidoreductase 
that catalyzes these modifications (9).  Propionicin F is a narrow spectrum sactibiotic 
produced by Propionibacterium freudenreichii that displays antimicrobial activity 
against other strains of P. freudenreichii only (8).  Propionicin F is a 43-amino acid 
bacteriocin which undergoes significant N and C-terminal proteolytic modifications. 
Indeed, 101 N-terminal and 111 C-terminal residues are removed to yield the mature 
biologically active 43-amino acid propionicin F peptide. The genetic locus 
responsible for production of propionicin F consists of a structural gene, pcfA, as 
well as genes thought to encode a SAM protein, a proline peptidase and ABC 
transporter proteins. A gene located downstream of pcfA, designated pcfB, encodes a 
radical SAM protein, the precise role of which has yet to be ascertained (8, 11). 
Thurincin H is also a sactibiotic produced by another B. thuringiensis strain which 
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displays antimicrobial activity against a variety of Gram-positive bacteria including 
Staphylococcus aureus, L. monocytogenes and other Bacillus species (7, 12). The 
mature thurincin H is encoded by the three genes thnA1, thnA2 and thnA3, organised 
in tandem repeats on the B. thuringiensis SF361 chromosome. The gene cluster for 
thurincin H biosynthesis consists of a total of 10 open reading frames (ORFs), three 
of which are structural genes. Other genes in the thurincin H operon include a 
bacteriocin processing gene (thnB), a transport protein gene (thnT), an immunity 
gene (thnI) (12). In addition, a transcription regulator gene (thnR), as well as ABC 
transporter genes are involved while ThnP, a putative leader sequence peptidase, 
assumes a bacteriocin processing role. The 3-D structure of thurincin H has recently 
been elucidated and it emerged that thurincin H consists of four sulphur to α-carbon 
cross links (13). 
To date, many different bacteriocins have been expressed in heterologous hosts, 
including sakacin P (14), nisin (15), divercin V41 (16), enterocin P (17), lacticin 
3147 (18), planosporicin (19), labyrinthopeptins (20), leucocin C (21), Ala(0) 
actagardine (22), pediocin PA-1 (23), enterolysin A (24). However, to date, no 
sactibiotic gene cluster has been heterologously expressed. Here, we describe the 
heterologous expression of the sactibiotic thuricin CD in B. subtilis 1012, using the 
Bacillus expression vector, pHCMC05. Furthermore, we highlight the importance of 
the thuricin CD ABC transporter system and post-translational 
modification/processing genes in thuricin CD production. We show that while the 
presence of the entire thuricin CD gene cluster results in heterologous production in 
B. subtilis, constructs that lack a subset of genes fail to produce thuricin CD.  
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Materials and Methods 
Strains and growth conditions 
B. thuringiensis DPC6431 (1) and B. subtilis 1012 (provided by the Bacillus Genetic 
Stock Center, Columbus, USA) were grown in Brain Heart Infusion (BHI) (Oxoid 
Ltd, Basingstoke, Hampshire, England) agar and broth at 37°C with vigorous 
agitation. Chemically competent E. coli Top10 cells (Invitrogen, Carlsbad, USA) 
were grown in Luria Bertani (LB) medium supplemented with 1.5% agar. B. firmus 
NRS854 and B. thuringiensis subsp. huazhongensis (both provided by the Bacillus 
Genetic Stock Centre, Columbus, USA) were grown on BHI agar and broth at 37°C 
with vigorous agitation. C. difficile indicator strains were kindly provided by the 
Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. These C. difficile 
indicator strains were grown on Fastidious Anaerobic Agar (LabM Ltd; Lancashire, 
UK) supplemented with 7% defibrinated horse blood (TCS Biosciences, Botolph 
Claydon, Buckingham, UK) for 48 hours in an anaerobic workstation (Davidson & 
Hardy). Overnight cultures of C. difficile strains were grown for 18 hours in 
Reinforced Clostridium Medium (RCM) broth (Oxoid Ltd; Basingstoke, Hampshire, 
England) under anaerobic conditions. RCM broth was boiled and allowed to 
equilibrate in an anaerobic workstation prior to inoculation. E. coli Top10 
transformants were selected on LB agar plates supplemented with 100µg/ml 
ampicillin and B. subtilis 1012 transformants were selected on BHI agar 
supplemented with chloramphenicol (7.5µg/ml). A list of strains and constructs used 




General molecular biology techniques 
B. thuringiensis DPC6431 genomic DNA was isolated using the Invitrogen PureLink 
Genomic Extraction kit (Invitrogen, Carlsbad, California, USA), following 
manufacturer’s instructions. The thuricin CD gene cluster consisting of 
trnIFGβαCDE and the promoter upstream of trnI was amplified using the 
oligonucleotides pre11forBamH1 and trnrevSma1 by PCR using Phusion high-
fidelity Polymerase (New England Biolabs, Knowl Piece, Hitchin, UK). The PCR 
product was digested with BamH1 and Sma1 (Roche Diagnostics, Mannhein, 
Germany) and ligated into similarly digested pHCMC05 vector (25) using T4 DNA 
ligase (Roche Diagnostics). The ligation mixture was introduced into chemically 
competent E. coli Top10 cells (Invitrogen) as an intermediate host. E. coli 
transformants were screened by colony-PCR using multiple cloning site and insert 
primer combinations to identify colonies containing a plasmid with an insert of 
appropriate size. Such plasmids were extracted from E. coli using the Roche High 
Pure plasmid isolation kit (Roche Diagnostics, Mannhein, Germany) and again 
checked, through digestion using BamH1 and Sma1, to confirm the presence of an 
insert of correct size. The recombinant plasmid was then introduced into chemically 
competent Bacillus subtilis subsp. subtilis 1012 cells. pHM2 (trnβαCDE) was 
constructed in the same manner using the trnβforBamH1 and trnrevSma1 
oligonucleotide pair while pre11forBamH1 and trnαrev2Sma1 primers were used to 
construct pHM3 (trnIFGβα). The Pspac promoter of pHCMC05 was induced with 
IPTG (Invitrogen). DNA sequencing to ensure the integrity of the constructs was 
performed by Source BioScience, Dublin, Ireland. A list of oligonucleotides used in 
this study is included in Table 2. 
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Development of competence of B. subtilis 1012 
B. subtilis 1012 was made naturally competent using the procedure described in 
Yasbin et al. with some minor modifications (26). Briefly, a 100ml stock of Medium 
A consisted of the following: 81ml sterile distilled water, 9ml 10x Bacillus salts and 
10ml of 10x medium A base. Medium A base consisted of yeast extract, casamino 
acids and glucose. Medium B was made up by adding 100µl of 50mM CaCl2.2H20 
and 100µl of 250mM MgCl2.6H20 to 10ml of medium A. A few colonies of B. 
subtilis 1012 were inoculated into 20ml of medium A in a 100ml conical flask such 
that the starting optical density (OD600) was 0.1. This was incubated at 37°C with 
vigorous agitation. Optical density readings were taken every 30 minutes and T0 was 
noted at OD600 of approximately 0.5. This was the point at which the culture 
departed logarithmic phase and entered stationary phase. The culture was incubated 
for a further 90 minutes (T90), at which point, 100µl of the culture was diluted into 
900µl of medium B. The diluted culture was again incubated for 90 minutes at 37°C 
with vigorous agitation. At this point, 250ng of the relevant recombinant pHCMC05 
plasmids were added to the competent B. subtilis 1012 cells and incubated at 37°C 
with agitation for a further 30 minutes. B. subtilis 1012 transformants were selected 
on BHI agar plates supplemented with 7.5µg/ml chloramphenicol.  
                                         
Well diffusion assays 
The production of thuricin CD from cell-free supernatants (CFS) of B. thuringiensis 
DPC6431 and B. subtilis 1012 constructs was assessed against a range of C. difficile 
and Bacillus indicators using the well diffusion assay, as described in Rea et al. (1) 
with some minor modifications. Briefly, 1ml of overnight cultures of B. 
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thuringiensis DPC6431 and B. subtilis 1012 constructs were centrifuged twice in a 
table-top microcentrifuge at 12,000rpm for 10 minutes. Sensitive C. difficile 
indicator strains were grown overnight for 18 hours in RCM broth in anaerobic 
conditions. 20ml of molten RCM agar (or BHI agar for Bacillus indicators) cooled to 
50°C was seeded with 50µl of the overnight culture of the indicator strain (0.25% 
inoculum). Once the agar solidified, 4.6mm diameter wells were made using a sterile 
Pasteur pipette and 50µl of the cell free supernatants of B. thuringiensis DPC6431 or 
the B. subtilis 1012 constructs were added to the wells. The agar plates were 
incubated at 37°C for Bacillus indicators and in an anaerobic workstation (Davidson 
& Hardy) at 37°C for C. difficile indicators. Diameters of zones of inhibition were 
measured after overnight growth of the indicators. The pH of BHI broth was adjusted 
using 2M HCl or 2M NaOH. All assays were performed in triplicate. 
 
Proteinase K sensitivity of antimicrobial-containing cell-free supernatants 
The sensitivities of antimicrobial-containing cell-free supernatants (CFS) to 
proteinase K (Sigma) was assessed using the checkerboard broth microdilution 
assay, as described by Orhan et al. with some minor modifications (27). Here, 
instead of using purified antimicrobial peptides and/or antibiotics, we used CFS from 
overnight cultures of B. thuringiensis DPC6431 and B. subtilis 1012 
(trnIFGβαCDE)(pHM149) and proteinase K stocks, diluted in the same manner as in 
a checkerboard assay. Briefly, the CFS from B. thuringiensis DPC6431 and B. 
subtilis (pHM149) was isolated by centrifuging overnight cultures at 12,000rpm for 
10 minutes in a table-top microcentrifuge. The cell-free supernatants were then filter-
sterilised using 0.45µm filters (Phenomenex). 0.5 mg/ml stock solutions of 
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proteinase K were made up in BHI broth. 100µl of a proteinase K stock solution was 
serially diluted from right to left along a microtitre plate and a fixed volume (50µl) 
of CFS from an overnight culture of B. subtilis 1012(pHM149) or B. thuringiensis 
DPC6431 was added to each well. 50µl of a sensitive Bacillus indicator containing 
approximately 5 x 10
5
 cells/ml was then introduced into each of the wells such that 
the final volume was 0.2ml per well. The microtitre plates were incubated at 37°C 
for 18 hours. The sensitivities of the cell-free supernatants were determined by 
calculating the minimum concentration of proteinase K which inhibited the 
antimicrobial activity of thuricin CD present in the supernatants. The relative 
sensitivities of supernatants from B. thuringiensis DPC6431 and B. subtilis 
(pHM149) to proteinase K were compared. The minimum concentration of 
proteinase K was defined as the lowest concentration of proteinase K at which 
growth of the indicator strain first appeared (i.e. the least amount of proteinase K 
required to disrupt the antimicrobial actions of thuricin CD present in the 
supernatants). This permitted the quantification of active peptides present in the 
supernatants from both strains, grown under the same conditions. Due to addition of 
proteinase K, CFS and indicator strains in the same well, all proteinase K 
concentrations were consequently diluted 1:2, while cell free supernatants were 
diluted 1:4. The pH of BHI broth was adjusted from pH5-pH9, using 2M HCl and 







Heterologous expression of thuricin CD in B. subtilis 1012  
The putative thuricin CD gene cluster, consisting of the eight genes trnIFGβαCDE 
(Fig 1), including the native promoter, was cloned downstream of the IPTG-
inducible promoter Pspac in the E. coli/Bacillus shuttle vector pHCMC05 and the 
construct (hereafter designated pHM149) was introduced into B. subtilis 1012 to 
generate B. subtilis (pHM149). Well diffusion assays with CFS from overnight 
cultures of B. subtilis (pHM149), using the thuricin CD-sensitive B. firmus NRS854 
strain as an indicator established that the introduction of pHM149 successfully 
conferred an antimicrobial-producing phenotype that was not evident in strain B. 
subtilis 1012 (Fig 2). Well diffusion assays were also conducted with 1 mg/ml 
proteinase K added in wells adjacent to the CFS to ensure that zones of inhibition 
were due to the thuricin CD peptides (data not shown).  Mass spectrometry of B. 
subtilis (pHM149) partially purified preparations was conducted to ensure that the 
strain was producing thuricin CD (Fig 3). 
A range of C. difficile indicator strains were used to compare the antimicrobial 
activity of strain B. subtilis (pHM149) relative to the natural B. thuringiensis 
DPC6431 producer. Without IPTG induction, zone sizes produced by B. subtilis 
(pHM149) ranged from 53%-67% of those produced by the natural producer 
DPC6431. Induction of the Pspac promoter within pHM149 with 1mM IPTG resulted 
in an increase in zone sizes, with values ranging between 71-78%, compared to the 
natural producer. Induction with higher concentrations of IPTG (5mM) led to a 
further increase in zone sizes, varying from 76-86%, compared to those produced by 
DPC6431 (Table 3). 
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The bioactivity of thuricin CD produced by DPC6431 and B. subtilis (pHM149) was 
also assessed and compared in order to find the optimal pH conditions required for 
secretion of thuricin CD. Well diffusion assays with supernatants from strains grown 
under different pH conditions were employed to this end (Table 4).  Using the zone 
sizes obtained with DPC6431 and B. subtilis (pHM149) (induced with 1mM IPTG) 
grown at pH7 as standards, the production levels of thuricin CD at different pH 
conditions were compared.  DPC6431 produced the highest levels of thuricin CD at 
slightly alkaline pH conditions with zone sizes averaging 119.75% and 126.5% at 
pH8 and pH9 respectively, relative to zone sizes at pH7 (representing 100%). In 
contrast, B. subtilis (pHM149) did not secrete any thuricin CD into the growth 
medium when grown at alkaline pH conditions, with a complete lack of zones of 
inhibition. B. subtilis (pHM149) produced the highest levels of thuricin CD at pH7 
(Table 4). 
 
Use of proteinase K in order to precisely quantify relative thuricin CD production 
levels 
In order to quantify the precise minimum concentrations of proteinase K required to 
inhibit the antimicrobial activity of thuricin CD present in supernatants of DPC6431 
and B. subtilis (pHM149) induced by different concentrations of IPTG, we 
conducted broth-based checkerboard assays as described by Orhan et al. (27) (Table 
5). This assay is the opposite of traditional minimum inhibitory concentration (MIC) 
assays, whereby the MIC is defined as the lowest concentration of an antimicrobial 
required to completely inhibit the growth of the target organism after a fixed time 
point. Here, the minimum concentration of proteinase K required was defined as the 
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lowest concentration needed to completely inhibit/inactivate the antimicrobial 
activity of thuricin CD present in the supernatants i.e. the minimum concentration of 
proteinase K at which growth of the target strain first appeared.  Two thuricin CD 
indicator strains B. firmus NRS854 and B. thuringiensis subsp. huazhongensis were 
used for these assays. With respect to B. firmus NRS854, 3.906 µg/ml of proteinase 
K was required to completely inhibit the bioactivity of thuricin CD present in the 
supernatants of DPC6431. In contrast, only 0.488 µg/ml proteinase K was sufficient 
to inhibit the bioactivity of supernatants from B. subtilis (pHM149) without IPTG 
induction. 1.953 µg/ml proteinase K was enough to disrupt the antimicrobial actions 
of thuricin CD in supernatants of B. subtilis (pHM149) induced with 1mM IPTG. 
However, 3.906 µg/ml proteinase K i.e. a quantity identical to that needed inactivate 
the thuricin CD produced by DPC6431, was required to disrupt the antimicrobial 
activity of thuricin CD present in the supernatants of B. subtilis (pHM149) induced 
with 5mM IPTG. Against the indicator B. thuringiensis subsp. huazhongensis, 1.953 
µg/ml proteinase K was the minimum amount required to prevent the antimicrobial 
activity of thuricin CD present in supernatants of DPC6431. Only 0.244 µg/ml 
proteinase K was needed to inactivate the antimicrobial component of supernatants 
from B. subtilis (pHM149) without IPTG induction, whereas 0.977 µg/ml proteinase 
K was needed to completely inhibit the antimicrobial action of supernatants from B. 
subtilis (pHM149) induced with 1mM IPTG. 1.953 µg/ml proteinase K was required 
to sufficiently inactivate the thuricin CD present in the supernatants from B. subtilis 
(pHM149) induced with 5mM IPTG (Table 5).  
Similar proteinase K checkerboard assays were conducted to compare and contrast 
the relative levels of thuricin CD present in the supernatants of DPC6431 and B. 
subtilis (pHM149) (induced with 1mM IPTG) when grown at different pH 
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conditions (Table 6). With respect to B. firmus NRS854, 3.906 µg/ml proteinase K 
was the minimum amount required to disrupt the activity of thuricin CD in 
supernatants of DPC6431, grown at pH5, pH6 and pH7. However, 7.813 µg/ml was 
needed to completely inhibit the activity of thuricin CD in the supernatants of 
DPC6431 grown at pH8 and pH9. In contrast, 1.953 µg/ml proteinase K was 
adequate to disrupt the inhibitory activity of thuricin CD in supernatants of B. 
subtilis (pHM149) (induced with 1mM IPTG) grown at pH5, 6 and 7 against the 
indicator B. firmus NRS854.  Identical patterns were apparent against the indicator 
B. thuringiensis subsp. huazhongensis. Against both B. firmus NRS854 and B. 
thuringiensis subsp. huazhongensis indicators, the supernatants of B. subtilis 
(pHM149) grown at pH8 and pH9 did not exhibit any antimicrobial activity (Table 
6), corroborating with results obtained with well diffusion assays (Table 4). 
 
Deletion of specific genes from the thuricin CD cluster highlights their importance 
with respect to antimicrobial production 
Constructs containing truncated versions of the full thuricin CD gene cluster were 
made in order to assess the resultant impact on thuricin CD production.  PCR 
products trnβαCDE and trnIFGβα were cloned into pHCMC05 and designated 
pHM2 and pHM3 respectively. Although both constructs contained the thuricin CD 
structural genes (trnβα), pHM2 lacked the thuricin CD ABC transporter genes 
(trnFG) as well as the recently-discovered immunity gene trnI, whereas pHM3 
lacked the putative post-translational modification/processing genes (trnCDE). The 
genes trnβαCDE and trnIFGβα were again cloned downstream of the IPTG-
inducible Pspac promoter in pHCMC05 and introduced into electrocompetent B. 
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subtilis 1012 cells to generate B. subtilis (pHM2) and B. subtilis (pHM3) 
respectively. While pHM2 lacked the native B. thuringiensis promoter located 
upstream of the entire gene cluster, pHM3 also contained the native promoter, in 
addition to Pspac. The sub-clones B. subtilis (pHM2) and B. subtilis (pHM3) were 


















This study describes the process that facilitated the production of thuricin CD in a 
heterologous host for the first time. The purpose of this ‘proof of concept’-type study 
was to confirm that the putative thuricin CD cluster, previously defined through 
bioinformatics analysis (1), possessed all of the genes required to facilitate 
production of the sactibiotic and to assess the importance of a number of genes 
within the cluster with respect to thuricin CD production. Due to its non-pathogenic 
and generally regarded as safe (GRAS) status, compounded by its ability to secrete 
foreign proteins and its quick growth rate, Bacillus subtilis was selected as a 
heterologous host species for expression of thuricin CD (28, 29). Indeed, B. subtilis 
has been used for several years in industry for the production of foods, enzymes, 
beverages, detergents and other products (28). As B. subtilis 1012 is insensitive to 
thuricin CD and since it belongs to the Bacillus genus, and therefore more likely than 
other genera to express genes from B. thuringiensis, it proved to be an ideal host 
with respect to heterologous expression as well as investigations of 
export/immunity/modification genes. This is important as the use of constructs 
containing the thuricin CD structural genes but lacking genes that contribute to 
immunity could have made these constructs unstable in a thuricin CD-sensitive 
background.  
Although B. subtilis is a useful host for production of foreign proteins, the 
production of extracellular proteases degrading the foreign protein as well as the lack 
of stable vectors have caused problems in the past. The use of plasmids employing 
the theta mode of replication has proved successful with respect to overcoming 
difficulties with stability of vectors. Examples of such plasmids include pAMβ1 and 
pBS72 (29, 30, 31). More recently, in order to circumvent problems relating to 
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structural stability of expression vectors to be used in B. subtilis, stable vectors based 
on the shuttle vector pMTLBS72 were constructed by Nguyen and co-workers (25). 
The use of the expression vector pHCMC05 demonstrating high structural stability 
(25) was therefore used in this study. The strain B. subtilis 1012 has a naturally high 
ability to secrete foreign proteins. It was recently used by Ilk et al. to express an 
endotoxin-free S-layer/allergen fusion protein (32).  
Bacteriocin gene clusters typically consist of several genes, often organised into 
operons. These genes include the biosynthetic structural gene(s), immunity gene(s), 
post-translational modification/processing gene(s), export/translocator gene(s), as 
well as signal transduction/quorum sensing genes (although these may be located 
outside the bacteriocin gene cluster) (33, 34, 35, 36, 37).  In the majority of cases, 
the full gene clusters are required for heterologous production of the bacteriocin. 
However, an exception to the rule includes the sactibiotic propionicin F, which was 
expressed as a thioredoxin fusion protein in E. coli BL21 (DE3) cells, by merely 
cloning in part of the pcfA structural gene (38). 
In this study, we first established that the full thuricin CD gene cluster, including the 
putative B. thuringiensis DPC6431 promoter, when cloned downstream of the IPTG-
inducible Pspac promoter of pHCMC05, successfully conferred a thuricin CD-
producing phenotype. Furthermore, the production of thuricin CD in B. subtilis 1012 
due to the introduction of the full thuricin CD gene cluster (trnIFGβαCDE) in 
pHM149 established that these eight genes are sufficient for thuricin CD production 
and confirms that open reading frames located upstream and downstream of the 
thuricin CD gene cluster are highly unlikely to be involved in thuricin CD 
production, maturation and export. As B. subtilis (pHM149) produced thuricin CD 
without IPTG induction, it was clear that the native thuricin CD promoter was able 
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to function in the B. subtilis host. We then sought to compare and contrast the 
production levels of thuricin CD by the natural producer (B. thuringiensis DPC6431) 
and B. subtilis (pHM149) induced with varying concentrations of IPTG. 
Unsurprisingly, induction of pHM149 with IPTG resulted in increased levels of 
thuricin CD production, with 5mM IPTG concentrations resulting in thuricin CD 
levels comparable to the natural DPC6431 producer.  
As assessment of thuricin CD production levels by DPC6431 grown at different pH 
conditions confirmed that thuricin CD was produced over a wide range of pH 
conditions as was previously reported (1). In contrast, B. subtilis (pHM149) failed to 
exhibit any bioactivity at alkaline pH conditions. This could perhaps be attributed to 
the production of extracellular proteases by the B. subtilis 1012 host at alkaline pH 
conditions, which may recognise and degrade foreign peptides. Indeed, studies have 
described increased efficiencies of enzyme production by B. subtilis hosts in slightly 
alkaline conditions (28, 29). Manabe and co-workers also found increased 
efficiencies of α-amylase AmyK38 secretion by B. subtilis in alkaline conditions 
(28). In a separate study, the same authors noted a decrease in the secretion of the 
extracellular enzyme alkaline cellulase Egl-237 in low pH conditions (29). 
Alternatively, inefficient folding of foreign proteins in the B. subtilis 1012 
heterologous host under such alkaline conditions may contribute to the lack of 
thuricin CD activity present in the supernatants. 
The use of checkerboard assays in this study, using precise concentrations of 
proteinase K, permitted the relative quantification of thuricin CD secreted into the 
growth medium by DPC6431 and B. subtilis (pHM149) under different conditions. 
Similar patterns were observed as in well diffusion assays whereby the levels of 
production of thuricin CD by B. subtilis (pHM149) induced with high concentrations 
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of IPTG were comparable to DPC6431 production levels. Importantly, both assays 
clearly demonstrated that a basal level of thuricin CD is still produced by B. subtilis 
(pHM149) without IPTG induction, verifying that the native thuricin CD promoter is 
indeed functional in the B. subtilis 1012 background.  
The lack of thuricin CD production by B. subtilis (pHM2) and B. subtilis (pH3) 
indicated that the entire set of genes from the thuricin CD gene cluster are most 
likely required for production, instead of a subset of genes. This is not surprising as 
bacteriocin production typically requires transport/export, post-translational 
modification, maturation, regulation, immunity genes, in addition to the biosynthetic 
structural genes. Prior to this study, in silico investigations had indicated that TrnFG 
are likely components of an ABC transporter system, involved in the export of 
thuricin CD peptides (1). As B. subtilis (pHM2), lacking trnIFG, failed to produce 
thuricin CD, it is likely that TrnFG are involved in export of the thuricin CD 
peptides out of the cell. TrnI is a small protein and is unlikely to be involved in the 
export of thuricin CD peptides out of the cell but instead may be involved in 
sequestering Trnα and Trnβ peptides, serving an immunity function. As B. subtilis 
1012 is already insensitive to thuricin CD, it is unlikely that the lack of trnI has any 
impact on the viability of the B. subtilis host and production of thuricin CD. 
Therefore, the lack of thuricin CD production by B. subtilis (pHM2) is most likely 
due to a lack of the ABC transporter genes. Such ABC transporters are generally 
involved in the export of bacteriocins from their respective producer cells (39, 40). 
Indeed, ABC transporters are amongst the most common proteins found in biological 
systems (41). They consist of an ATPase domain(s), which is typically highly 
conserved. This ATPase domain binds and breaks down ATP resulting in the release 
of energy for downstream processes. Generally, ABC transporter systems are 
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comprised of 2 hydrophilic ATP binding cassette domains found in the cytoplasm 
and 2 integral membrane domains which are hydrophobic (42). ABC transporter 
systems are predominantly associated with the export and import of molecules but 
can also be associated with other biological processes. 
B. subtilis (pHM3) lacking trnCDE, also failed to produce thuricin CD. This can 
most likely be attributed to the lack of post-translational modifications due to the 
absence of the radical S-adenosylmethionine genes (trnCD) and consequent lack of 
formation of the sulphur to α-carbon bridges in both peptides, resulting in a lack of 
bioactivity. TrnE is a putative C-terminal processing peptidase and plays a minor 
role in thuricin CD immunity but the precise mechanisms by which it functions 
remain unclear. As it serves an immunity function, the lack of TrnE is unlikely to 
have an impact on the ability of B. subtilis 1012 to produce thuricin CD. Thus, the 
lack of thuricin CD production by B. subtilis (pHM3) is likely to be due to the 
absence of trnC and trnD. Based on previous bioinformatics studies, trnC and trnD 
were predicted to encode for post-translational modification genes involved in 
formation of the characteristic sulphur to α-carbon bridges associated with 
sactibiotics (1). Similar to TrnC and TrnD, AlbA is the radical S-adenosylmethionine 
(SAM) enzyme involved in the generation of sulphur to α-carbon crosslinks in the 
sactibiotic subtilosin A (9, 43). AlbA forms the cross links between cysteines and 
threonine and between cysteine and two phenylalanines residues before the 
subtilosin A leader peptide is cleaved off (43). One radical SAM enzyme is predicted 
to form four sulphur to alpha α-cross links found in the sactibiotic thurincin H (12). 
Since two radical SAM genes are found in the thuricin CD cluster, it is anticipated 
that one gene each is responsible for modifying Trnα and Trnβ respectively (1, 6). 
Such sulphur to α-carbon linkages occur between the cysteinyl sulphur and S21, 
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T25, T28 residues in Trnα and between the cysteinyl sulphur and T21, A25, Y28 
residues in Trnβ. 
In conclusion, the production of thuricin CD in a heterologous host has been 
described for the first time in this study. The thuricin CD production levels by the B. 
subtilis host are comparable to the natural producer, when induced with high 
concentrations of IPTG. The study also indicates that TrnFG and TrnCD are crucial 
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Tables and Figures 
Table 1: List of strains and constructs used in this study. 
Strain/Construct/Plasmid Source 
E. coli Top10 cells 
B. thuringiensis DPC6431 
B. subtilis 1012 
Invitrogen 
Rea et al 2010 
BGSC
a 
pHCMC05 Nguyen et al 2005 
pHM149 (pHCMC05trnIFGβαCDE) This study 
pHM2 (pHCMC05ΔtrnIFG) This study 
pHM3 (pHCMC05ΔtrnCDE) 
B. firmus NRS854 
B. thuringiensis subsp. huazhongensis 
C. difficile CF5 017
b 
C. difficile M68 017 
C. difficile 630 012 
C. difficile BI-9 
C. difficile CD305 023 
C. difficile M120 078 
C. difficile Liv024 001 
C. difficile TL174 015 
C. difficile Liv022 106 
C. difficile CD196 027 
C. difficile TL178 002 




























Table 2: Oligonucleotides used in this study. Restriction sites are highlighted in 
bold and underlined.  
Oligonucleotide Sequence 5’ to 3’ 
pHCMC05 MCS for GGTGTGGCATAATGTGTGGAATTGTG 
pHCMC05 MCS rev TACTGATCAACTGATCCACCTGA 
Pre11for BamH1 GTTGGATCCCACTGTAATGGAATTTATG 
Trn rev Sma1 GACCCGGGTAATATTCAGAAAGTATCT 
Trnβ for BamH1 CAGGGATCCGAAGAAGAGGATCTTAAA 
















Table 3: Antimicrobial activity of B. thuringiensis DPC6431 versus B. subtilis 
(trnIFGβαCDE). Comparison of the bioactivity of B. thuringiensis DPC6431
a
 and 
B. subtilis 1012 (trnIFGβαCDE)
b 
induced with different concentrations of IPTG, 
against C. difficile indicator strains, as measured by well diffusion assays. Zone sizes 
are averages of triplicate experiments. Zone sizes expressed as a percentage (in 
parentheses) of zone sizes produced by B. thuringiensis DPC6431. 
c
C. difficile strain 















































































































Table 4: Bioactivity against C. difficile indicators at different pH conditions. 
Zone sizes are averages of triplicate well diffusion assays. Numbers in parentheses 
indicate zone sizes expressed as percentages of zone sizes obtained with B. 
thuringiensis DPC6431 and B. subtilis 1012 (trnIFGβαCDE) respectively, grown at 
pH7. 
a
B.t, Bacillus thuringiensis DPC6431 grown at different pHs; 
b
B.s, Bacillus 




C. difficile strain name, followed by ribotype. 
C. difficile 
straind 
B.ta pH5 B.t pH6 B.t pH7 B.t pH8 B.t pH9 
































































































C. difficile strain B.s
b pH5 B.s pH6 B.s pH7 B.s pH8 B.s pH9 




11.5±0.87 NZc NZ 




12.5±0.5 NZ NZ 









11.92±0.38 NZ NZ 




11.83±0.52 NZ NZ 




13.0±0.5 NZ NZ 




12.67±0.58 NZ NZ 




12.75±0.5 NZ NZ 




12.75±0.66 NZ NZ 




12.75±0.43 NZ NZ 




12.58±0.63 NZ NZ 




12.5±0.87 NZ NZ 
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Table 5: Proteinase K assays to compare bioactivity of B. subtilis 
(trnIFGβαCDE) induced with IPTG. Minimum concentrations of proteinase K 
required to completely inhibit the antimicrobial activity of thuricin CD present in 
supernatants of 
a
B. thuringiensis DPC6431and 
b
B. subtilis 1012 (trnIFGβαCDE) 
induced with different concentrations of IPTG. Proteinase K concentrations 


































Table 6: Proteinase K assays to compare bioactivity at different pH conditions. 
Minimum concentrations of proteinase K (expressed in µg/ml) required to inhibit the 





B. subtilis 1012 (trnIFGβαCDE), induced with 1mM IPTG, grown at 
different pHs. 
c 














































Fig 1: Schematic of the thuricin CD gene cluster. Genetic organisation of the 
thuricin CD gene cluster containing the eight genes trnIFGβαCDE.  Genes involved 
in thuricin CD immunity (trnIFG) are shaded in dark grey. trnFG genes (dashed 
outlines) are likely to have dual functionality, involved in both immunity and in 
export of the thuricin CD peptides. The two structural genes (trnβ and trnα) are 
shaded in black. The two post-translational modification genes (trnCD), encoding 
radical S-adenosylmethionine proteins are depicted in white. The last gene in the 
cluster, trnE, shaded in light grey encodes for a peptidase, which may be involved in 
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Fig 2. Bioactivity of B. subtilis 1012 constructs. Well diffusion assay against B. 
firmus NRS854 using supernatants from A) B. subtilis 1012 (trnIFGβαCDE) induced 
with 5mM IPTG; B) B. thuringiensis DPC6431; C) B. subtilis 1012 wild type;  D) B. 
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Fig 3:  
 
 
     
 
Fig 3. MS spectra of thuricin CD produced by B. subtilis 1012 (trnIFGβαCDE). 
Mass spectrometry profile of B. subtilis 1012 (trnIFGβαCDE) expressing thuricin 
CD.  Predicted mass: Trnα= 2763. Observed mass: Trnα= 2786.32 (addition of Na
+
 
adduct ion), 2764.87 (addition of H
+
 adduct ion) and 2802.05 (addition of K
+
 adduct 
ion). Predicted mass:  Trnβ=2861. Observed mass: Trnβ=2884.15 (addition of Na
+
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The development of resistance to bacteriocins amongst target microorganisms is a 
potential concern. We examined whether resistance could occur to the sactibiotic 
thuricin CD, a bacteriocin with a narrow spectrum of inhibition which includes 
Clostridium difficile, Listeria monocytogenes and Bacillus firmus. The purpose of 
this study was to assess whether resistance to thuricin CD developed amongst 
different target organisms, investigate the mechanisms of resistance involved and 
gain an insight into the mode of action of the bacteriocin. Low-level resistance was 
observed in L. monocytogenes, B. firmus and C. difficile following repeated exposure 
to the bacteriocin. Phenotypic assessments of thuricin CD-resistant mutants in this 
study revealed minor alterations in sensitivities of some mutants to the β-lactam 
group of antibiotics. It was also established that L. monocytogenes mutants exhibited 
decreased growth rates in the presence of the sugar mannose. To the best of our 
knowledge, these findings are the first relating to the development of low-level 










Bacteriocins are ribosomally synthesised peptides produced by bacteria, and 
generally exhibit antimicrobial activity against other (usually closely-related) 
bacteria (1).  Thuricin CD is a bacteriocin produced by Bacillus thuringiensis 
DPC6431 with potent antimicrobial activity against a variety of Clostridium difficile 
virulent isolates as well as some Bacillus species and some strains of Listeria 
monocytogenes (2). Thuricin CD consists of two peptides, Trnα and Trnβ, both of 






 amino acid 
residues (2, 3). These post-translational modifications involve the formation of three 
sulphur to α-carbon bridges, which are crucial for thuricin CD antimicrobial activity 
(2). Recently, a novel nomenclature system has been devised for bacteriocins and 
thuricin CD has been included in a class of bacteriocins called sactibiotics (4). Other 
sactibiotics include propionicin F, subtilosin A and its T6I derivative, as well as 
thurincin H, produced by another strain of B. thuringiensis (4, 5, 6, 7). Studies using 
a human distal colon ex vivo model have shown that thuricin CD was as effective as 
metronidazole and vancomycin at controlling C. difficile numbers. However, in 
contrast to these antibiotics, the bacteriocin had minimal impact on the commensal 
gut microbiota (8). This is a significantly beneficial trait, as one of the main 
predisposing factors which leads to recurrent C. difficile-associated diarrhea (CDAD) 
is the extensive collateral damage to the gut microbiota caused by broad-spectrum 
antibiotics, resulting in a loss of ‘colonization resistance’ which in turn leads to 
overgrowth of C. difficile (9). Although resistance to metronidazole and vancomycin 
amongst C. difficile has rarely been reported, the overuse of such antibiotics and the 
development of resistance amongst target C. difficile strains remains a realistic 
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possibility (1, 10, 11, 12). The possibility that C. difficile or other targets could 
become resistant to thuricin CD has not been investigated previously. Indeed, 
resistance to bacteriocins belonging to the sactibiotic group in general has yet to be 
reported. 
The potency of thuricin CD against C. difficile has recently been further highlighted 
through the determination of minimum inhibitory concentrations (MICs) against 
nineteen clinical isolates (13). The study revealed that in terms of molar 
concentrations, thuricin CD was consistently more potent than metronidazole, 
vancomycin and the lantibiotic actagardine against all nineteen C. difficile targets – 
the MIC of thuricin CD ranged from 0.703 µg/ml-2.812 µg/ml against the nineteen 
isolates investigated in the study. Furthermore, the efficacy of combinatorial therapy 
against C. difficile was also highlighted in the study, with thuricin CD-ramoplanin 
and thuricin CD-vancomycin combinations proving most effective (13). Recently, 
the bioavailability of thuricin CD was also assessed using murine and porcine 
models of infection (14). Using a murine model, the study revealed that rectal 
administration of thuricin CD peptides proved to be an effective therapy and resulted 
in a 1.5 log decrease in C. difficile numbers in stool 1 hour after treatment when 
compared to the control group, whereas a total 3-log decrease was apparent 6 hours 
post-treatment, relative to the control group (14).   
Although resistance to sactibiotics has not been previously investigated, a number of 
studies investigating the mechanisms of resistance to other bacteriocins have been 
conducted (15-20). The emergence of intermediate levels of resistance in 
Enterococcus faecalis and L. monocytogenes strains to class IIa bacteriocins has 
previously been reported
 
(16, 17, 20) and has been attributed to attenuated levels of 
expression of the permease component of the mannose phosphotransferase system 
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(17, 21, 22, 23). Other studies have reported the development of resistance to the 
lantibiotic nisin, in a variety of strains including Streptococcus bovis (24), L. 
monocytogenes (25-29), Clostridium botulinum (27), Streptococcus thermophilus 
(30) which can be attributed to changes in the cell wall, especially in the 
phospholipid/membrane fatty acid composition (25, 27, 28). Several other factors 
have been shown to contribute to nisin resistance. A nisin resistance gene, encoding 
a 35kDa nisin resistance protein (NSR) is responsible for nisin resistance amongst 
Lactococcus lactis strains which do not produce nisin (31). The study showed that 
NSR is located on the cell membrane and functions as a protease, removing six C-
terminal amino acids from nisin. Thus, strains possessing this nsr gene are 
insensitive to nisin. Another study showed that the two component system 
BraS/BraR is involved in nisin resistance in Staphylococcus aureus (32). Kramer et 
al. conducted DNA-microarray based analysis of nisin-resistant L. lactis IL1403 
mutants and concluded that the primary mechanisms governing nisin resistance 
include: i) preventing nisin from actually reaching the membrane, ii) inhibiting nisin 
insertion into the cell membrane, iii) extruding nisin from the membrane and iv) 
decreasing the acidity of the extracellular medium causing nisin to bind to the cell 
wall (33). In another study, Bergholz and co-workers showed that the response 
regulator LiaR contributes to development of nisin resistance in L. monocytogenes in 
the presence of salt (34). The emergence of spontaneous resistant mutants of L.  
lactis IL1403 with low-level resistance to another lantibiotic, lacticin 3147, was also 
described in a separate study (35). Regardless of their modes of action, bacteriocins 
and indeed any antimicrobials which have the potential to be used in the clinic or in 
food, should be investigated thoroughly with respect to the potential for resistance 
development amongst target strains. Due to the limited use of bacteriocins in clinical 
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settings thus far, our knowledge of resistance is largely based on laboratory-based 
studies.  In general, studies investigating attenuated sensitivity to lipid II-targeting 
bacteriocins have suggested that resistance could be attributed to diminished access 
to the receptor and/or involves alterations in the bacterial cell envelope (33, 36, 37). 
Development of resistance to the microcin MccJ25, which has intracellular targets, 
has been shown to be due to specific mutations in the genes encoding RNA 
polymerase subunits (38). Mutations in the DNA gyrase-encoding gene has been 
recognised as a mechanism of resistance development to MccB17 (39). 
The objective of this study was to assess the possible development of low, 
intermediate and high levels of resistance to the novel bacteriocin, thuricin CD. More 
specifically, we investigated the emergence of thuricin CD resistance in C. difficile, 
L. monocytogenes and B. firmus strains. It emerged that low-level resistance to 
thuricin CD was only possible through serial exposure to incrementally increasing 
concentrations of the bacteriocin. It is notable from these studies that L. 
monocytogenes 33013 mutants exhibiting low-level resistance to thuricin CD also 
displayed decreased growth rates in the presence of the sugar mannose, with a 








Materials and Methods 
Bacterial strains and growth conditions 
L. monocytogenes 33013 was routinely cultured in Brain Heart Infusion (BHI) 
(Oxoid Ltd, Basingstoke, Hampshire, England) agar and broth at 37°C with 
agitation. B. firmus NRS854 was also grown on BHI agar and broth at 37°C with 
vigorous agitation. C. difficile strains Liv024 R001, TL174 R015 and CD196 R027 
were grown in an anaerobic workstation (Davidson & Hardy) at 37°C on Fastidious 
Anaerobic Agar (LabM Ltd; Lancashire, UK) supplemented with 7% defibrinated 
horse blood (TCS Biosciences Ltd; Botolph Claydon, Buckingham, UK) and 
cycloserine/cefoxitin antibiotics (LabM Ltd). C. difficile liquid cultures were 
routinely grown in Reinforced Clostridium Medium (RCM) (Oxoid Ltd; 
Basingstoke, Hampshire, England) at 37°C in an anaerobic workstation.  
 
Thuricin CD preparation 
Thuricin CD α and β peptides were purified as in Rea et al.  with minor 
modifications (2). Briefly, subsequent to the elution of the preparation containing the 
antimicrobial fraction, the preparation was subjected to rotary evaporation (Buchi) in 
order to further concentrate the antimicrobial-containing fraction. The Trnα and Trnβ 
peptides were then separated by reverse phase-high performance liquid 
chromatography (RP-HPLC). 4ml volumes of the concentrated preparation were 
added to a Proteo Jupiter reverse phase-HPLC column (250 x 10mm, 4μ, 90Å).  The 
RP-HPLC column was previously equilibrated with 25% acetonitrile containing 
0.1% trifluoroacetic acid (TFA). A gradient of 25-75% acetonitrile 0.1% TFA over 
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35 minutes was set up, in order to elute the Trnα and Trnβ peptides from the column. 
A flow rate of 2.5ml/min was used and the eluent was monitored at 214 nm.   
 
Minimum inhibitory concentration determinations 
Minimum inhibitory concentration (MIC) assays were conducted as in Field et al., 
with some minor modifications (40). Briefly, overnight cultures of L. monocytogenes 
33013, B. firmus NRS854, C. difficile Liv024 R001, C. difficile TL174 R015, C. 
difficile CD196 R027 (and mutants thereof) were grown in the appropriate 
conditions as mentioned above. The overnight cultures were sub-cultured in BHI 
broth (for L. monocytogenes and B. firmus) and RCM broth for C. difficile until mid-
log phase (OD600 of 0.5) was attained, at which point the culture was diluted 1/5000 
and 100µl inoculated into each well in a 96-well plate (inoculum of 5 X 10
5
 cfu/ml), 
to which serially diluted antimicrobial had been added (total volume of 0.2ml). The 
96-well plates were incubated for 18 hours under appropriate conditions and the MIC 
determined. The MIC was defined as the lowest concentration of the antimicrobial 
which completely inhibited the growth of the target strain after 18 hours of 
incubation. The following antibiotics were purchased from Sigma Aldrich: 
chloramphenicol, erythromycin, tetracycline, cephradine, ceftazidime hydrate, 
bacitracin, penicillin G, oxacillin, ampicillin, ramoplanin, metronidazole and 
vancomycin. Purified actagardine was kindly provided by Novacta Biosystems Ltd. 
(BioPark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire, 
UK). MICs were determined in the same manner as described above for these 
commercial antibiotics and actagardine and any differences in MICs between wild 
type and mutant strains were noted. All assays were conducted in triplicate.  
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Isolation of thuricin CD-resistant mutants 
Thuricin CD-resistant mutants were isolated using the same principles as described 
in Macwana et al. and Severina et al. with some minor alterations (15, 41). Here, 
instead of using agar-based spot assays and overlay assays, we exposed the thuricin 
CD indicator strains to precise concentrations of purified thuricin CD by conducting 
MIC assays as described above and incubating the 96-well plates for prolonged 
periods of time (24 hours).  Any resistant mutants were isolated by plating 20µl of a 
mixture from a turbid well in a microtitre plate onto BHI agar (for L. monocytogenes 
and B. firmus) or Fastidious anaerobic agar, supplemented with 7% defibrinated 
horse blood and cycloserine/cefoxitin antibiotics (for C. difficile). A single colony 
from each exposure was isolated and further subjected to incrementally increasing 
concentrations of thuricin CD in 96-well microtitre plates as described above. An 
isolated colony from each exposure was further subjected to several rounds of 
serially increasing exposure to thuricin CD and mutants stocked at each stage of 
resistance development. 
 
Kill curve and growth curve analysis 
Time-kill studies and growth curve analysis with L. monocytogenes 33013 and 
mutants thereof were conducted as in Field et al. with some minor modifications 
(40). Briefly, overnight cultures containing approximately 10
9
 cfu/ml of the relevant 
indicator strains were diluted to 10
7
 cfu/ml in a final volume of 1ml of BHI broth. A 
sub-inhibitory concentration (2.4µM) of thuricin CD against the relevant indicator 
was added in this final volume of 1ml and incubated at 37°C. Aliquots were taken at 
time points 60 minutes and 300 minutes and viable cell counts were conducted to 
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enumerate the cell numbers as cfu/ml. Viable counts were performed by diluting 
aliquots 1/10 in BHI broth and enumeration on BHI agar plates after 24 hours to 
calculate the numbers killed due to the specific concentration of thuricin CD being 
tested. Growth curves experiments were conducted in exactly the same manner as 
MIC assays as described above with absorbance readings taken hourly at 600nm 
(OD600) using a Spectromax 340 spectrophotometer (Molecular Devices, Sunnyvale, 
California) and  the sensitivity of L. monocytogenes strains to environmental stresses 
such as salt, pH, lysozyme and cetylpyridinium chloride (Sigma Aldrich) was 
assessed. The pH of BHI broth was adjusted using 2M HCl and/or 2M NaOH as 
appropriate. Time-kill studies with C. difficile strains were conducted as described 
by Rea et al.
 
(2). All assays were performed in triplicate. 
 
Genomic DNA extractions 
Genomic DNA extractions were performed using the Invitrogen PureLink Genomic 
Extraction kit (Invitrogen, Carlsbad, California, USA), following manufacturer’s 
instructions. 16S rRNA sequencing was performed using universal 27F and 1492R 
oligonucleotides to ensure mutants were derivatives of the parental strains. 16S 
sequencing was performed by Source BioSciences (Dublin, Ireland). Genomic DNA 
extractions of C. difficile wild type strains and their respective thuricin CD-resistant 
mutants have been sent to the Wellcome Trust Sanger Institute, Cambridge, UK for 
whole-genome sequencing, in order to gain insights into the mode of action of 




Thuricin CD exhibits highly potent antimicrobial activity against clostridial species, 
especially C. difficile. C. difficile is an opportunistic pathogen and C. difficile 
infection primarily occurs due to disruptions of the gut microbiota caused by broad 
spectrum antibiotics.  While thuricin CD has a very narrow spectrum of activity, it 
also kills some L. monocytogenes and Bacillus species.  In this study we initially 
attempted to isolate strains of C. difficile, L. monocytogenes and B. firmus with 
attenuated sensitivity to thuricin CD. 
 
Resistance to thuricin is very low in C. difficile strains 
Previous investigations relating to resistance to thuricin CD, using an agar-based 
approach and direct plating of C. difficile to isolate thuricin CD-resistant mutants 
indicated that the propensity for resistance development was extremely low 
(frequency of approximately 10 
-9 
)(Rea et al. unpublished data).  For this reason, we 
attempted to induce resistance to thuricin CD amongst the three C. difficile strains 
(Liv024 R001, TL174 R015 and CD196 R027) by serially exposing each of the  
strains to incrementally increasing concentrations of thuricin CD. Despite this 
approach, insensitivity to thuricin CD could only be increased to a maximum of 8-
fold after which no growth occurred. Thuricin CD MIC values for C. difficile Liv024 
R001, C. difficile TL174 R015, C. difficile CD196 R027 were 2.812 µg/ml, 1.406 
µg/ml and 1.406 µg/ml respectively (Table 1). The MICs of thuricin CD against 
resistant mutants of the above-mentioned strains were 11.248 µg/ml, 8.436µg/ml and 
2.812µg/ml respectively. Differences in the MICs of several antibiotics against the 
wild type C. difficile strains and resistant mutants thereof were negligible and merely 
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differed by two-fold in some cases.  Statistically significant differences (P<0.05) 
were apparent between each of C. difficile wild type strains and their respective 
thuricin CD-resistant mutants, after 5 hours of incubation in the presence of sub-
lethal 0.225µM (for TL174 R015 and CD196 R027) and 0.45µM (for Liv024 R001) 
thuricin CD concentrations (Fig 1). 
 
Phenotype of thuricin CD-resistant B. firmus mutants 
Similar to C. difficile, resistance to thuricin CD was acquired by serially exposing B. 
firmus NRS854 to increasing concentrations of the bacteriocin. The MIC of thuricin 
CD against wild type B. firmus NRS854 was 0.703 µg/ml. Thuricin CD-resistant B. 
firmus NRS854 mutants, designated Bf1-Bf5, had MIC values of 2.812 µg/ml (Bf1, 
2 and 3) or 5.624 µg/ml (Bf4 and 5)( Table 2). While no differences in sensitivities 
of B. firmus NRS854 and its thuricin CD-resistant mutants to chloramphenicol (all 
2.42µg/ml) and erythromycin (all 18.35µg/ml) were noted, subtle differences in β-
lactam antibiotic MIC values were apparent. The MIC values for penicillin G against 
B. firmus mutants were two to four-fold less than those of the wild type B. firmus 
strain (Table 2). Oxacillin and ampicillin MIC values were also two to four-fold less 
for the B. firmus thuricin CD-resistant mutants than the wild type. One mutant, Bf2 
displayed a two-fold decrease in sensitivity to cephradine relative to the wild type, 
with an MIC of 0.436 µg/ml compared to 0.218 µg/ml against B. firmus NRS854 
wild type. In contrast, two mutants, Bf1 and Bf4, exhibited slight increases in 
sensitivity to ceftazidime with MICs of 0.683µg/ml and 1.366µg/ml respectively, 
compared to an MIC of 2.73µg/ml against the wild type. Finally, sensitivity to 
cetylpyridinium chloride and lysozyme was unaltered (Table 2). 
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Phenotype of thuricin CD-resistant L. monocytogenes mutants 
As was the case with C. difficile and B. firmus strains, resistance was developed by 
serially exposing L. monocytogenes 33013 to incrementally increasing thuricin CD 
concentrations in a stepwise manner.  The MIC of thuricin CD against wild type L. 
monocytogenes 33013 was 14.06 µg/ml while the L. monocytogenes 33013 thuricin 
CD-resistant mutants designated Lmr1, Lmr2 and Lmr3 had corresponding MICs of 
28.12 µg/ml, 56.24 µg/ml and 112.48 µg/ml respectively (Table 3). The 
resistance/sensitivity of these mutants to other antimicrobials was tested and 
negligible differences were noted between the wild type and resistant mutants. When 
grown for 5 hours in the presence of sub-lethal (2.4µM) concentrations of thuricin 
CD, cfu/ml numbers of the L. monocytogenes 33013 wild type merely increased by 
approximately two-fold of the original starting inoculum. This was significantly less 
(P <0.05) than the approximately 1.5-log increases in cfu/ml counts for each of 
Lmr1, Lmr2 and Lmr3 after 5 hours of incubation (Fig 2). 
The growth rates of the L. monocytogenes strains in BHI broth supplemented with 
the sugars mannose, galactose or glucose was also compared (Fig 3A, 3B and 3C 
respectively). In the presence of 5% mannose, Lmr1, Lmr2 and Lmr3 exhibited 
statistically significant decreased growth rates (P<0.05) compared to the wild type 
(Fig 3A), whereas no differences were apparent in the presence of 5% galactose (Fig 
3B). In the presence of 5% glucose, Lmr1, Lmr2 and Lmr3 exhibited statistically 
significant increased growth rates (P<0.05) relative to the wild type (Fig 3C). No 
differences were apparent when L. monocytogenes 33013 wild type and mutants 
were grown at varying pH conditions of pH5, pH6 and pH7 (Fig 4A, 4B and 4C 
respectively). Similarly, no differences were apparent between the wild type and 
mutants under osmotic stress (6.25% sodium chloride), in the presence of lysozyme 
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or when challenged with the quaternary ammonium compound, cetylpyridinium 
chloride (Fig 4D, 4E and 4F respectively). The findings of these growth curve 
analyses indicate that cross resistance amongst thuricin CD-resistant L. 
monocytogenes mutants to environmental stresses such as osmotic stress, pH stress 


















This study is focussed of the emergence of resistant mutants of thuricin CD due to 
serial exposure to the bacteriocin. A comprehensive assessment of the phenotypic 
characteristics of such mutants was also conducted, in particular assessing the 
possibility of cross resistance to other antimicrobials and stressors. The subtle 
differences in antibiotic susceptibilities across thuricin CD-resistant L. 
monocytogenes, B. firmus and C. difficile investigated in this study may be due to the 
different cell wall compositions in these species. Thus, mutations of certain targets as 
a consequence of thuricin CD resistance development may result in minor variations 
in antimicrobial sensitivity and differences in phenotypes across species.  
The antimicrobial susceptibilities of thuricin CD-resistant L. monocytogenes, B. 
firmus and C. difficile mutants in terms of MICs were conducted in this study. It was 
interesting to note that one L. monocytogenes 33013 mutant, Lmr3, was two-fold 
more sensitive to cephradine compared to its wild type parental derivative. 
Cephradine is a cephalosporin, belonging to the β-lactam class of antibiotics (42). β-
lactam antibiotics exert their antimicrobial effects by disrupting the formation of 
peptidoglycan cross links in bacterial cell walls (43). Penicllin binding proteins 
(PBPs) are involved in this process of cross linking the peptidoglycan in bacterial 
cell walls (44). Cephalosporins and other β-lactams inhibit the actions of PBPs such 
as transpeptidases (45). Altered cephalosporin sensitivity had previously been 
reported by Guinane et al. with respect to lacticin 3147-resistant variants of L. lactis 
IL1403 (37). In that study, it was found that all eight lacticin 3147-resistant L. lactis 
IL1403 mutants displayed slight increases in sensitivity to cephradine and other 
cephalosporin antibiotics.  A link between altered cephalosporin sensitivity and 
nisin-resistance in L. monocytogenes isolates has also been reported in previous 
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studies (46, 47). Increased sensitivities of B. firmus thuricin CD-resistant mutants to 
the penicillin group of antibiotics were also apparent in our study. The β-lactam ring 
of penicillin binds to the PBP DD-transpeptidase, thus inhibiting its ability to 
catalyse the cross linking of peptidoglycan while at the same time, bacterial enzymes 
hydrolysing the peptidoglycan cell walls continue working, thus weakening the cell 
wall and causing cell death (43, 48, 49). The C. difficile TL174 R015 thuricin CD-
resistant mutant displayed increased sensitivity to the β-lactam ceftazidime. Subtle 
alterations in sensitivities to the cell wall-targeting antimicrobials ramoplanin, 
actagardine and vancomycin amongst C. difficile mutants indicate that cell wall 
changes may have taken place as a consequence of thuricin CD resistance 
development. Interestingly, all 3 thuricin CD-resistant variants of L. monocytogenes 
33013 displayed two-fold increases in resistance to the macrolide erythromycin, 
compared to the wild type parental strain. Erythromycin is an antibiotic which 
possesses bacteriostatic activity by binding to the 50S subunit of the 70S rRNA 
complex of the bacterial ribosome. It interferes with the transfer of tRNA within the 
rRNA complex (50). This can potentially be attributed to a mutation in an erm gene, 
resulting in hyper-expression of an erythromycin resistance gene. In a recent study, 
spontaneous resistant mutants of S. aureus, exhibiting resistance to a bacteriocin 
complex produced by Bacillus subtilis LFB112 were isolated (19). Similar to our 
findings, the resistant S. aureus mutants also displayed increased sensitivity to some 
antimicrobial agents with the exception of chloramphenicol. Interestingly however, 
changes in membrane fatty acid composition were not thought to be associated with 
bacteriocin resistance in S. aureus, as the compositions of wild type and resistant 
variants were largely similar in that study (19). 
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L. monocytogenes 33013 and thuricin CD-resistant Lmr1, Lmr2 and Lmr3 were also 
subjected to growth curve analysis and time-kill studies in our study. MIC assays are 
limited by the fact that they provide end-point reads after a fixed time point. In 
contrast, growth curve assays can illustrate the effects of an antimicrobial or 
environmental stress such as salt and pH on the viability of the target strain on an 
ongoing basis over a period of time. All three L. monocytogenes thuricin CD-
resistant mutants exhibited decreased growth rates in the presence of mannose and 
increased growth rates in glucose, compared to the parental strain. However, it 
remains unclear whether this is an indirect adaptive response as a consequence of 
resistance development or whether the Man-PTS functions as a putative receptor for 
thuricin CD, and will be the focus of targeted research in the future. Nonetheless, it 
is tempting to speculate that mutations in the Man-PTS operon of thuricin CD-
resistant L. monocytogenes mutants may contribute to the apparent differences in 
metabolism of mannose and glucose. The membrane components IIC and IID of the 
Man-PTS act as receptors for bacteriocins such as the class IIa pediocin-like 
bacteriocins, as well as the class IIc bacteriocin lactococcin A (16, 51, 52, 53). While 
lactococcin A merely targets the Man-PTS from Lactococcus strains, the Man-PTS 
from several genera including Listeria, Enterococcus and Lactobacillus is targeted 
by class IIa bacteriocins (54, 55, 56). It was shown that class IIa bacteriocins bind a 
single extracellular loop in the IIC protein of the Man-PTS, whereas lactococcin A 
binds many regions of IIC and IID proteins for target specificity (57). The Man-PTS 
found in the inner membrane of sensitive E. coli strains, also functions as a target for 
the microcin E492 (58).  
A recent study described a global transcriptional analysis of L. monocytogenes 
isolates which developed spontaneous resistance to the bacteriocin sakacin P (18). 
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Similar to our findings, Tessema et al. observed diminished growth rates of sakacin 
P-resistant L. monocytogenes isolates on mannose while no difference was found 
when grown on cellobiose in that study (18). The Man-PTS, apart from acting as a 
receptor for class IIa bacteriocins such as sakacin P as mentioned above, is also 
involved in transporting mannose (18). In another study, Kjos and co-workers 
isolated L. lactis and L. monocytogenes mutants resistant to lactococcin A and noted 
that the mechanisms of resistance to lactococcin A was associated with attenuated 
expression of Man-PTS (16). However, in the case of some lactococcin A-resistant 
mutants, expression of Man-PTS was not affected and the mechanisms of resistance 
amongst such mutants remain unclear. Nonetheless, a connection between resistance 
development and altered metabolism of different sugar substrates was apparent in the 
study (16). Other studies have also reported that resistance to class IIa bacteriocins in 
L. monocytogenes is associated with downregulation of the Man-PTS genes (17, 23, 
59).  
The ability of target strains to develop resistance or attenuated sensitivity to 
bacteriocins is a potential problem in clinical settings and especially in the food 
industry, where bacteriocins such as nisin are already used. Serial exposure to nisin 
leading to the development of stable mutants of Streptococcus pneumoniae was 
described in a study (60). While it is clear that alterations in lipid II are not involved 
in the development of resistance to nisin, more recent studies have highlighted the 
roles of Nisin-Resistant Proteins and two component systems involved in attenuated 
sensitivity to the lantibiotic (32, 34, 59). Similar to nisin-resistant S. pneumoniae 
mutants described by Severina and co-workers, thuricin CD-resistant mutants in this 
study have also been isolated by serially exposing sensitive strains to increased 
thuricin CD concentrations (41). Alterations in the cell envelope, such as changes in 
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the thickness of the cell wall, fluidity and charge of the cell membrane and/or cell 
wall or combination of the aforementioned factors are generally attributed to the 
development of resistance to bacteriocins (24, 28, 60, 61, 62, 63, 64). A combination 
of the above may be involved in the development of thuricin CD-resistant mutants 
described in this study. Cross-resistance to other bacteriocins and/or environmental 
stresses is also a potential problem, especially in the food industry whereby the use 
of hurdle technology is of paramount importance in order to preserve food. It is 
noteworthy in this regard that Lrm1, Lrm2 and Lrm3 did not display increased 
tolerance to salt or pH stress.  
In conclusion, this study gives a detailed account of the development of low-level 
resistance to the sactibiotic thuricin CD amongst five sensitive strains and also 
reports the MICs of a range of antimicrobials against these five indicators and their 
respective thuricin CD-resistant mutants. Thuricin CD-resistant mutants of L. 
monocytogenes 33013, B. firmus NRS854, C. difficile Liv024 R001, C. difficile 
TL174 R015 and C. difficile CD196 R027 displayed two-fold to eight-fold increases 
in thuricin CD MICs. The emergence of thuricin CD-resistant mutants due to 
repeated exposure to the bacteriocin, as described in this study, may provide an 
insight into the mechanism of action of this unusual bacteriocin, while also providing 







This work was funded by the Irish Research Council for Science, Engineering and 
Technology (IRCSET).  We would like to thank Alimentary Health Ltd. for 



















1. Cotter PD, Hill C, Ross RP.  2005. Bacteriocins: developing innate 
immunity for food. Nat. Rev. Microbiol.  3:777-88. 
 
2. Rea MC, Sit CS, Clayton E, O'Connor PM, Whittal RM, Zheng J, 
Vederas JC, Ross RP, Hill C. 2010. Thuricin CD, a posttranslationally 
modified bacteriocin with a narrow spectrum of activity against Clostridium 
difficile. Proc. Natl. Acad. Sci. U. S. A.  107:9352-7. 
 
3. Sit CS, McKay RT, Hill C, Ross RP, Vederas JC. 2011. The 3D structure 
of thuricin CD, a two-component bacteriocin with cysteine sulfur to α-carbon 
cross-links. J.  Am. Chem. Soc.  133:7680-3. 
 
4. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, 
Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik 
DJ et al. 2013. Ribosomally synthesized and post-translationally modified 
peptide natural products: overview and recommendations for a universal 
nomenclature. Nat. Prod. Rep.  30:108-60. 
 
5. Brede DA, Faye T, Johnsborg O, Odegård I, Nes IF, Holo H. 2004. 
Molecular and genetic characterization of propionicin F, a bacteriocin from 
Propionibacterium freudenreichii. Appl. Environ. Microbiol. 270:7303-10. 
 
207 
6. Zheng G, Yan LZ, Vederas JC, Zuber P. 1999. Genes of the sbo-alb locus 
of Bacillus subtilis are required for production of the antilisterial bacteriocin 
subtilosin. J. Bacteriol. 181:7346-55. 
 
7. Lee H, Churey JJ, Worobo RW.  2009. Biosynthesis and transcriptional 
analysis of thurincin H, a tandem repeated bacteriocin genetic locus, 
produced by Bacillus thuringiensis SF361. FEMS Microbiol. Lett.  299:205-
13. 
 
8. Rea MC, Dobson A, O'Sullivan O, Crispie F, Fouhy F, Cotter PD, 
Shanahan F, Kiely B, Hill C, Ross RP.  2011. Effect of broad- and narrow-
spectrum antimicrobials on Clostridium difficile and microbial diversity in a 
model of the distal colon. Proc. Natl. Acad. Sci. U. S. A.  108:4639-44. 
 
9. Hookman P, Barkin JS. 2009. Clostridium difficile associated infection, 
diarrhea and colitis. World J. Gastroenterol.  15:1554-80. 
 
10. Lynch T, Chong P, Zhang J, Hizon R, Du T, Graham MR, Beniac DR, 
Booth TF, Kibsey P, Miller M, Gravel D, Mulvey MR. 2013. 
Characterization of a stable, metronidazole-resistant Clostridium difficile 
clinical isolate. PLoS One.  8:e53757. 
 
 
11. Peláez T, Cercenado E, Alcalá L, Marín M, Martín-López A, Martínez-
Alarcón J, Catalán P, Sánchez-Somolinos M, Bouza E. 2008. 
208 
Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. 
Microbiol. 46:3028-32. 
 
12. Pituch H, Obuch-Woszczatyński P, Wultańska D, Meisel-Mikołajczyk F, 
Łuczak M. 2005. A survey of metronidazole and vancomycin resistance in 
strains of Clostridium difficile isolated in Warsaw, Poland. Anaerobe. 
11:197-9. 
 
13. Mathur H, O'Connor PM, Hill C, Cotter PD, Ross RP.2013. Analysis of 
anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, 
ramoplanin, and actagardine, both singly and in paired combinations. 
Antimicrob. Agents Chemother.  57:2882-6. 
 
14. Rea MC, Alemayehu D, Casey PG, O'Connor PM, Lawlor PG, Walsh M, 
Shanahan F, Kiely B, Ross RP, Hill C.2014. Bioavailability of the anti-
Clostridial Bacteriocin Thuricin CD in Gastrointestinal Tract. Microbiology 
160:439-45. 
 
15. Macwana S, Muriana PM. 2012. Spontaneous bacteriocin resistance in 
Listeria monocytogenes as a susceptibility screen for identifying different 
mechanisms of resistance and modes of action by bacteriocins of lactic acid 
bacteria. J. Microbiol. Methods 88:7-13. 
 
209 
16. Kjos M, Nes IF, Diep DB. 2011. Mechanisms of resistance to bacteriocins 
targeting the mannose phosphotransferase system. Appl. Environ. Microbiol.  
277:3335-42. 
 
17. Tessema GT, Møretrø T, Kohler A, Axelsson L, Naterstad K.  2009. 
Complex phenotypic and genotypic responses of Listeria monocytogenes 
strains exposed to the class IIa bacteriocin sakacin P. Appl. Environ. 
Microbiol.  75:6973-80. 
 
18. Tessema GT, Møretrø T, Snipen L, Axelsson L, Naterstad K.2011. 
Global transcriptional analysis of spontaneous sakacin P-resistant mutant 
strains of Listeria monocytogenes during growth on different sugars. PLoS 
One. 6:e16192. 
 
19. Liu BS, Li GG, Yu ZQ, Han B, Zhang RJ. 2011. Evaluation of Bacteriocin 
Resistance in Staphylococcus aureus against the Bacteriocin Complex 
Secreted by Bacillus subtilis LFB112. Journal of Animal and Veterinary 
Advances. 10:1743-1749. 
 
20. Opsata M, Nes IF, Holo H. 2010. Class IIa bacteriocin resistance in 
Enterococcus faecalis V583: the mannose PTS operon mediates global 
transcriptional responses. BMC Microbiol. 10:224. 
 
21. Héchard Y, Pelletier C, Cenatiempo Y, Frère J. 2001. Analysis of 
sigma(54)-dependent genes in Enterococcus faecalis: a mannose PTS 
210 
permease (EII(Man)) is involved in sensitivity to a bacteriocin, mesentericin 
Y105. Microbiology. 147:1575-80. 
 
22. Arous S, Dalet K, Héchard Y. 2004. Involvement of the mpo operon in 
resistance to class IIa bacteriocins in Listeria monocytogenes. FEMS 
Microbiol. Lett.  238:37-41. 
 
23. Gravesen A, Ramnath M, Rechinger KB, Andersen N, Jänsch L, 
Héchard Y, Hastings JW, Knøchel S. 2002b. High-level resistance to class 
IIa bacteriocins is associated with one general mechanism in Listeria 
monocytogenes. Microbiology. 148:2361-9. 
 
24. Mantovani HC, Russell JB.2001. Nisin resistance of Streptococcus bovis. 
Appl. Environ. Microbiol.  67:808-13. 
 
25. Ming X, Daeschel MA. 1993. Nisin resistance of foodborne bacteria and the 
specific resistance responses of Listeria monocytogenes Scott A. J. Food 
Prot.  56:944–948. 
 
26. Davies EA, Adams MR. 1994. Resistance of Listeria monocytogenes to the 
bacteriocin nisin. Int. J. Food Microbiol.  21:341–347. 
 
27. Mazzotta AS & Montville TJ.  1997. Nisin induces changes in membrane 
fatty acid composition of Listeria monocytogenes nisin-resistant strains at 
10°C and 30°C. J. Appl. Microbiol.  82:32–38. 
211 
 
28. Verheul A, Russell NJ, Van'T Hof R, Rombouts FM, Abee T. 1997. 
Modifications of membrane phospholipid composition in nisin-resistant 
Listeria monocytogenes Scott A. Appl. Environ. Microbiol.  63:3451-7. 
 
29. Gravesen A, Jydegaard Axelsen AM, Mendes da Silva J, Hansen TB, 
Knøchel S. 2002a. Frequency of bacteriocin resistance development and 
associated fitness costs in Listeria monocytogenes. Appl. Environ. Microbiol.  
68:756-64. 
 
30. Garde S, Avila M, Medina M & Nunez M.  2004. Fast induction of nisin 
resistance in Streptococcus thermophilus INIA 463 during growth in milk. 
Int. J. Food Microbiol. 96:165–172. 
 
31. Sun Z, Zhong J, Liang X, Liu J, Chen X, Huan L. 2009. Novel mechanism 
for nisin resistance via proteolytic degradation of nisin by the nisin resistance 
protein NSR. Antimicrob. Agents Chemother.  53:1964-73. 
 
32. Hiron A, Falord M, Valle J, Débarbouillé M, Msadek T. 2011.  Bacitracin 
and nisin resistance in Staphylococcus aureus: a novel pathway involving the 
BraS/BraR two-component system (SA2417/SA2418) and both the 
BraD/BraE and VraD/VraE ABC transporters. Mol. Microbiol. 81:602-22. 
 
212 
33. Kramer NE, van Hijum SA, Knol J, Kok J, Kuipers OP. 2006. 
Transcriptome analysis reveals mechanisms by which Lactococcus lactis 
acquires nisin resistance. Antimicrob. Agents Chemother. 50:1753-61. 
 
34. Bergholz TM, Tang S, Wiedmann M, Boor KJ. 2013. Nisin resistance of 
Listeria monocytogenes is increased by exposure to salt stress and is 
mediated via LiaR. Appl. Environ. Microbiol.  79:5682-8. 
 
35. Guinane CM, Cotter PD, Hill C, Ross RP. 2006. Spontaneous resistance in 
Lactococcus lactis IL1403 to the lantibiotic lacticin 3147. FEMS Microbiol. 
Lett.  260:77-83. 
 
36. Piper C, Draper LA, Cotter PD, Ross RP, Hill C.  2009. A comparison of 
the activities of lacticin 3147 and nisin against drug-resistant 
Staphylococcus aureus and Enterococcus species. J. Antimicrob. 
Chemother.  64:546-51. 
 
37. Collins B, Curtis N, Cotter PD, Hill C, Ross RP. 2010. The ABC 
transporter AnrAB contributes to the innate resistance of Listeria 
monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. 
Antimicrob. Agents Chemother. 54:4416–4423. 
 
38. Yuzenkova J, Delgado M, Nechaev S, Savalia D, Epshtein V, 
Artsimovitch I, Mooney RA, Landick R, Farias RN, Salomon R, 
213 
Severinov K.  2002. Mutations of bacterial RNA polymerase leading to 
resistance to microcin j25. J. Biol. Chem.  277:50867-75. 
 
39. del Castillo FJ, del Castillo I, Moreno F. 2001. Construction and 
characterization of mutations at codon 751 of the Escherichia coli gyrB gene 
that confer resistance to the antimicrobial peptide microcin B17 and alter the 
activity of DNA gyrase. J. Bacteriol. 183:2137-40. 
 
40. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, 
Hill C, Ross RP. 2012. Bioengineered nisin A derivatives with enhanced 
activity against both Gram positive and Gram negative pathogens. PLoS One. 
7:e46884. 
 
41. Severina E, Severin A, Tomasz A.  1998. Antibacterial efficacy of nisin 
against multidrug-resistant Gram-positive pathogens. J. Antimicrob. 
Chemother.  41:341 
 
42. Holten KB, Onusko EM. 2000. Appropriate prescribing of oral beta-lactam 
antibiotics. American Family Physician. 62:611–20. 
 
43. Fisher JF, Meroueh SO, Mobashery S.  2005. Bacterial Resistance to β-
Lactam Antibiotics:  Compelling Opportunism, Compelling Opportunity. 
Chemical Reviews. 105:395–424. 
 
44. Georgopapadakou NH. 1993. Penicillin-binding proteins and bacterial 
resistance to beta-lactams. Antimicrob. Agents Chemother.  37:2045-53. 
 
214 
45. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, 
Mitsuhashi S. 1988. Mechanism of action of cephalosporins and resistance 
caused by decreased affinity for penicillin-binding proteins in Bacteroides 
fragilis. Antimicrob. Agents Chemother. 32:1848-53. 
 
46. Gravesen A, Sørensen K, Aarestrup FM, Knøchel S.  2001. Spontaneous 
nisin-resistant Listeria monocytogenes mutants with increased expression of 
a putative penicillin-binding protein and their sensitivity to various 
antibiotics. Microb. Drug Resist.  7:127-35. 
 
47. Cotter PD, Guinane CM, Hill C. 2002. The LisRK signal transduction 
system determines the sensitivity of Listeria monocytogenes to nisin and 
cephalosporins. Antimicrob. Agents Chemother. 46:2784-90. 
 
48. Nguyen-Distèche M, Leyh-Bouille M, Ghuysen JM.  1982. Isolation of the 
membrane-bound 26 000-Mr penicillin-binding protein of Streptomyces 
strain K15 in the form of a penicillin-sensitive D-alanyl-D-alanine-cleaving 
transpeptidase. Biochem. J. 207:109-15. 
 
49. Chambers HF. 1999. Penicillin-binding protein-mediated resistance in 
pneumococci and staphylococci. J. Infect. Dis. 179:S353-9. 
 
50. Tenson T, Lovmar M, Ehrenberg M.  2003. The Mechanism of Action of 
Macrolides, Lincosamides and Streptogramin B Reveals the Nascent Peptide 
Exit Path in the Ribosome. Journal of Mol. Biol.  330:1005–1014. 
215 
 
51. Dalet K, Cenatiempo Y, Cossart P, Hechard Y.  2001. A σ54-dependent 
PTS permease of the mannose family is responsible for sensitivity of Listeria 
monocytogenes to mesentericin Y105. Microbiology. 147:3263–3269. 
 
52. Ramnath M, Arous S, Gravesen A, Hastings JW, Héchard Y. 2004. 
Expression of mptC of Listeria monocytogenes induces sensitivity to class IIa 
bacteriocins in Lactococcus lactis. Microbiology. 150:2663-8. 
 
53. Diep DB, Skaugen M, Salehian Z, Holo H, Nes IF.  2007. Common 
mechanisms of target cell recognition and immunity for class II bacteriocins. 
Proc. Natl. Acad. Sci. U. S. A.  104:2384–2389.  
 
54. Eijsink VG, Skeie M, Middelhoven PH., Brurberg MB, Nes IF.  1998. 
Comparative studies of class IIa bacteriocins of lactic acid bacteria. Appl. 
Environ. Microbiol.  64:3275–3281. 
 
55. Holo H, Nes IF. 1989. High-frequency transformation, by electroporation, of 
Lactococcus lactis subsp. cremoris grown with glycine in osmotically 
stabilized media. Appl. Environ. Microbiol.  55:3119–3123. 
 
56. Kjos M, Nes IF, Diep DB. 2009. Class II one-peptide bacteriocins target a 
phylogenetically defined subgroup of mannose phosphotransferase systems 
on sensitive cells. Microbiology. 155:2949–2961. 
 
216 
57. Kjos M, Salehian Z, Nes IF, Diep DB.  2010. An extracellular loop of the 
mannose phosphotransferase system component IIC is responsible for 
specific targeting by class IIa bacteriocins. J. Bacteriol. 192:5906–5913. 
 
58. Bieler S, Silva F, Soto C, Belin D.  2006. Bactericidal activity of both 
secreted and nonsecreted microcin E492 requires the mannose permease. J. 
Bacteriol. 188:7049–7061. 
 
59. Ramnath M, Beukes M, Tamura K, Hastings JW. 2000. Absence of a 
putative mannose-specific phosphotransferase system enzyme IIAB 
component in a leucocin A-resistant strain of Listeria monocytogenes, as 
shown by two-dimensional sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. Appl. Environ. Microbiol.  66:3098-101. 
 
60. Kramer NE, Smid EJ, Kok J, de Kruijff B, Kuipers OP, Breukink E. 
2004.  Resistance of Gram-positive bacteria to nisin is not determined by 
lipid II levels. FEMS Microbiol. Lett. 239:157-61. 
 
61. Bierbaum G, Sahl HG. 1987. Autolytic system of Staphylococcus simulans 
22: influence of cationic peptides on activity of N-acetylmuramoyl-L-alanine 
amidase. J. Bacteriol. 169:5452-8. 
 
62. Abachin E, Poyart C, Pellegrini E, Milohanic E, Fiedler F, Berche P, 
Trieu-Cuot P.  2002. Formation of D-alanyl-lipoteichoic acid is required for 
adhesion and virulence of Listeria monocytogenes. Mol. Microbiol.  43:1–14. 
 
217 
63. Maisnier-Patin S, Richard J.  1996. Cell wall changes in nisin-resistant 
variants of Listeria innocua grown in the presence of high nisin 
concentrations. FEMS Microbiol. Lett.  140:29-35. 
 
64. Crandall AD, Montville TJ. 1998. Nisin resistance in Listeria 
monocytogenes ATCC 700302 is a complex phenotype. Appl. Environ. 
















Tables and Figures 
Table 1: Minimum inhibitory concentration values of antimicrobials against C. 
difficile and thuricin CD-resistant mutants. MICs of several antimicrobials 
against C. difficile Liv024 R001, C. difficile TL174 R015, C. difficile CD196 R027 
and their thuricin CD-resistant mutants. MIC values are indicated in µM with µg/ml 












































































































































































































































































Table 2: Minimum inhibitory concentration values of antimicrobials against B. 
firmus NRS854 and thuricin CD-resistant mutants. MIC figures are indicated in 
µM with µg/ml values included in parentheses. Mutants designated Bf1-Bf5. 
 






















































































































































































Table 3: Minimum inhibitory concentrations of antimicrobials against L. 
monocotogenes 33013 and thuricin CD-resistant mutants. MIC values are 
indicated in µM with µg/ml values included in parentheses. Mutants designated 
Lmr1-Lmr3. 





















































































































Fig 1: Kill curve analysis of C. difficile strains and respective thuricin CD-
resistant mutants. Survival and growth of C. difficile Liv024 R001, C. difficile 
TL174 R015, C. difficile CD196 R027 and their respective thuricin CD-resistant 
mutants when challenged with 0.225µM (for TL174 R015 and CD196 R027) and 

















Fig 2. Survival studies of L. monocytogenes 33013 and thuricin CD-resistant 
mutants. Survival and growth of L. monocytogenes 33013 and its thuricin CD-
resistant mutants when challenged with a sub-lethal dose of thuricin CD (2.4µM). 

























Growth curve analysis of L. monocytogenes 33013 and thuricin CD-resistant 
mutants. Growth curve of L. monocytogenes 33013 and its thuricin CD-resistant 
mutants when grown in Brain Heart Infusion broth, supplemented with 5% mannose 




































Fig 4: Growth kinetics of L. monocytogenes 33013 and thuricin CD-resistant 
mutants under stressful conditions. Growth curve analysis of L. monocytogenes 
33013 and its thuricin CD-resistant mutants when grown in Brain Heart Infusion 
broth at pH5 (A), pH6 (B), pH7 (C),  supplemented with 6.25% sodium chloride (D), 


















The recurrence of CDAD post-antibiotic use is an ongoing problem that must be 
addressed. CDAD is primarily caused by broad spectrum antibiotics, often leading to 
perturbations of the commensal gut microbiota, resulting in a cyclic pattern of 
recurrent CDAD. This thesis describes the work conducted with thuricin CD, a 
narrow spectrum bacteriocin with potent anti-C. difficile activity. As a result of these 
attributes, thuricin CD has the potential to replace or at least be used in conjunction 
with traditional antibiotics such as metronidazole and vancomycin for treatment of 
CDAD. This thesis describes the developments made with respect to thuricin CD, 
including the heterologous expression of thuricin CD, the identification of the 
thuricin CD immunity genes, insights into the mechanisms of development of low-
level resistance to thuricin CD and its effectiveness in combating C. difficile, when 
used in combination with other antimicrobials. In addition, the thesis contributes to 
our understanding of the biology of the newly-designated sactibiotic group of 
bacteriocins. 
Chapter I describes the processes involved in C. difficile infection, focussing on 
hypervirulent and toxin-variant strains, toxin production, diagnosis, traditional 
treatment modalities and novel/alternative treatment options which may be used in 
the future for CDAD. In particular, it focuses on the mechanisms of pathogenesis of 
hypervirulent/toxin-variant C. difficile strains and describes the potential of novel 
antimicrobials such as fidaxomicin, ramoplanin, tigecycline as well as bacteriocins 
such as thuricin CD, LFF571 and NVB302. Furthermore, the 
advantages/disadvantages of novel treatment options are discussed. In addition, the 
potential of alternative adjunctive treatment options such as probiotics, faecal 
bacteriotherapy, ion-binding resins and vaccines are discussed in Chapter I. 
228 
Chapter II focuses on antimicrobial combination studies against a range of C. 
difficile clinical isolates. In this chapter, the MICs of thuricin CD against 19 C. 
difficile isolates are determined and compared with the three antibiotics 
metronidazole, vancomycin and ramoplanin as well as against the bacteriocin 
actagardine, belonging to the lantibiotic group. These MICs indicate that in terms of 
molar concentrations, thuricin CD consistently performs better than metronidazole, 
vancomycin and actagardine. Ramoplanin yields the lowest MICs against the 
majority of the C. difficile isolates tested in this study in terms of molar 
concentrations. Antimicrobial combination studies using the five antimicrobials 
mentioned above were conducted against 13 C. difficile clinical isolates using broth-
based checkerboard assays, resulting in a total of 117 combinations assessed. Out of 
these 117 combinations, 34 were found to have partial synergistic/additive effects. 
Significantly, ramoplanin/actagardine combinations proved particularly effective 
with partial synergistic/additive effects obtained against 61.5% of C. difficile strains 
tested. Although it has been acknowledged that there are limitations with in vitro 
studies, especially with C. difficile, the findings of this study could form the basis for 
downstream in vivo studies with murine/porcine models of infection and possibly 
clinical trials, with the ultimate goal to find effective combinations to be used in the 
clinic against cases of CDAD. 
Chapter III focused on gaining a better insight into the immunity systems employed 
by B. thuringiensis DPC6431, to protect itself from the antimicrobial actions of 
thuricin CD i.e. to prevent self-killing. A number of constructs encompassing the 
putative thuricin CD immunity determinants were constructed and introduced into 
the thuricin CD-sensitive indicator L. monocytogenes 33013. The results from this 
study helped to identify the immunity genes in the thuricin CD gene cluster. It 
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emerged that four genes are involved in providing protection against thuricin CD. 
Significantly, as part of this study, it emerged that an open reading frame located 
upstream of trnF is in fact an immunity gene, encoding a small hydrophobic 
transmembrane immunity protein. Extensive in silico analysis of this novel protein, 
designated TrnI, indicated that it consists of two transmembrane helices and is 
predicted to function by aggregating thuricin CD or somehow interfering with the 
ability of the thuricin CD peptides to bind the target site/receptor. This dedicated 
immunity protein TrnI may function in a similar manner to LanI proteins in 
lantibiotic immunity systems. Further studies will help to disclose the precise 
mechanisms by which the newly-discovered TrnI peptide functions in providing 
immunity. In silico analysis of TrnG also indicated that it is a hydrophobic protein, 
consisting of 6 transmembrane helices and forms the integral membrane domain of a 
fully functional ABC-transporter system TrnFG, also involved in thuricin CD 
immunity.   
The main focus of Chapter IV was the cloning and expression of thuricin CD in a 
heterologous host. Since the thuricin CD producer is B. thuringiensis DPC6431, it 
appeared logical to employ a Bacillus strain as a heterologous host. Due to its 
insensitivity to thuricin CD, compounded by its ability to express heterologous 
proteins and its GRAS status, B. subtilis 1012 was chosen as a heterologous host and 
the IPTG-inducible pHCMC05 expression vector was selected to this end. Cloning 
of the full length of the thuricin CD gene cluster, encompassing the putative 
biosynthetic, immunity, post-translational modification and export machinery into 
pHCMC05 resulted in the production of thuricin CD in the B. subtilis 1012 host. 
This result confirmed that the eight genes of the putative thuricin CD gene cluster 
were essential for the production of biologically active thuricin CD. Downstream 
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assays were conducted to compare the levels of production of thuricin CD by the 
natural producer and the heterologous host, and it emerged that the B. subtilis host 
failed to produce thuricin CD at alkaline pH conditions.  Cloning of truncated 
versions of the full construct, with either the ABC-transporter genes or the post-
translational modification genes excluded, resulted in loss of thuricin CD production 
in the B. subtilis host. This ‘proof of concept’-type study confirmed that each of the 
genes in the thuricin CD gene cluster are essential for production. Furthermore, this 
development of a system for the heterologous production of thuricin CD will allow 
future random/site-directed mutagenesis studies to be conducted, in order to isolate 
variants with enhanced bioactivity.  
As part of Chapter V of this thesis, low-level thuricin CD resistant mutants across 
three sensitive species were isolated, with the ultimate view to gain an insight into 
the mode of action of thuricin CD. Low-level thuricin CD resistant mutants of L. 
monocytogenes 33013, B. firmus NRS854, C. difficile Liv024 R001, C. difficile 
TL174 R015, C. difficile CD196 R027 were isolated by exposing the strains to 
incrementally increasing concentrations of thuricin CD in a stepwise manner. It was 
apparent from phenotypic assays that minor variations in sensitivities to different 
antimicrobials did exist amongst the thuricin CD-resistant mutants. However, a lack 
of a direct link between attenuated sensitivity to thuricin CD and slightly altered 
sensitivity to other antimicrobials suggests that different mechanisms of resistance 
development may be involved amongst different mutants. Nonetheless, altered 
growth rates of thuricin CD-resistant L. monocytogenes mutants in the presence of 
the sugars mannose and glucose suggests that the mannose phosphotransferase 
system may be a potential receptor for thuricin CD. 
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Overall, the work presented in this thesis answers some of the fundamental questions 
about thuricin CD biology, genetics, development of attenuated sensitivity amongst 
target strains and efficacy when used in combination with other antimicrobials. Such 
findings could have significant implications in the potential use of thuricin CD in the 
clinic. The major issues relating to the treatment failure of CDAD have been 
highlighted and this thesis addresses these issues by seeking alternative therapeutic 
combinations and investigating the propensity for thuricin CD resistance 
development. Furthermore, the development of a heterologous host system and the 
identification of the immunity systems employed by the thuricin CD producer may 
serve as a foundation for the eventual over-production of thuricin CD. Such 
developments will help to expedite the processes involved in the deployment of 
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